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Summary
Biodegradable polymers have important uses both in surgery and as 
drug delivery devices. Bacterially produced poly D-3-hydroxybutyrate 
(PHB) and its copolymers with poly 3-hydroxyvalerate (P(HB-HV)) have 
emerged as new candidates for use in surgery, e.g. bone replacement 
and skin grafting, and use as controlled drug delivery devices.
Current literature available on the biocompatibility of these
polymers and their degradation products is limited. Chapters 3-6
describe a number of in vitro and in vivo techniques used to assess 
their biocompatibility in soft tissue.
Chapter 3 describes the effect of PHB, P(HB-HV) and their monomers on 
the growth parameters of CH0-K1 cells. No significant effect on cell 
growth when treated with PHB and P(HB-HV) was observed. However at 
monomer concentrations >10mg/ml (HB) and >15mg/ml (HV) cell 
cytotoxicity was observed. This was believed to be due to an osmotic 
effect.
Chapter 4 describes the effect of the polymers and their monomers on 
macrophage accumulation number when injected intraperitoneally into 
CLFP mice. Significant increases (p<0.01) in macrophage accumulation 
number was evident in the PHB and P(HB-HV) injected mice over days 
6-8 when compared to injection of vehicle alone. The effect on
macrophage activation, as indicated by PGE2 production and release, 
was assessed. The polymers and monomers significantly increased
(p<0.01) PGEz production and release during the first 15 minutes of 
culture when compared to control cultures, but these levels decreased
to control levels within 24 hours. The effect of the polymers and 
monomers on macrophage cytotoxicity was also assessed using LDH 
(lactate dehydrogenase) production and release as a marker. 
Significant increases in LDH production and release was only observed 
the with the monomers. The effect was again believed to be osmotic.
Blood compatibility of PHB and P(HB-HV) with reference to reported, 
blood compatible materials was assessed using plasma protein and 
platelet adhesion experiments. Significant increases (p<0.01) in 
fibrinogen adsorption and platelet adhesion was seen on P(HB-HV) 
films when compared to PHB and the reference materials.
Chapter 6 investigated the effect of PHB, P(HB-HV) and their monomers 
on the in vivo soft tissue inflammatory response using histological, 
vascular permeability and enzyme histochemical methods of assessment. 
Generally an acute inflammatory effect was evident which subsides 
after 14 days. High concentrations of the monomers were well 
tolerated.
Finally the in vitro and in vivo release kinetics of inulin from PHB 
P(LA-GA) and PLA melt extrusions were investigated. At physiological 
and accelerated conditions in vitro drug release appeared to follow 
zero-order kinetics. However drug release in vivo from the PHB/inulin 
melt extrusions was negligible.
Hypotheses for the above observations are discussed in each chapter 
and comparison of in vitro and in vivo assessment of polymer 
biocompatibility.
CHAPTER 1. Introduction.
1.1 Applications of biomedical polymers.
A number of review articles on the use of materials in medicine and 
dentistry have suggested that many structural parts of the human body 
could be replaced by some type of plastic and/or metal device (Miller, 
1978; Pines, 1978). The term ’biomaterial’ is often designated to such 
materials and may be defined as Ma material that is used in the 
treatment of patients, and at some stage, interfaces with the tissue 
for a significant length of time so that the interaction between the 
tissue and the material is an important factor in the treatment” 
(Williams, 1981). In 1986 the European Society for Biomaterials 
convened a consensus development conference on the theme ’Definitions 
of Biomaterials’. It has since been agreed by the conference members 
to define a biomaterial as "a non viable material, used in a medical 
device, intended to interact with biological systems” (Williams, 
1988).
The field of biomedical polymers continues to show steady 
growth in both basic research and application. Such polymers include 
totally implanted devices such as prosthetic devices, drug delivery 
devices, and materials used in the mouth for dental treatment, whether 
placed on the oral mucosa or located in the enamel, dentine or pulp 
chamber. According to statistics from the University Hospitals of 
Case-Western Reserve University, U.S.A., 9-15% of autopsies reveal 
some type of implant in the patient (Anderson, 1981). This number 
coupled with the number of people worldwide that have dental fillings, 
dentures and contact lenses, have made the development and application 
of polymeric biomaterials an increasingly important field (Falcetta, 
1974; Tighe, 1976; Andrade, 1976).
UU6
The material requirements for such diverse biomedical 
applications vary markedly according to the application being 
considered and it is therefore unlikely that one single polymer would 
be of use in all situations. The breadth of applications in which 
typical biomedical polymers are involved are listed in table 1.1. 
Polymeric materials fall into two broad categories, nonbiodegradable 
and biodegradable, the applications of which are discussed below.
1.2. Non biodegradable polymers for use in anatomical/organ 
replacement.
Non-biodegradable polymers are used in the development of artificial 
organs, limb and joint replacements, and artificial skin grafts. 
Possibly the most spectacular area of application is in the production 
of an artificial organ. The ultimate aim of artificial organ design 
is such that the organ is capable of implantation into the body
whereupon it is able to replace totally the function of the diseased
or disabled organ. However, even with the progress made over the last 
20 years within the field of biomedical technology, this has y^t to be 
achieved.
One of the major problems encountered with any artificial organ 
is that of blood compatibility, since virtually all organs either 
handle blood directly (heart, blood vessels) or come into contact with 
blood in a membrane exchange reaction (kidneys, lungs). Numerous 
polymeric systems have been investigated with regard to their blood 
compatibility. The criteria required for acceptable blood 
compatibility is described in detail in chapter 5. Polyethylene 
terephthalate mesh tubing (Dacron), and polytetrafluoroethylene 
(Teflon) tubings are at present the most acceptable polymers for use
in large blood vessel replacement (Kotte-Mar^iiant et al, 1989).
Table 1.1







































Knitted Dacron has been used for over 25 years as an arterial vascular 
prosthesis in the replacement of diseased large and medium sized 
arteries (Sauvage et al, 1978), primarily because its porosity allows 
tissue ingrowth and promotes graft healing, even though Dacron is 
recognised to be highly thrombogenic (Kotte-Marchant et al,, 1986; 
Hamlin et al., 1978; and Berger et al., 1972). The thrombogenicity of
Dacron is not of major consequence in high flow vessels, such as the 
aorta, but becomes a major factor in small diameter vessels with low 
flow. Polyether urethanes are now superceeding all previous polymers 
for use in cardiovascular systems and, in terms of blood 
compatibility, are at present reported to be the best materials 
(Lyman, 1974; and Stupp et al., 1977; Ito et al 1989). However the
durability of these polymers in cardiovascular systems is required to 
exceed the life span of the patient and the polymer must exhibit 
compatibility with the other body fluids and tissues. Therefore much 
research is still required on the polyetherurethanes in some areas of 
biomaterial application.
Progress of research in the use of artificial kidneys and lungs 
has suffered great setbacks in finding a biomaterial which has 
adequate blood compatibility coupled with good membrane 
characteristics. The situation with artificial lungs is particularly 
poor, as blood-membrane interface area is much greater and blood 
compatibility therefore becomes even more critical (Chien, 1980).
The use of polymers where long term contact with blood does not 
occur has advanced to a greater extent than those uses which imply 
long-term contact with blood. A major use of polymers in surgery has 
been replacement of soft-tissue such as the prosthetic breast and 
testicles. The major requirements of such soft-tissue replacement 
polymers include; no adverse reactions with body t i s s i n o  fibrous
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in-growth and a consistency similar to the natural material being 
replaced. To date the major polymer used in such applications has been 
polydimethylsiloxane (Chien, 1980). Artificial limb and joint 
replacement, where blood compatibility is not as important as
durability and long term stability, has also progressed steadily and 
is the subject of many review articles of polymers in surgery 
(Geblein, 1981; Hulbert et al, 1973., Charnley, 1976). Plastic can now 
be used as one of the articular surfaces in an artificial hip or knee, 
for example in metal/ plastic total joint replacements (total 
arthroplasties), or as an alternative to metal in joints where only 
one of the natural surfaces is replaced by an artificial material 
(hemiarthroplastie). However in both these circumstances there is the 
possibility that wear particles from the articular surface will 
accumulate in the synovial membrane or the joint capsule leading to 
inflammation. (Charnley, 1970). A further use of such polymers is as a 
cement to interlock a metal prosthesis within a bone. Polymers used as 
cements include polymethylmethacrylate. However, even this polymer of 
known biocompatibility (Langer et al., 1981) has been reported to
induce tissue necrosis at sites adjacent to the cement (Willert et 
al., 1974; Feith, 1975).
1.3. Nonbiodegradable polymers for use as controlled drug delivery
devices.
Recently, a great deal of interest has centered on the idea of 
utilizing biocompatible polymers to regulate the delivery of 
pharmaceuticals and veterinary drugs. Controlled release systems have 
been defined as those which result in the delivery of an active agent 
from a device to a target site at a rate and for a duration that are 
controlled by the device itself (Mills and Davis, 1987). Such devices
may offer several important advantages over conventional therapy, 
these include: 1) maintenance of optimal drug concentrations in body 
tissues, resulting in greater efficiency of treatment. 2) avoidance 
of peaks and troughs in drug concentrations resulting in fewer side 
effects and enhanced saftey. 3) ability to administer drugs with 
narrow therapeutic indices or short biological half lives. 4) greater 
patient compliance and convenience resulting from the use of fewer 
administrations per unit time.
A controlled release delivery system is a combination of a
biologically active agent with the excipient, a polymeric material. In
monolithic devices the drug is uniformly mixed with a polymeric matrix
and is present either in the dissolved or dispersed form. For a
dissolved drug Fick’s law of diffusion applies for the release
kinetics (Boer et al., 1987, Langer and Peppas, 1981), whereas the
release of dispersed drug can be described by Higuchi’s equation,
(Higuchi, 1961), (see chapter 7). In the mid 1960’s investigations of
approaches for incorporating drugs into solid polymers began. In
initial studies drugs were placed in the inside lumen of dialysis
*
(Waitz, 1963) or silicone (Folkman and Long, 1964) tubing, or evenly 
distributed through a polyethylene matrix (Desai et al., 1965). In the 
1970’s, systems were developed to continuously release large molecular 
weight drugs (Mw >600) from solid polymers. Ethylene-vinyl acetate and 
ethylene-glycol methacrylate copolymers and various hydrogels were the 
most sucessful in this regard (Langer and Folkman, 1976). A 
representative of this type of drug delivery device is the 
Syncro-Mate-B implant, engineered to release norgestamet in the 
sub-cutaneous tissue at a rate of 504mcg/cm2/day for up to 16 days, 
for oestrus control and synchronization in livestock (Chien, 1980). 
This implant system uses an ethyleneglycol methacrylate polymer as the
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controlling vehicle. A Nitro-Dur system, also of the matrix type is 
designed to be applied onto intact skin to provide a continuous 
transdermal infusion of 500ug/cm2/day of nitroglycerin, in the 
treatment of angina pectoris. This matrix system uses an aqueous 
solution of a water-soluble polymer, glycol and polyvinyl alcohol to 
form a polymer gel and thereby control the release of the active drug.
Other polymeric drug delivery systems include reservoir systems 
which enclose the drug within an inert polymer membrane (see table 
1.2). Although in practice resevoir systems will not deliver drugs at 
a constant rate either initially, or towards the end of their working 
life. An initial burst effect is seen due to membrane saturation with 
the drug following storage (Hadgraft and Guy, 1987), and ultimately a 
decrease in drug release occurs at the end of the systems life, as the 
driving force for diffusion through the membrane decreases and the 
release rate decreases with time (Smith and Lonsdale, 1985). Examples 
of commercially manufactured reservoir systems include the Ocusert 
device, which delivers pilocarpine to the eye for the treatment of 
glaucoma (Stewart and Novak, 1978), and the Progestasert system which 
was a uterine contraceptive system capable of delivering progesterone 
to the uterus for the duration of one year (Brenner et al., 1975). 
Other reservoir systems currently used and with increasing popularity 
include the Trans iderm-Nitro system engineered to achieve a 
transdermal absorption of 500ug/cm2/day of nitroglycerin for the 
relief of angina attacks, and Estraderm which administers a controlled 
dose of estradiol transdermally over 3-4 days for postmenopausal 
women. In these reservoir membrane systems the polymeric membrane used 
to control drug delivery is an ethylene vinyl acetate copolymer 
(Chien, 1980).
Other nonbiodegradable polymer systems employed as controlled
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drug delivery systems include particulate systems which can be 
injected locally, e.g. into joints for the treatment of arthritis, 
(Ratcliffe et al., 1984). Recently such systems have shown potential 
in passive targetting of drugs to organs (Tomlinson et al., 1984). 
These particulates are varied in design and manufacture and may 
release their contents as a reservoir, as in the case of 
microencapsulated systems or more commonly as matrices.
All these implanted nonbiodegradable polymeric drug delivery 
systems require surgical removal once all the drug has been released, 
in order to eliminate the potential health risks associated with 
non-degrading foreign substances remaining in the body for an 
indefinite period of time. This is neither acceptable or convenient to 
patients. A new generation of biodegradable polymers has now emerged 
for use in controlled drug delivery devices and other procedures which 
themselves degrade with time avoiding the necessity for surgical 
removal.
1.4. Biodegradable polymers for use in surgery.
The terms bioabsorbable, bioerodible and biodegradable are 
frequently used interchangeably. The definitions that different 
authors give to these terms also vary. Williams (1982) defined 
biodegradation as the biological breakdown of a polymeric material, 
whereas Gilding (1981) defined the term biodegradable as any polymer 
that undergoes in vivo degradation. Biodegradable polymers have two 
major applications in surgery: the temporary scaffold and the
temporary barrier.
The temporary scaffold includes the absorbable suture. Suture 
design requires the biodegradable polymer to hold both sides of a 
wound in close apposition until sufficient collagen synthesis has
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taken place to hold the wound together unassisted. Since 70-80% of 
total collagen synthesis usually occurs within the first three weeks 
after suturing, the final 20-30% requiring periods of 3-6 months, 
absorbable sutures therefore required to be structurally stable for at 
least the first three weeks of implantation. Amongst the most widely 
used absorbable sutures today are those made from polyglycolate (PGA), 
market ted as Dexon and a copolymer of lactate and glycolate P(GA/LA), 
marketted as Vicryl. Within the body these polymers are reported to 
begin filament breakdown between 21-28 days and are totally eliminated 
from the body after 80 days. (Reed, 1978; Wilson et al,, 1981). The 
original Dexon sutures were stiff due to the rigidity caused by 6 
denier filament of this highly crystalline material. However recently, 
a 2 denier filament, Dexon-S, was made and had mechanical properties 
very similar to silk. These biodegradable polymers are biocompatible 
within the soft tissue that they are implanted and have a mechanical 
strength superior to that of catgut. (Frazza and Schmitt, 1971; 
Gilding and Reed, 1981).
Poly-D-L-lactate, (PLA), is amorphous and since it *has no 
dimensional stability is of no use for sutures (Hodge, 1971). It is a 
hydrophobic polymer and remains in vivo for at least 2-3 years when 
fabricated as plates and screws, (Getter et al,, 1972; Leray, 1979).
Blood vessels, ureter, bladder, bile duct and heart valve design 
could, if tailored and fabricated suitably using biodegradable 
polymers, allow tissue ingrowth and partial regeneration of the 
natural structure. In the latter cases the polymer is acting ini tally 
as a temporary scaffold (Lauritzen et al,, 1983).
Biodegradable polymers have also been used as temporary 
barriers in the fields of tendon, spinal and open-heart surgery. A 
temporary barrier prevents surgical adhesions, caused by blood
clotting and later fibrosis, occurring between the sliding surfaces of 
the tendon, or cardiac wall and the pericardial sac. These polymeric 
barriers remain in situ until all the fibrin has been phagocytosed and 
are then degraded to an innocuous product which is excreted. Such 
devices have proved to be invaluable aids to the surgeon.
Other potential uses for biodegradable polymers in surgery 
include materials for absorption of blood during surgery. The use of 
biodegradable polymers has the advantage that, if the material was 
inadvertently left in the body, the surgeon would not have to 
reoperate to retrieve it, since the material would eventually degrade.
Newer applications for biodegradable polymers are those of 
controlled drug delivery systems, some of which are discussed below 
and in further detail in chapter 7.
1.5. Biodegradable polymers as controlled drug delivery devices.
In the application of drug delivery, biodegradable polymers 
when appropriately designed have the advantage that the drug vehicle 
degrades to a non-toxic product which negates the need for surgical 
removal once all the drug has been released. Early work on 
biodegradable polymers concentrated on the release of low molecular 
weight drugs. Biodegradable implants for the controlled delivery of 
narcotic antagonists were first descibed by Yolles et al., (1973). The 
delivery devices were either drug loaded films or drug loaded polymer 
powders suspended in a dispersing agent ( Yolles et al., 1974, 1975 
and Leafe et al., 1974). In a continuation of this work the
application of the biodegradable polyester, poly-L-lactate, was 
extended to a number of different drugs (Yolles et al., 1975). 
Poly-L-lactate and racemic polylactate were later used for controlled 
delivery of contraceptives in the form of monolithic devices
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(Jackanicz et al., 1973) and as reservoir devices for the delivery of 
narcotic drugs (Thies, 1976; Mason et al., 1978).
Research is now directed towards the release of macromolecules 
from these biodegradable polymers. Wise et al., (1987) highlighted the 
delivery of biological mediators, normally proteins and peptides, 
using a biodegradable polymer as the vehicle. Polypeptides cannot be 
given orally as they are deactivated by proteolytic enzymes in the 
gastrointestinal tract and are therefore administered parentally. 
However such drugs often have very short biological half lives and 
frequent injections are required to produce an effective therapy. 
Biodegradable polymers may therefore be useful in controlling the 
delivery of these polypeptides and at the same time protect the 
peptide from degradative effects. Current examples that exist for the 
controlled drug delivery of peptides and proteins largely utilise the 
polyglycolate-polylactate (P(GA-LA) systems. Such a commercial product 
which was developed using P(GA-LA) copolymers is Zoladex, manufactered 
by ICI pic for the controlled delivery of an analogue of luteinising 
hormone releasing hormone (LHRH) (Hutchinson and Furr, 1985). The 
controlled release of peptides from P(GA-LA) systems has been studied 
extensively (Sanders et al. , 1984, 1985 and 1986; Heller et al., 1987; 
Kaetsu et al., 1987).
The biodegradable polymer poly D-3-hydroxybutyrate (PHB) and 
related copolymers poly 3-hydroxybutyrate-valerate (P(HB-HV)) have 
recently been studied as potential biodegradable drug delivery systems 
and as a temporary scaffold in surgery. A more detailed description 
these polymers is given below.
1.6. Poly-D-3-hydroxybutyrate (PHB) and copolymers with 
3-hydroxyvalerate (P(HB-HV)).
1.6.1.Synthesis and structure.
1.6. Poly-D-3-hydroxybutyrate (PHB) and copolymers with 
3-hydroxyvalerate (P(HB-HV)).
1.6.1.Synthesis and structure.
PHB is a naturally occurring polymer, synthesised and metabolised by 
a range of micro-organisms, including Azobacter beijeinckii, Bacillus 
cereus and Alcaligenes eutrophus. Its microbial synthesis and 
metabolism have been studied by many workers (Williamson and 
Wilkinson, 1958; McRae and Wilkinson, 1958; Alper et al., 1963;
Senior et al., 1972 and Emenuwa, 1981). PHB is believed to act as an
energy reservoir in these bacteria, and is produced in response to an 
imbalance of growth brought about by nutrient limitation (Dawes and 
Ribbons, 1964; Dawes and Senior, 1974)
PHB was first isolated and characterised in 1925, by Lemoigne 
at the Pasteur Institute in Paris and since then it has been 
extensively studied. It is a highly crystalline thermoplastic with a 
melting point of approximately 180°C and is structurally related to 
the aliphatic polyesters polv -D-lactate and polyglycolate (figure
1.1.) As shown, its carbonyl oxygen and methyl group alternate on 
every other carbon atom along the backbone of the chain. The carbon 
is assymetric and of the ^ configuration. This structure has been -f 
supported by the following chemical evidence :
1) hydrolysis, saponification or heating of PHB yields 3-hydroxybutyric 
acid
2) the empirical formula corresponds to (C-iH602 )n
3) autolysis yields 3-hydroxybutyric acid (Baptist et al., 1964).
Recent work has shown that some bacteria produce a copolyester 
of hydroxyvalerate and hydroxybutyrate i.e. P(HB-HV) (Collins, 
1982; Holmes et al., 1981). P(HB-HV) can be biosynthesised by 
culturing the micro-organism in a medium containing a mixture of
13
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methylacetate. (Holmes et al., 1981). The effect of incorporating HV 
units into the PHB chain is to modify the crystalline morphology and 
lower the melting point resulting in a decrease in stiffness but 
increase toughness (Akhtar et al., 1987).
Literature has shown that PHB and its copolymers ultimately 
biodegrade to CO2 and energy in micro-organisms. However in cases of 
non-enzymatic degradation the degradation product of the homopolymer 
is 3-D-hydroxybutyric acid, (HB). This is a natural constituent of 
blood being one of three ketone bodies and its typical concentration 
in whole human blood is 0.5mg/100ml (Documenta Geigy, 1962). This 
concentration can greatly increase in states of fasting, ketosis, 
diabetes and pregnancy, and has been reported to increase to 
30g/100ml in severe cases of diabetes, (Shaffer and Marriot, 1913). 
Such high concentrations of HB in blood appear to be well tolerated 
and therefore it is unlikely that degradation of the polymer in vivo 
to this product will result in systemic toxicity. The additional 
degradation product of the copolymers P(HB-HV), 3-D-hydroxyvaleric 
acid (HV), is not a natural constituent of blood, but because of its 
structural similarity to HB it is thought to be well tolerated. The 
rate of biodegradation of PHB and P(HB-HV) depends on the environment 
in which the polymer is placed; the greatest rate of biodegradation 
has been reported in anaerobic sewage and well watered soil, slower 
rates result following subcutaneous or intramuscular implantation in 
animals, and the rate of degradation in vitro is slower still 
(Holland et al., 1987)
Patents relating to the extraction and use of PHB were filed 
in the U.S.A. 25 years ago (Baptist, 1962, 1965). Recently PHB has
attracted industrial attention as a possible candidate for large 
scale biotechnological production (King, 1982; Howells, 1982) due to
its high tensile strength, comparable to that of isotactic 
polypropylene, and its complete biodegradation. PHB has been 
proposed for use as sutures, gauzes, bone plates, splints, and 
microcapsules for controlled drug release. Many investigators are now 
looking at this biomaterial to deliver drugs in a controlled manner 
similar to biodegradable polyesters such as copolymers of 
poly(lactate-co-glycolate) marketted as Zoladex, to control the 
release of LHRH, and similar potent peptides (Hutchinson and Furr, 
1987).
1.6.2.Degradation of PHB and P(HB-HV)
The rate of degradation of PHB and its copolymer both in vivo and in 
vitro has been investigated by a number of workers. Miller and 
Williams (1987) studied the degradation of monofilaments of PHB and 
P(HB-HV) in vivo and in vitro. Little change in tensile properties 
was evident in either case although irradiation was found to reduce 
molecular weight of the polymer and increase its susceptibility to 
degradation. Increasing the valerate content also increased the 
rate of degradation by decreasing the sample crystallinity and the 
resistance to hydrolytic attack correlated with the differences in 
crystallinity of each of the preparations. Bissery et al. , (1984) 
found no evidence of PHB degradation in their work on the controlled 
release of a drug from ’biodegradable’ PHB microspheres. Holland et 
al., (1987) have suggested that one possible reason for the relative 
stability of the drawn PHB monofilaments reported by Miller and 
Williams (1987) may be due to a high degree of crystallinity, a 
typical consequence of the extrusion process used to produce 
monofilament fibres. Holland also showed that the rate of polymer 
degradation was dependent on the morphological form of PHB observing
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differences between solvent cast films, melt pressed discs, injection 
moulded samples and compressed tablets. These various forms of PHB 
had different resistances to hydrolytic attack, the least resistant 
being compressed tablets and then solvent cast films < melt pressed 
discs < injection moulded samples. The reason being a greater degree 
in porosity of compressed tablets etc. thereby increasing the 
effective surface area for degradation. The rate of degradation of 
PHB is also influenced by 01. An increase in 01 increased the rate of 
degradation suggesting that the degradation mechanism was base 
catalysed as would be expected for ester hydrolysis (Holland et al., 
1987) These authors further showed that the molecular weight of the 
polymer had a profound influence on the apparent weight loss per unit 
time. Low molecular weight polymers broke into smaller fragments 
earlier resulting in more rapid apparent loss of weight. Majid 
(1987), investigated the hydrolysis of PHB and copolymers P(HB-HV) 
using solvent-cast films at different values of pH at 37°C. Weight 
loss was measured and appeared to follow a zero-order pattern. A, 
surface erosion degradative mechanism was then suggested. The rate of 
degradation increased as the 01 was increased and was therefore 
base-catalysed and not acid-catalysed. All copolymers degraded more 
rapidly than PHB but the maximum degradation occured at 12.3mole% 
PHV. Yasin et al., (1989) blended P(HB-HV) copolymers with
polysaccharides to accelerate the rate of hydrolytic degradation. The 
polysaccharides increased the internal porosity and therefore 
collapse of the matrix was more rapid. These authors believed that 
the potential value of these blends extend from surgical devices, 
such as surgical clips, to drug delivery systems. In vivo work by 
Baptist (1965), showed that PHB films, after 8 weeks implantation 
into rabbit leg muscle, had begun to break up with an assumed weight
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loss, however Frazza and Schmitt (1971) found that even after 90 days 
implantation in vivo no gross changes were apparent.
It can be summarised that degradation of PHB is dependent on 
both the material characteristics as well as environmental conditions. 
More carefully controlled experiments are required to describe fully 
the characteristics of degradation of PHB and P(HB-HV).
1.6.3.Drug release from PHB and P(HB-HV) copolymers.
Korstako et al. (1984), prepared PHB matrix tablets as sustained 
release formulations using 7-hydroxyethyltheophylline (HET) as a 
model drug. Drug loadings, between 5% and 80% w/w were used and in 
vitro release studies performed in non-sterile 0.9% NaCl at 37°C. 
Where the drug loading was below 30%, drug release took place over a 
period of 50 days, but at drug loadings between 60-80% w/w the 
release was completed within 24 hours. Release of drug occured 
initially from the surface then proceeded by diffusion through the 
aqueous pores formed by water penetration of the matrix of the 
tablet. The degradation of PHB had no significant effect on the 
release of HET in vitro. When these polymer matrices were implanted 
subcutaneously into the neck crease of mice the release rate of HET 
was found to be 2-3 times slower when compared to the in vitro 
release rates.
Bissery et al., (1984) studied the release of an anticancer 
drug, lomustine 1- (2 chloro-ethvl) -3-cyclohexyl-nitrosourea, (CCNU), 
from solvent evaporated PHB microspheres, both in vitro and in vivo. 
In vitro, in buffer of pH 7.2 at 37°C, more than 90% of loaded drug 
(7.4% w/w) was released in 10 hours. In vivo the loaded raicrospheres 
were injected intravenously into mice bearing AKR leukemia but had 
little effect on increasing the life span of the animals.
Juni et al. (1986), also prepared PHB microspheres containing 
the anticancer drug, aclarubicin hydrochloride, using a solvent 
evaporation method. The release rate of the drug from the 
microspheres was measured in vitro. 10% of the drug was released in 5 
days in an isotonic NaCl solution at 37°C. . In an attempt to modify 
the release pattern of the drug, ethyl and butyl esters of fatty 
acids with more than 12 and 10 carbon atoms in the acyl chains were 
included and shown to enhance the release rate of the drug.
Brophy and Deasev (1986) prepared PHB and P(HB-HV) 
microspheres containing suspended sulphamethiazole using a solvent 
evaporation process and measured drug release rate both in vitro and 
in vivo. As the drug loading increased from 16-50%, the time to 50% 
release (t50%) decreased significantly in vitro. Decreasing the 
particle size also increased the rate of release. Copolymers 
containing 17 and 30 mole percent HV enhanced the sustained release 
in vitro. In vivo the sulphamethiazole plasma profile in six dogs 
showed that drug release was extended and uniform.
Gould et al. (1987) studied release rates of fluorescein 
isothiocyanate labeled dextrans from compressed tablets of PHB and 
P(HB-HV) containing the porosigens microcrystalline cellulose and 
lactose. At low porosigen levels drug release was matrix controlled. 
The release rate was also independent of solution pH except unless 
the aqueous solubility of the drug was itself a function of pH. In 
summary, the manner in which the drug is mixed with the polymer, the 
resulting crystallinity and porosity are important determinants of 
the rates and mechanisms of release.
1.6.4.Biocompatibility of PHB ^
Little literature is available on the biocompatibility of these
polymers. Korsatko et al. (1984) implanted tablets of PHB 
subcutaneously into the neck creases of mice. On histological 
examination an initial acute inflammatory reaction was seen and a 
mild inflammatory reaction continued throughout a 20 week observation 
period. These authors also used tissue culture techniques to 
determine the effect of PHB on cellular growth rate and metabolic 
function. The experiments indicated no significant differences in 
cellular growth or metabolism between control cultures and those 
exposed to PHB. Juni and Nakano (1987) reported on the apparent 
biocompatibility of PHB microspheres once implanted into the thigh 
muscle of rats. An initial mild inflammatory reaction was observed 
and after four weeks of implantation, the microspheres became 
encapsulated by connective tissues.
The biocompatibility of P(HB-HV) copolymers, their degradation 
products and the effect of different physical forms when implanted in 
vivo have not been reported. The following section describes 
biocompatibility testing as a whole and the rationale in the design 
of experiments to determine the biocompatibility of PHB, P(HB-HV) 
and their degradation products with reference to positive and 
negative controls.
1.7. BIOOOMPATIBILITY.
1.7.1 Biocompatibility and Biofunctionability - Definitions 
Any new materials that become components of medical devices or drug 
delivery systems are required to be biofunctional and biocompatible 
within the cellular environment in which they are placed. 
Biofunctionability relates to the intended performance of the 
material, and ideally, the material should function as originally 
intended throughout the entire implantation period. Biocompatibility
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is considered a property of a material and is defined as "the ability 
of a material to perform with an appropriate host response in a 
specific application" (Williams, 1988). Biocompatibility should be 
defined in terms of the conditions of use, (the specific 
application), and therefore there can be no such thing as a 
universally "biocompatible material". It is a term used to describe 
the state of affairs when a biomaterial exists in a physiological 
environment without either the material adversely and significantly 
affecting the body, or the environment of the body adversely or 
significantly affecting the biomaterial. These are two very broad 
aspects of biocompatibility but are very much interrelated, for it is 
often an adverse effect on a material by the physiological fluids 
which leads to release of particulate or soluble material from the 
biomaterial, which in turn leads to an adverse response from the 
tissues. Biocompatibility is therefore largely concerned with 
chemical reactions that take place between the body fluids and the 
implanted materials and the physiological responses to these 
reactions. Thus, the biocompatibility of plastics, at least in the 
context of soft tissue response, is to a large extent controlled by 
the manner in which the surrounding fluids extract residual monomers, 
additives and degradation products. This, perhaps, is an 
oversimplification of the effects of the material on the host and 
vice versa, as there is great complexity in these interfacial 
reactions.
The biocompatibility of metals and polymers may be influenced 
by many factors in addition to their chemistry. The mechanical 
relationship between implant and tissues can modify the response, 
which may arise either through relative movement at the interface and 
may influence the cellular response, or otherwise be due to the
relationship between implant and tissues can modify the response, 
which may arise either through relative movement at the interface and 
may influence the cellular response, or otherwise be due to the 
chemical reaction, or through the inequality of the elastic moduli 
which can alter the stress distribution in the tissue and 
consequently influence fibrogenesis and osteogenesis. The physical 
form of the implant has clearly been shown to be an important factor 
in biocompatibility in the context of the soft tissue response which 
includes the inflammatory response and carcinogenesis. For example, 
powdered material produces quite different effects to solid 
materials.
1.7.2.Criteria for biocompatibility testing.
Items falling outside the domain of drugs but which are used 
in medicine, dentistry and other animal or human applications which 
may involve contact with biological systems do not fall under any 
regulatory body in regard to toxicity testing programs. Therefore the 
safety evaluation programme is ultimately at the discretion of the 
manufacturer. However guidelines for biocompatibility testing have 
been developed and are discussed in section 1.7.4. Several kinds of 
reactions that would represent valid reasons for subjecting new 









probably the most prevalent one is local tissue response. If the 
response is of a mild nature the body will generally overcome the 
toxic property imparted by the implant. Local irritancy is caused by 
a number of factors such as the physical form of the implant, 
(Matalaga et al., 1976), the surgeons skill in implanting the device 
(Rae, 1980) bacterial contamination, (Williams, 1981), and the 
presence of leachable constituents. A number of biological tests, 
both in vivo and in vitro, have been used and still are used to 
determine the potential of an implant to cause a local tissue 
response, and these are discussed in detail in Chapters 3-6. Often 
the in vitro tests are more sensitive and the material may produce a 
toxic response that may not be detected when the implant is placed 
directly into tissue. The site of implantation is also an important 
factor as to the reactivity of the implants (Williams, 1973; Hench 
and Etheridge, 1982; van Blitterswijk et al., 1985).
Systemic toxicity is an important consideration in 
biocompatibility testing and may occur if a constituent of the 
material is absorbed into the circulatory system. The extent of 
toxicity therefore depends on the dose reaching a particular site. 
Pathological changes at distant tissues and organs may be reversible, 
or the damage may be of sufficient intensity that the body cannot 
reverse the damage. In clinical situations there have been reports of 
death or adverse effects when methylmethacrylate cement has been used 
in orthopaedic practice to anchor hip prostheses to the bone. The 
monomers can be absorbed and will produce systemic toxicity when the 
level of the chemical reaches 50ml/kg of body weight (Hornsey et al., 
1969). These low molecular weight acrylic monomers are reported to 
cause an initial increase in respiration followed by a fall. 
Hypotensive responses will occur almost immediately after the
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chemical is administered to animals and the deaths of the animals 
have usually been ascribed to respiratory failure, even though now 
there is some indication that the compounds may produce cardiac 
arrest (Autian, 1975). Silicone coating placed on the surfaces of 
tubings used in extracorporeal devices lias also been reported to 
cause the death of several patients attributable to tiny fragments of 
the silicone coating breaking away from the tubings and entering the 
circulatory system causing embolization (Lindberg et al., 1961).
Allergic responses may be induced with certain chemicals used 
in the manufacture of biomaterials. For example, curing agents such 
as mercaptobenzothiazole, antioxidants such as monobenzylether of 
hydroquinone and phenylbetanaphthylamine (Autian, 1973). It has been 
reported that polymethylmethacrylate dentures caused an allergic 
response in some patients, (Crissey, 1965). However, reported 
clinical cases of allergic responses from manufactured plastic 
devices are quite rare. Little is known of the possible allergic 
responses to implants of medical devices that have long-term contact 
with tissue. Biodegradation of the polymer could release an agent 
having sensitisation potential, thereby bringing an adverse effect 
that may not be traced to the degradation product or even the 
implant.
One of the most important tests in establishing 
biocompatibility is that of blood compatibility, i.e. the potential 
of a material to be thrombogenic. The unsolved problems in the 
development of cardiovascular biomaterials include a definition of 
the basic mechanisms of blood-material interactions and its 
consequences and identification of predictive tests of clinical 
performance of materials. Many diverse materials have been used 
successfully in clinical and experimental cardiovascular
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applications. Polyetherurethanes, carbons, Dacron, expanded Teflon 
and siloxanes have all been used in cardiovascular devices; 
polyvinylchloride is widely used for blood collection and storage. 
However, no single material has been defined as ideal, perhaps 
because these materials have been used in a variety of applications 
ranging from static (blood bags) to dynamic (heart valves). In the 
early research on circulatory assist devices, polyurethane polymers 
and copolymers with polydimethylsiloxane were identified as materials 
having potentially favourable interactions with blood. Reports have 
been presented demonstrating that certain silicone ball-shaped rubber 
heart valves absorbed lipoidal constituents from the blood and 
resulted in cracks or other alterations in the shape of the ball 
necessitating removal of the valve (Raible, 1966). Acceptable 
materials have not yet been identified for long term use in low-flow 
situations; autologous materials are still preferred as vascular 
grafts for small diameter vessels and coronary bypass procedures. The 
use of biodegradable polymers for use as vascular grafts has recently 
emerged and is discussed in detail in chapter 5.
One important aspect of biocompatibility is the potential of a 
polymeric implant to cause cancer. Cancer may occur through physical 
effects (solid state carcinogenesis), the presence of carcinogenic 
chemicals in the polymer or the development of a carcinogen during 
the period of implantation. A completely new biomaterial must be 
evaluated for its possible carcinogenic properties. Recently certain 
in vitro mutagenicity tests, using specific bacterial lines, such as 
those proposed by Ames (1975), have been used as rapid methods of 
ascertaining the carcinogenic potential of these biomaterials. 
However there is much controversy in the literature of toxicology and 
safety evaluation as to the most satisfactory model and design of
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animal study to predict the carcinogenic activity of a polymer in 
humans. The debate also continues as to the appropriateness of using 
the subcutaneous tissues of rats for the testing of solid materials 
such as plastics, because it is recognised that rat subcutaneous 
tissues are much more sensitive than human with regard to the 
development of tumours. The use of dogs or subhuman primates for 
testing the carcinogenic potential of polymers is also precluded as 
the latent period for development of tumours is several fold longer 
than the 6 month to a year period observed in rodents. Testing for 
the carcinogenic activity of polymer implants often follows the acute 
toxicity screening programme, once a new biomaterial is considered to 
be biocompatible for its specific application. However such testing 
was beyond the scope of this work due to the long periods required 
for completion of such tests.
1.7.3.Development of toxicity programmes.
Dixon and Rickert (1933) published a paper on tissue response 
to foreign materials. Dental materials were implanted subcutaneously 
and intra-muscularly in rabbits and, over a 6 month period, the 
animals were killed and the tissue surrounding the implant was 
prepared for histopathological examination. The above authors were 
among the first to develop a histopathological scoring system for 
tissue response for use in this type of toxicity testing. In the late 
1950’s, with an increase in the number and variety of disposible 
plastic devices used (collection and storage devices for drugs, 
biological fluids and diagnostic products) Brewer and Bryant (1960) 
utilized an intramuscular implantation test to determine their 
saftey. This consisted of preparing the samples as thin rods and 
introducing them by way of a hypodermic needle into the paravertebral
muscles of rabbits. After three days the animals were killed and the 
sites examined for gross tissue response. Any samples which revealed 
tissue responses were considered to fail the test. Lawrence et al. 
(1963) in their study of a number of polyvinyl chloride 
administrative devices, utilised the method of Brewer and Bryant, but 
extended their implantation period to 7 days. The method of Brewer 
and Bryant was adopted in 1965 by the United States Pharmacopeia as 
one of the biological tests for testing plastics to be used for 
containers and items having contact with parental products. The 
official test requires the use of a polyethylene negative control.
Powell et al. (1970) devised a toxicity evaluation programme 
for dental materials. These authors employed a tissue culture test, 
intramuscular and intradermal administation to rabbits and also 
dermal and ocular tests in rabbits. The latter two tests were 
concluded not to be suitable experiments.
Turner and associates (1973) studied the subacute tissue 
response of a number of medical and dental items using essentially 
the same USP implantation test as that described above. Both gross 
observations and histopathological examinations of tissue are the 
prominent means of evaluating the response of implants. In 1976 the 
Materials Science Toxicology Laboratories developed a Primary Acute 
Toxicity Screening Programme for new biomaterials. In 1977, Autian 
published the test procedures. The biological responses were graded 
according to the intensity and all of the scores ranging from 0 (no 
response in any test) to 1500 (most intense response for every test) 
were then compiled into the Cumulative Toxicity Index (CTI). 
Materials having CTIs below 100 were considered good candidates for 
further consideration for biomedical applications. Greater sensivity 
of biocompatibility testing can be achieved by the use of
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histochemical methods and by examining the fixed tissue by electron 
microscopy (Salthouse et al., 1976). The use of enzyme histochemical 
techniques for assessment of the biocompatibility of a new material 
is described in detail in chapter 6 in relation to the in vivo 
assessment of PHB, P(HB-HV) and their degradation products.
Other workers in the field of biomaterials have established 
specific techniques for the assessment of biocompatibility specific 
to the material’s application these techniques are considered in 
detail in subsequent chapters.
1.7.4.Present guidelines for safety and toxicity testing of 
biomaterials.
In the last decade, a number of countries and organisations have 
developed general guidelines for the testing of toxicity and safety 
of medical materials and devices. In the United States a number of 
biological testing programmes for safety of new biomaterials and 
devices have evolved. As early as 1965, the United States 
Pharmacopeia (USP) included a section on the biological testing of 
polymers to be used with parenteral products. The tests included
implantation of the polymer into rabbit muscle tissue with subsequent 
biological tests to be performed on extracts (using four extracting 
media). Extracts of the polymer are also assessed using an 
intracutaneous test in rabbits for irritancy and in a systemic
toxicity test in mice.
Each year the guidelines are revised. Presently the preferred 
animal model is the rabbit and the implantation test involves the 
preparation of 10 x 1mm diameter sterile test strips, which are
implanted by means of a hypodermic needle. Four strips of a control
(designated the USP Negative Control Plastic RS) are used. Four
strips of the test material are implanted on one side of the spine in 
each of two rabbits , 2.5 to 5cm from the mid-line and parallel to 
the spinal column. Two strips of the control are similarly implanted 
into the opposing muscle. The animals are sacrificed 72 hours after 
implantation and the tissue around the centre portion of each implant 
is examined microscopically with attention given to the presence or 
absence of haemorrhage and encapsulation.
The Federation Dentaire International (1980) published 
recommended standard practices for the biological evaluation of 
dental products including a sub-cutaneous (s.c.) implantation test. 
In the F.D.I. recommended practice, guinea pigs are specified, 
although other animals may be used. Its tests are rigorous in detail 
and involve the examination of the s.c. tissue for the presence of 
necrosis, inflammation and the resorption of material at two and 
twelve weeks. A specific scale of toxicity is given to the materials 
according to the degree of inflammation.
The American Standards for Testing and Materials (ASTM) have 
also published a number of standard practices for biocompatibility 
testing. The rabbit is the recommended animal, but the rat or other 
species are allowed. Implantation procedures are very similar to 
those specified in the USP. Gross observations are recorded at 7 days 
and histopathology is performed at 7, 30, and 90 days. If the
performance of the polymer in this initial short term test is 
promising, the biomaterial is tested on a longer term basis with 
histopathology carried out at 2, 3, 8, 12, 52, and 104 weeks in the
rat.
In Great Britain the British Standards Institution provides a 
set of recommendations for toxicity tests with a defined set of 
acceptable and nonaccepatable criteria. In the implantation test New
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Zealand rabbits are specified, into which two positive and two 
negative controls and four test specimens are implanted. The implants 
are left in place for 2 days before the animal is killed. Macroscopic 
observations and then histological preparations are carried out. The 
assessment of results are in subjective in that a reaction is 
considered negative either if there is no reaction or if there is a 
reaction that can be attributed to experimental trauma (typically 
asymmetrical, nonnecrotic and noninflammatory) and positive if there 
is necrosis and/or inflammation symetrically around the implant.
Many workers believe the above tests are too simplistic in 
nature and very subjective to individual interpretation. More 
astringent biocompatibility testing is required to give quantitative 
data.
1.8. Scope of Present Study.
The work presented in the following chapters studies the 
biocompatibility of PHB, P(HB-HV) and their degradation products 
utilising both in vivo and in vitro techniques. Acute and chronic 
aspects of the implant-host interactions have been evaluated 
including vascular permeability changes; inflammatory response in 
terms of cellular infiltration, assessed by microscopy and enzyme 
histochemical techniques; macrophage activation and blood 
compatibility.
One possible application of these polymers, controlled drug 
delivery, has been assessed both in vivo and in vitro, in terms of 
biocompatibility and the kinetics of drug release.
CHAPTER 2. Materials and Methods,
This chapter has been divided into 4 sections for convenience.
Sections 2.1-2.3 describe in vitro techniques used to assess polymer 
and monomer biocompatibility and Section 2.4 describes in vivo 
techniques.
2.1 Cell culture.
2.2 Effect on macrophage population (activation/inhibition).
2.3 Protein/platelet adsorption.
2.4 In vivo assessment of the soft tissue inflammatory response.
2.1. Cell culture: Materials and Methods
2.1.1. Equipment
Laminar flow hood; 2m, horizontal displacement type; Fell Clean Air 
(1971) Ltd., Newhaven, Sussex.
The surfaces of the hood were swabbed with 70% cdianol before and 
after use.
Incubator; LEEC PF2 anhydric incubator with forced air circulation, 
Laboratory and Electrical Engineering Co, Nottingham.
The thermostatic controls were adjusted to maintain a temperature of 
37.5°C +/-1°C.
Centrifuge; Beckman bench centrifuge model no. TJ-6; Beckman 
Industrial Estate Mervue, Galway, Ireland.
Adjustable replicating pipettes;
Pipette Effective volume range
Gilson pipetman P20 2-20ul
Gilson pipetman P200 20-200ul
Gilson pipetman P1000 200-1000ul
Gilson pipetman P5000 1000-5000ul
Pipettes with disposable polypropylene tips were obtained from 
Anachem Ltd., Luton, Beds. Pipettes were periodically checked to 
ensure accurate and reproducible sample delivery.
Liquid Nitrogen Freezer; Union Carbide model No. LR-33-10; Union 
Carbide UK Ltd., Cleveland, in which ampoules containing the stock 
cultures were held in the liquid N2 refrigerant or in its overlying
u u  *
vapour.
Freezing unit; Union Carbide BF-6 biological freezer, aplug type 
device designed for use with the LR-33-10 freezer. This unit is 
capable of cooling eight 2ml ampoules to below -70°C at a cooling 
rate of between 0.5°C and 7°C per minute.
Haemocytometer; standard double grid improved Nebauer-type blood cell 
haemocytometer with coverslips; Fisons Ltd., Loughborough, Leicester.
Microscopes;
1) For examination of growing cell cultures under phase contrast an 
inverted biological microscope, Wild M40, Wild Heerberg Ltd.,
Heerberg, Switzerland, was used. This fitted with the appropriate
condensers and xlO and x20 objectives gave magnifications of xl87 and 
x375 respectively.
2) For haemocytometer and other cytological preparations an Amplivial
*
microscope, Carl Zeiss Jena, CZ Scientific Instruments Ltd., Boreham 
Wood, Herts, was used. With fitted condenser and both plain and 
phase-ringed plane field objectives (xl6, x40, xlOO) this instrument
allowed transmitted light and phase contrast microscopy at
magnifications of x256, x640 and xl600 respectively.
Disposable cell culture plasticware; Tissue culture (T/C) grade 
disposable 25cm2 plasticware was obtained pre-sterilized from Flow 
Laboratories Ltd., Rickmansworth, Herts. 90mm T/C petri-dishes with 
triple vents were also obtained from Flow Laboratories. 2ml 
polypropylene screw-capped ampoules for liquid nitrogen cell storage
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were obtained pre-sterilized from Sterilin Ltd., Feltham.
Glassware; 100ml and 500ml bottles for the storage of solutions and 
media were obtained with caps from Flow Laboratories Ltd, Herts.
150ml and 500ml soda glass ’medical1 flat bottles were obtained from 
Fisons Ltd.
2.1.2. Cell Line
CHO-K1; a L-Proline requiring Chinese Hamster Cell line (Kao and Puck 
1968) were cultured and characterized at Bath by R.S. Dewdney (1982). 
These cells were used in experiments between passages 30 and 40. 
History of CHO-KI cell line
CHO-K1 is a well characterized cell line established as American Type 
Culture Collection (ATCC) Certified Cell Line (CCL) 61. It was 
derived as a subclone from the parental CHO line by Kao and Puck 
(1968) and shares most of its properties. CHO itself was one of a 
series of clones isolated from a culture initiated in 1957 from a 
biopsy of Chinese Hamster ovary (Puck et al 1958). CHO cells were 
initially fibroblast-like but have undergone several hundred passages 
since then and the cells of the K1 subclone more closely resemble 
epithelial cells. CHO-KI is hardy, reliable and routinely grown at 
37.5°C as monolayers on glass or plastic culture flasks in nutrient 
media containing relatively low levels of Foetal Calf Serum, (5%v/v) 
Under optimum conditions the cells grow rapidly with a population 
doubling time of less than 16 hours and show high single-cell 
plating efficiences, (Raetz et al., 1982). These characteristics 
coupled with the ability to grow easily in suspension, aswell as on 
solid surfaces, are advantageous in many types of experiment.
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2.1.3. Cell Culture Materials
Water; Double glass distilled water (DDH2O) was used in the 
preparation of all solutions and media. This was produced by a 6KW,
4.5 litre per hr bi-distillation Fi-stream still, model 2903 fitted 
vi.th a Fi-stream pre-ionizer, Fisons Ltd, Loughborough. DDH2G was 
sterilized by autoclaving at 121°C for 15 minutes in 100 and 500ml 
volumes.
Phosphate Buffer Saline (PBS) : Formula [g.l1 in DDH2O]- sterilized







*A buffer was also used in the absence of these salts and is referred 
to as PBSA.
Trypsin solution: A filter sterilized 2.5% w/v solution of trypsin 
obtained from Flow Laboratories. This was diluted to a working 
strength of 0.025%w/v in the presence of 0.02% EDTA in PBSA and 
stored as 8ml volumes in 10ml glass bijou bottles at -20°C.
Additives for cell culture media: Antibiotic solution:
Penicillin(5,000iu ml-1) and streptomycin (5,OOOmicro-grammes ml-1] 
solution obtained in 100ml unit quantities from Flow Laboratories. 
200mM L-Glutamine (Flow Laboratories)
lOOmM L-Proline (Flow Laboratories)
Sodium bicarbonate: obtained as a sterile 7.5%w/v solution from Flow 
Laboratories and stored at room temperature.
Media: Modified Ham’s F10 medium (MF10)
Prepared aseptically:- 
428ml sterilized DDH2O
50ml lOx concentrate of Ham’s F10 medium (without L-Glutamine and NaHCCte 
component) from Flow Laboratories




8ml 7.5% w/v NaHCOa
Stored in 100ml volumes at 4°C and used within 4 weeks.
Sera: All culture media were supplemented with 5% v/v FCS. (MF10V)
PCS from two different batches was used during the course of this 
study. These had previously been tested for their ability, as a 
supplement to culture medium, to satisfactorily support the clonal 
growth of relevant mammalian cells.
Batch 1 BN: 601109 Sera-Labs Ltd, Crawley, Sussex.
Batch 2 BN: 601103 Sera-Labs Ltd, Crawley, Sussex.
The sera was stored frozen at -20 °C until use.
Cryoprotectants: Glycerol: Analar grade (Fisons Ltd) stored at room
temperature protected from moisture. 2-3ml volumes were sealed in 
glass ampoules and sterilized by dry heat (160°C for 1 hour).
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Biological Stains: Methylene blue (BOH Chemicals) was prepared as a 
5% w/v solution in 50%v/v methanol. It was used to stain mammalian 
cell colonies attached to tissue culture plates.
Replica plating materials:
Nunclon plastic tissue culture petri dishes, 90mm diameter, Rosklide, 
Denmark. Polyester mesh; 17um Polymon mesh, Plastok Associates Ltd, 
Birkenhead. Circles of mesh were cut using a 85mm diameter template, 
with a notch at the edge to facilitate matching of replicas. Glass 
ballotini; 4.5-5.5mm in diameter, were obtained from BDH Chemicals 
Ltd, Poole, England.
General Methods
2.1.4.Gases and Gassing Procedures 
Gases:
Cylinders of N2 , CO2 and 5% CO2 in air mixture (5% CO2 and 20% O2 in 
N2) were obtained from Air Products Limited, Bristol Gas flowmeter: 
Floating needle type, 0.1-1.0 min~1 (Rotameter Manufacturing Co. 
Ltd., Croyden.) calibrated for use with CO2 . Plastic incubation 
boxes: Rigid, clear plastic boxes, 3.25 litre volume (A.Gallenkamp
and Co Ltd, Finsbury Square, London) Gas-tight tape: British Standard 
gas-tight tape, 2. 5cm wide (Intech Tapes Ltd, Manchester.)
All cell culture media contained a bicarbonate pH buffer 
system designed to equilibrate with an atmosphere of 5% CO2 in air. 
All air-tight culture bottles and flasks were therefore charged with 
such a gas mixture, introduced at low flow rate through a sterilized 
Pasteur pipette plugged with vion-absorbent cotton wool. Cell culture
dishes and other non-sealable vessels were placed in plastic 
incubation boxes into which a metered volume (150ml) of pure CO2 was 
introduced through a plugged pipette. These boxes were sealed with 
gas-tight tape. If only a few plates were put into a particular box, 
an open 9cm petri dish filled with water was added, to prevent 
excessive evaporation from culture medium during incubation.
Cell Culture Methods
2.1.5. Maintenance of cell line: CHO-K1 is capable of growth on glass
surface and thus stock cultures were routinely maintained in MF10V 
medium in 125ml clear soda-glass "medical flat" bottles at 37.5°C. 
Under these conditions cells grew as a monolayer on the bottom 
surface of each horizontally placed bottle. Cultures were not allowed 
to reach the point where release of cells from a confluent monolayer 
began since this can lead to increased heterogeneity within cell 
populations (Ham and Puck 1962). The routine subculture protocol was 
designed so that cells remained at all times in a condition of active 
growth and never achieved full confluence.
2.1.6. Preparation of cell suspensions from monolayer cultures: The 
essential manipulation involved in maintaining the CHO-K1 cell line 
was subculture. This operation required that cells be obtained in 
suspension prior to transfer to fresh culture vessels. Cells once in 
suspension could also be greatly diluted and plated so that colonies 
arose from single cells, a procedure fundamental to many experiments.
For a routine sub-culture the medium had to be clear with no 
floating cellular debris and not unduly acidic or basic, as colour 
indicated by its phenol red component. Cell growth was required to be 
greater than 50% confluent and the cells were required to have a 
normal appearance i.e. normal epithelial morphology.
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The medium was removed from the culture and the cells rinsed 
gently with 5ml of 0.05% trypsin solution. This solution was then 
discarded and another 1ml of trypsin added. The culture was incubated 
for about 5minutes at 37.5°C and then shaken vigourously. Detachment 
of cells was checked microscopically. The cells were gently aspirated 
with a Pasteur pipette, to break up clumps and produce a uniform 
suspension and then added to 5ml of complete medium in a 16mm T/C 
tube. Though the serum and Ca2* and Mg2+ ions in the medium 
protected the cells against continued deleterious enzyme action, the 
carried over trypsin was further diluted as soon as possible to 
minimise any risk of cell damage. Subculture or experimental 
manipulation of cells was therefore carried out immediately after 
trypsinisation.
2.1.7 Determination of cell suspension density: This was achieved by 
means of a haemocytometer count. Cells were thoroughly mixed 
immediately before sampling. A small volume was withdrawn from just 
below the surface of the suspension and introduced into the 
haemocytometer chamber. A total cell count was performed on eight 
large squares of the haemocytometer grid under low power (x256) phase 
optics. If the cell density was greater than 150 per large square, at 
which point cell counting was impeded by crowding , the suspension was 
diluted with medium and sampling and counting repeated. In the event 
of a very low density (less than 25 per square), the cells were 
concentrated by centrifugation, resuspended in a smaller volume and 
resampled.
The large squares of the haemocytometer had an area of 1mm2 and 
when the coverslip was pressed down over the grid, the depth of the 
chamber was 0.1mm2. The total volume over each large square was
therefore:
1 x 1 x 0.1 = 0.1mm3 = 0.0001cm3 = 10_4ml.
The total cell count per ml i.e. the cell density, was given by : 
cell ml-1 = 104n where n was the the average number of cells per 
large square.
2.1.8. Subculture routine:
Cells were subcultured at low inoculation density three times 






Fresh cultures had to be initiated with small inocula not only 
because cells were to be maintained in vigourous growth, but also 
because F10 medium , which was designed to support the clonal growth 
of CHO cells is not particularly well suited to supporting' dense 
populations (Ham 1965). Aliquots of counted cell suspension were 
added to 14.5ml volumes of MF10V in standard 125ml culture vessels 
and evenly distributed by gentle aspiration followed by agitation.
Ham’s F10 contains a bicarbonate pH buffer system designed to 
equilibrate with a 5% CO2 in air atmosphere (Ham 1963), therefore 
such a gas phase had to be provided in all cultures. The culture 
bottles were purged with the said gas mixture for 10-15 seconds and 
capped air-tight, prior to incubation. Bottles were incubated flat 
for maximum surface area for growth. Incubation, at 37°C, was in the 
dark because cytotoxic photoproducts are known to form from certain
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ccanponents of mammalian cell culture media (Wang et al. 1974).
2.1.9. Cell storage:
5 x 105 cells were routinely stored in the presence of 
cryoprotectant, 8% glycerol, in liquid N2 (at -196°C).
2.1.10. Cell recovery from storage: After removal from the liquid N2
refrigerator the contents of an ampoule were rapidly thawed at 37°C.
The cells were transferred by Pasteur pipette to 14ml of MF10V in a 
culture bottle and gently mixed. The bottle was gassed with 5% CO2 
and incubated. Invariably, within a couple of hours cells attached to 
the bottom glass surface and after three days had grown sufficiently 
to be passaged and subsequently handled as a routine stock culture.
2.1.11. Dilution Plating:
The plating of a small number of single cells into T/C petri-dishes, 
and their subsequent growth into macroscopic colonies, was 
fundamental to the replica plating and colony formation assays 
carried out. The following protocol was the basis for all dilution 
plating procedures. 4.9ml aliquots of culture medium in 50 mm T/C 
petri-dishes were equilibrated in plastic incubation boxes at 37.5°C 
in a humidified 5% CO2 in air atmosphere. Attachment of cells can 
occur rapidly at 37°C (Ham and Puck, 1963) and therefore to prevent 
cell loss all other media and solution were used at room temperature.
A cell suspension was prepared and the cell density determined, the 
counted cell suspension being serially diluted to a final density of 
103 viable cells ml-1. Replicate 0.1ml volumes of the final dilution 
were added to the equilibrated T/C dishes and the cells evenly 
distributed by gentle circular agitation. Inoculated dishes were
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replaced in the incubation boxes with a 5% COz in air atmosphere. The 
boxes were sealed with gas-tight tape and incubated in darkness at 
37.5°C for 7-8 days. During incubation the dishes were left 
undisturbed to prevent the formation of erroneous satellite colonies.
2.1.12. Staining: To determine the plating efficiency of the cells, the 
medium was carefully poured off from the plates and then each flooded
with 5% methylene blue in 50%v/v methanol. After 30 minutes the 
dishes were rinsed under running tap water and allowed to dry.
Stained colonies were scored by the naked eye against a white 
background, with aggregates containing 50 or more cells qualifying as 
a surviving colony. Colonies of marginal size were examined under a 
binocular dissecting microscope to confirm that they fulfilled this 
criterion.
2.1.13. Determination of the growth parameters of CH0-K1 cells.
Inocula of 2x105 CHO-KI cells at passage 32 were subcultured with 5ml 
MF10V into a number of 25cm3 T/C flasks and incubated at 37.5°C. At 
intervals a culture was removed and its total cell number determined 
as follows.
The medium in the culture flask was withdrawn and placed in a 
16ram, graduated, V-bottomed test tube. The cell monolayer was washed 
with 2ml of trypsin solution and then disaggregated in 1ml of 
trypsin. Both wash suspension and suspended cells were added to the 
medium in the tube. To remove residual cells the flask was rinsed 
successively with two 1ml volumes of PBS. Removal of all the cells 
was confirmed by microscopic examination. To minimize cell loss due 
to adherence to glass surfaces, siliconized Pasteur pipettes were 
used for all above transferences. Cells were sedimented by
centrifugation and resuspended In about 0.5ml of supernatant. The 
suspension was adjusted to an expected cell density of
2.5xl05-1.5xl06 cells per ml with PBS and the volume of this final 
cell suspension noted. The cell density was determined by
haemocytometer counting a minimum of 400 cells, and the total cell 
number of the culture calculated.
CHO-K1 cell lines exhibit ’classical* growth kinetics, growth 
being divided into three distinct phases: (Figure 2.1.)
1) Lag phase: this is the time following sub-culture and seeding where 
there is little evidence of an increase in cell number. It is a
period during which the cell replaces elements of the glycocalyx lost 
during trypsinisation, attaches to the substrate and spreads out 
(Freshney, 1983).
2) Log phase: this is the period during which cell numbers increase
exponentially. It follows lag phase and is also known as the
exponential growth phase.
3) Stationary phase: towards the end of the log phase the culture
becomes confluent i.e. all the available growth surface is occupied 
and the cells are in contact with neighbouring cells, hence a 
reduction in cell growth rate follows (Freshney, 1983). Figure 2.1 
shows a typical growth curve of CHO-K1.
From such growth curves cultures were determined to have a lag time 
of 6-8 hours. After approxiamately 9-12 hours incubation time cell 
growth was exponential and could be represented by the equation:
Nt=No2kt
where No is the cell number at time 0, Nt is the cell number at time 
t and k is the exponential growth rate constant. The calculated value 
of k (hr-1) from the slope in figure 2.1 was 0.089 and therefore the
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Figure 2.1. Growth curve of CHO-K1 cells grown in Hams F10 + 
5% FCS ( ■ , ▼ , • ) .  Each point represents the mean of 3 
experiments. The s.d. in each case was < 5% of the mean.
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Exponential growth ended after approximately 40 hours and the cells 
proceeded to stationary phase by 60 hours.
2.1.14. Construction of growth curves
Strips of polymer films (3cm x 1cm) were cut and sterilized in an 
autoclave at 121°C for 15 minutes. Four strips were then suspended in 
25cm2 tissue culture flasks containing 5ml of modified Ham’s F10 
culture medium (MF10V) with a sodium bicarbonate buffering system to 
ensure a pH of 7.2 - 7.6. The flasks were then inoculated with 2 x 
105 cells per flask and growth curves constructed over a 60 hr 
period. In a separate experiment the cells were left in contact with 
the PHB or P(HB-HV) films for 48 hrs, reharvested into control medium 
and their subsequent growth followed. The degradation products, HB 
and HV as their sodium salts, were dissolved in the buffered media at 
concentrations of 1,3,5,10,15,20,25 and 35mg/ml and inoculated with 
2xl05 cells for the study of growth curves. The lag and population 
doubling times were then calculated and these parameters compared 
with those of untreated cultures. As a positive control for the 
effect of polymers on cell growth, polyacrylic acid (PAA), which is 
known to be cytotoxic was used in crosslinked gel form. 
Polymethylmethacrylate, (PMMA), a known non-cytotoxic material was 




The technique of replica plating is used commonly when working 
with bacteria and yeast but is less easily applied to maniDalian 
cells. The principle of replica plating involves the inoculation of 
low densities of single cells into petri dishes allowing the 
development of macroscopic colonies. The colonies are then ’’copied" 
onto e.g. polyester mesh (Raetz et al, 1982) overlayed with the 
chemical under test, and after specified (hours) exposure to these 
materials, the viable colonies stained with methylene blue. The 
corresponding positions on each replica plate can then be located and 
compared with the master plate.
Procedures
A. Preparation of materials.
Systematic preparation of both polyester and glass balls was 
essential for consistent results. Cleaning and sterilization were 
carried out before the first use; and both the glass balls and 
polyester could be used repeatedly after a recycling treatment.
Initial preparation and recycling of glass balls: The balls were
soaked overnight in 10%(w/v) nitric acid, then washed thoroughly in 
cold running water (2hr). They were subsequently soaked for two hours 
in sodium hypochlorite solution (12% available chlorine), diluted 1 
in 50 with water, then again washed thoroughly in running water. The 
glass balls were boiled in detergent (RBS) for 5 minutes, washed for 
several hours in running water, and then rinsed with four changes of 
distilled water, draining well each time. They were placed into a 
beaker, covered with foil, and sterilized by autoclaving.
Initial preparation and recycling of polyester : A batch of polyester
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circles (85mm diam. with notch) were soaked in dilute sodium 
hypochlorite solution (12% available chlorine) for about 30 minutes 
then washed in running water for 1-2 hours. The polyester was
boiled for 5 minutes in dilute KBS detergent and washed overnight in 
running water. The circles were then rinsed with four changes of 
distilled water and drained. Finally the circles were placed in 
stacks in a 90mm petri dish containing 95% ethanol so that all 
circles were immersed for 30 minutes. The ethanol was drained off and 
the sterilized circles were then ready for use.
B. Initial plating of the cells
The cells were prepared in single-cell suspension (normally by 
trypsinisation from the stock culture), and 100 added to the growth 
medium, and inoculated into 90mm tissue culture dishes.
C. Setting up primary replicas
After one week the medium was changed and the sterile polyester 
circles added (minimum of three) with the notches aligned. Sterile 
glass balls were gently tipped onto the polyester and spread with a 
sterile spatula to produce a complete single layer. The underside of 
the dish was marked at the position of the notch and the dishes 
incubated for one week at 37°C. The balls were then tipped off and 
5ml of warm PBS added to each dish. Each polyester circle was 
transferred to a new dish containing 7ml of growth medium. Colonies 
were now visible as opaque dots on the translucent mesh and once the 
colonies were established on each replica disc the test polymer 
circles, FHB, P(HB-HV), PMMA and PAA were laid over the polyester 
mesh and the culture incubated for 24,48 and 72 hrs. The effects on 
the growth of “established colonies were then observed following
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staining of the colonies with methylene blue and the results compared 
with a control polyester disc, i.e the master copy of the replica 
plates.
2.1.16. Effect of osmolarity and pH
The osmolarity of the media containing the monomers as their sodium 
salts was measured using a Camlab osmometer (Roebling). pH was 
determined using a combined pH electrode attached to an electronic pH 
meter (Coming). Two substances, NaCl and sucrose, in concentrations 
which gave similar pH and osmolarity readings to the monomer 
solutions were used as comparative indexes in the cellular toxicity 
testing of monomer solutions.
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2.2. Assessment of Macrophage activation : Materials and Methods.
2.2.1. Materials 
General materials: -
Sterilized disposable 5, 10 and 20ml syringes; Plastipak, Beckton 
Dickinson, Leicester.
Sterile disposabable 20 and 25 gauge needles; Plastipak, Beckton 
Dickinson, Leicester.
Sterile 15ml conical centrifuge tubes; Flow Laboratories, Herts. 
Sterile plugged pasteur pipettes; Richardsons, Leicester.
Sterile scissors and forceps.
Haemocytometer; standard double grid improved Neubauer-type, Fisons 
Ltd, Loughborough.
Sterile 24-well multidish; Flow Laboratories, Herts.
Giesma stain; Sigma Chemicals Co, Poole, Dorset.
Culture media:-
Heat inactivated foetal calf serum (heated at 56°C for 30 minutes), 
BN 61109; Flow Laboratories, Herts.
Peritoneal lavage medium :Hank’s Balanced salts; Flow Laboratories, 
Herts.
Macrophage culture medium :RPMI XI640 Medium IX with 20mM Hepes 
buffer without sodium bicarbonate and L-Gluatamine; Flow
Laboratories, Herts.
Test materials
Phosphate Buffered Saline (PBS) pH 7.3; Dulbecco’s, Qxoid Ltd, England. 
Powdered chalk (CaC03), Aldrich, Gillingham, Dorset.
PHB Mw 43,000, Marlborough Biopolymers; Teeside.
P(HB-HV) 12.6 mole% Mw 760,000, Marlborough Biopolymers; Teeside
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Polymethylmethacrylate; Aldrich Chemicals Ltd, Dorset.
Polyacrylic acid; Aldrich Chemicals Ltd, Dorset.
Thioglycollate broth; Difco laboratories, Surrey.
Zymosan (opsonised), Sigma Chemical Co, Poole, Dorset.
HB as the soduim salt, Sigma Chemicals Co, Poole, Dorset.
HV as the sodium salt, Sigma Chemicals Co, Poole, Dorset.
All test materials either as solutions or suspensions in PBS were 
sterilized at 121 °C for 15 minutes prior to use and tested for 
sterility.
Assay kits:-
Prostaglandin E2 radioimmnoassay kit, Amersham, Bucks.
Lactate Dehydrogenase diagnostic kit, Sigma Chemicals Co, Poole,Dorset.
Animals: -
Six to eight week old female mice of the CLFP strain, fed on labsure 
rat pellets and water ad libertum.
Methods
2.2.2. Production and collection of macrophages.
The kinetics and quantification of macrophage accumulation was 
studied using the method below. Six to eight week old female CLFP 
mice were injected with 0.5ml of the test material 
intraperitoneally, using a 20 gauge needle. Four days later the mice 
were killed by CO2 asphyxiation, their abdomens swabbed with 70% 
alcohol and 5ml of cold sterile Hank’s balanced salts containing 10U 
of heparin per ml, were injected into the peritoneal cavity. The
abdomen was massaged gently for 1-2 minutes, a 2cm incision was made 
in the abdominal wall and the peritoneal exudate collected with a 
pasteur pipette into conical centrifuge tubes. The cells obtained 
were harvested by centrifugation at 1500rpm (4°C) for 10 minutes and 
the supernatant discarded. The cell pellet was dispersed in 5ml of 
RPMI X1640 culture media. The cells were counted using a
haemocytometer and assessed for viability by phase contrast
microscopy. The macrophage population as a % of the total cell number 
was determined using a Giesma stain. Cell exudates were sometimes 
found to be contaminated with blood probably as a result of 
mechanical damage to internal tissues or organs during i.p. injection 
or cell collection. Exudates of this nature were discarded since the 
prescence of blood leukocytes interfered with the quantification of 
peritoneal macrophage accumulation.
2.2.3. Macrophage cultures
Peritoneal macrophages were suspended at a concentration of 2 xlO6 
macrophages per ml in the culture medium. 1ml aliquots of this 
suspension were then plated into each well of a 24-well microtitre 
plate. The cells were incubated for three hours at 37°C during which
time the macrophages adhered to the plastic substrate. Non -
adherent cells were subsequently removed by gentle aspiration of the 
medium, twice washing the plates with fresh culture medium 
supplemented with 10% heat inactivated foetal calf serum to maintain 
the macrophage cultures in vitro. The cultures were incubated for 24 
hours at 37°C in an atmosphere of 95% air- 5% CO2 prior to treatment 
with test materials and assessment of their phagocytic activity.
2.2.4. Coverslip cultures
Peritoneal macrophages elicited using 0.5ml PBS injected 4 days prior 
to culture, were suspended at a concentration of 2 xlO6 cells per ml 
in the culture medium. Sterile (12mm diam.) glass covers lips were 
placed aseptically into the wells of 24-place microtitre plates and 
0.5ml of the macrophage suspension seeded onto the surface of each 
coverslip. The cultures were incubated for 3 hours at 37°C in 95% air 
-5% 002 mixture to allow the macrophages to adhere to the glass 
substrate and non-adherent leukocytes removed by washing each well 
with culture medium. The test and control-treated coverslip cultures 
were then supplied with 1ml of fresh medium containing the test 
materials or medium alone as appropriate. These coverslip cultures 
were incubated as above for 15 hours, the medium removed and the 
cells fixed with 2.5% gluteraldehyde in Hank’s Balanced Salts before 
assessment of their appearance by scanning electron microscopy.
2.2.5. Macrophage activity assays
PGE2 assay:- After the macrophage cultures had been incubated for 24 
hrs the culture medium was removed and replaced with suspensions or 
solutions of the test materials in fresh media. The concentration of 
PGE2 in the test or control treated cultures was assayed at intervals 
(0-30mins, l-24hr) using a radioimmunoassay kit (Amersham UK 
procedure no. TRK 800).
2.2.6. Cell viability assay
Lactate dehydrogenase activity (LDH) was assayed in each control and 
test culture using a Sigma colourimetric assay kit (Procedure no. 
500) based on the following reaction :
054
LDH
PYRUVIC ACID + NADHA ™ —  LACTIC ACIC + NAD
The reaction equilibrium strongly favours reduction of pyruvate to 
lactate at a rate proportional to the amount of LDH. Pyruvic acid 
reacts with 2,4 dinitrophenylhydrazine to form an intensely coloured 
hydrazine which has peak absorbance at 450nm.
2.2.7. Scanning Electron Microscopy
Fixed macrophage cultures were rinsed in PBS (pH 7.4) and the cells 
post fixed in a 1% osmium tetroxide solution at room temperature for 
30 minutes. The specimens were again rinsed in PBS and dehydrated in 
an ascending series of alcohols (30 -100%), then critical point dried 
(Polaron Equipment, Watford, Herts.) The coverslips were then sputter 
coated with gold using a Edwards Pirani ID sputter coater S150B and 
observed with a scanning electron microscope, Jeol 330, U.S.A.
Assessment of blood comapatibility : Materials and Methods.
2.3.1. Materials.
Bovine Serum Albumin; Sigma Chemicals Co, Poole, Dorset.
Bovine Fibrinogen; Sigma Chemicals Co, Poole, Dorset.
Bovine gammaglobulin; Sigma Chemicals Co, Poole, Dorset.
PBS (pH 7.4) Dulbecco’s, Qxoid Ltd, England.
Sodium Iodide (125I) Solution, Amersham, U.K.
Sodium Chromate (51 Cr) Solution B.P., Amersham, U.K.
EDTA, Trisodium citrate, Glucose, Sephadex G15, Dextran Blue albumin, 
Chloramine T, KI, Sodium thiosulphate, Trichloroacetic acid were all 
purchased from Sigma Chemicals Co, Poole, Dorset.
Polydimethylsiloxane (PDS) as medical grade Silastic sheeting, 
non-reinforced; Dow Corning Co., Michigan, U.S.A.
Low density Polyethylene (PEE), Goodfellow Advanced Materials, 
Cambridge.
PHB, Mw 43,000; Marlborough Biopolymers, Teeside.
P(HB-HV), Mw 760K, 12.6% mole% HV, Marlborough Biopolymers, Teeside.
Methods.
2.3.2. Polymer film preparation
A standardised preparation of polymer film (appendix 1) was used to 
ensure the reproducibility of the surface characteristics of the 
film. Irregular roughness and pitting, which could enlarge the true 
surface area, was minimal and the films were stored in clean vials to 
protect the surfaces from particulate contaminants. Polymer films 
were cast using a solvent evaporation process onto clean glass 
plates, with the result that the glass plate side of the film 
appeared smooth whereas the air dried side had a higher surface area 
and appeared rough. Prior to use films were cut into 3cm x 1cm strips 
and cleaned in an ultrasonic bath with three changes of double 
distilled water. Films were then pretreated with PBS buffer (pH 7.4) 
for three hours preceeding the adsorption study. It was important to 
ensure that there were no air bubbles at the surface of the film as 




The adsorption of proteins is sensitive to pH, and to enable 
comparison of the adsorption measurements physiological ionic 
strength and pH was necessary. PBS (pH 7.4; I = 0.15M) was therefore 
used for all experimental work. This buffer was was made up 
immediately before each experiment, and therefore remained free of 
biological contaminents which could degrade proteins and produce 
false adsorption data. The PBS was degassed by bubbling with helium 
to avoid air bubble formation at the surface of the films.
2.3.4. Protein preparation
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Proteins were used as received with a purity of greater than 97% 
according to Sigma literature. Unlabeled protein solutions were 
made freshly prior to each experiment.
2.3.5. Preparation of radiolabelled protein
The most popular method for 1251 radiolabeling of proteins is the 
Chloramine T method where 125I is covalently bound to the tyrosine 
and to a lesser degree, the histidine residues of the protein 
molecule (Dube et al., 1964 and Freendtender, 1971). The protocol
used in this study was an adaptation of that originally described by 
Greenwood, Hunter and Glover (1963).
The entire radioiodination reaction was carried out at 
approximately 4°C using an ice bath. lOul of Na i25j solution 
(equivalent radioactivity = lmCi) was dispensed into a reaction tube 
followed by lOul of 0.1N HC1 to neutralise the solution. 200ul of PBS 
containing lOmg of the desired protein was added to the reaction tube 
followed by Chloramine T (lOug per mg of protein) andt he reaction 
mixture allowed to stand for 10 minutes. After 10 minutes 20ul of 
Na2S205 (12.5mg/ml) and 20ul KI (25mg/ml) were added to the mixture
to quench the reaction. The labeled protein 125I was separated from 
unbound 125I by gel filtration using a Sephadex G15 column (2.5cm 
diam. x 40cm).
2.3.6. Separation of labeled protein from unreacted iodide.
Sephadex G-15 was hydrated with PBS pH 7.4 containing the appropriate 
protein and packed into the column. This procedure was adopted to 
saturate the column with unlabeled protein to minimize the adsorption 
of labeled protein during the separation procedure. The column was 
calibrated using a dextran blue albumin conjugate to establish the
elution time corresponding to the void volume. Subsequently the 
iodination mixture was transferred to the prepared column and eluted 
with PBS. 1ml fractions were collected in polypropylene tubes until 
both the protein and free 125I had been collected. The radioactivity 
in each tube was measured using a gamma counter.
2.3.7a. Determination of free iodine.
The amount of free i25j the labeled protein fraction was
determined by precipitating one volume of the labeled protein with 
one volume of 50% trichloroacetic acid. The mixture was incubated at 
4°C for 30 minutes then pelleted in an Eppendorf centrifuge at 10,000 
x g for 3 minutes. 20ul of the supernatant was pipetted off and 
assayed using a gamma counter.
% Free iodine = cpm in 20ul of supernatant x 100
cpm in 20ul of eluted samples
2.3.7b. Calculation of the efficiency of iodination.
% efficiency = dpm of lOul of sample x total volume collected xlOO
lOul
dpm equivalent lmCi
Calculation of total protein content of the iodinated samples was 
estimated using the Lowry assay.
2.3.8. Rinse protocol
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At the end of each experiment the film samples were removed from the 
reaction tubes and rinsed three times in 10ml PBS. The washings were 
assayed for 125I. Films were soaked overnight in PBS and the wash 
assayed to establish the required rinse protocol. Proteins are 
adsorbed onto solid surfaces in at least two forms, a) a loosely 
bound relatively rapidly exchanged fraction and b) a more tightly 
bound, slowly or nonexchanging fraction. It appeared that most 
loosely bound protein was removed by three washes with PBS and in 
most cases an overnight soak did not result in further desorption.
Experimental methods.
2.3.9. Preferential adsorption.
Preferential adsorption is defined to distinguish between the 
difference in adsorption between labeled protein and its unlabeled 
counterpart. If labeled protein has a higher affinity than unlabeled 
a ’preferential* adsorption takes place. To ensure that 
radioiodination of the proteins did not affect their adsorption 
properties, a test for preferential adsorption was carried out. The 
adsorption of protein was determined using a wide range of specific 
activities by changing the ratio of the labeled to nonlabeled 
protein. If labeled protein was adsorbed to the same extent as 
non-labeled protein the net adsorption .would be independent of the 
quantities of labeled protein used. However if 125I protein was 
preferentially adsorbed, the apparent adsorption would be expected to 
increase as the ratio increased. Experiments were carried out for a 
series of solutions with constant net protein concentration (2mg/ml) 
which varied in the fraction of the total which was radiolabeled 
(0.001-0.1). After 2 hrs incubation at 37°C, the films were rinsed 
and the polymer film using a gammacounter. Results were expressed as
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the amount of labeled protein adsorbed to polymer film in ug/cm2.
2.3.10. Adsorption isotherms
Adsorption isotherm were determined by exposing the polymer films to 
a series of concentrations (0.001 to 2mg/ml) of each protein for 2 
hours.
2.3.11. Competitive adsorption
Competitive adsorption to the polymer films was investigated using a 
series of binary protein solutions in which the concentration of one 
protein (non-labeled) was varied and the concentration of a second 
(labeled) protein was kept constant. The ratios of unlabeled protein 
(I) to labeled protein (II) were 0, 0.001, 0.01, 1.0, 10, 20, 70 and 
100. After 2 hrs equilibration the films were thoroughly rinsed as 
described in section 2.3.8. and counted using the gamma counter.
2.3.12. Preparation of platelet suspension and isotope labeling.
40ml of rabbit blood was collected by gravity through a 19G needle 
into a polypropylene tube containing 1 part tri-sodium citrate 
solution (3.8%) to 8 parts of blood. Platelet rich plasma (PRP) was 
collected from the supernatant of blood which was centrifuged at 
1050rpm for 20 minutes. The platelet density per ml was determined 
using a thrombocytometer and adjusted to a final concentration of 4 x 
105/ml with PBS. lOul of 51Cr Sodium Chromate solution of specific 
activity lmCi was added to the PRP and incubated for 1 hr at 37°C. To 
stop the reaction 3ml EDTA (ImM) and glucose (5mM) was added and the 
prp was then rinsed three times with PBS to remove unbound 51Cr. The 
51Cr resides in the plasma membrane and cytoplasm, (Steiner and 
Baldini, 1970) and was assayed using a gamma counter. i
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2.3.13. Platelet adhesion experiments.
Polymer films were exposed to the labeled PRP for time periods of 1 
minute to 60 minutes to establish the kinetic profile of platelet 
adhesion for each surface. The adhesion number was defined : Adhesion 
number = number of platelets per 104 um2. The adherence of platelets 
to the polymer surfaces was analysed according to Whicher and Brash 
(1978) and determined by comparing the radioactivity of the surface 
with that of an aliquot of suspension of known platelet count. The 
surface count of 51Cr can be used to compute the number of platelets 
adhering per unit area when compared to the suspension count.
Platelet = no. of platelets per ul x 51Cr film surface count x 104
adhesion no. 51Cr count per ul PRP x polymer film area (um2)
per unit area
After establishing the kinetic profile the polymer films were 
precoated with either albumin, fibrinogen or gammaglobulin for three 
hrs and the platelet adhesion number determined as described.
Assessment of soft tissue inflammatory response : in vivo. Materials 
and Methods
2.4.1. Materials
Sterile 1ml syringes; Plastipak, Beckton and Dickinson, Leicester. 
Sterile 25 gauge needles; Plastipak, Beckton and Dickinson, 
Leicester.
PUB (Mw 43,000); Marlborough Biopolymers, Teeside.
P(HB-HV) (Mw 760,000) 12.6 mole% HV; Marlborough Biopolymers,
Teeside.
Hydroxybutyrate and hydroxyvalerate as sodium salts; Sigma Chemical 
Co., Poole, Dorset.
Methylcellulose; Aldrich Chemicals Ltd, Gillingham, Dorset. 
Polyacrylic acid; Aldrich Chemicals Ltd, Gillingham, Dorset. 
Polymethylmethacrylate; Aldrich Chemicals Ltd, Gillingham, Dorset. 
Formalin; BDH Chemicals Ltd, Poole, Dorset.
Zymosan; Sigma Chemical Co, Poole, Dorset.
%
Evan’s Blue Injection Ampoules (25mg/5ml); Harvey Laboratories Inc. 
Philadelphia, PA.
Histamine, 5HT; Sigma Chemicals Co, Poole, Dorset.
Concentrated Hydrochloric acid and sodium hydroxide; Fison’s
Laboratories, Loughborough.
Alkaline and acid phosphatase kits (Procedure no. 104); Sigma 
Chemicals Co, Poole, Dorset.
Preparation of polymer films and microspheres is described in 
appendix 1.
2.4.2.Methods
2.4.2.1. Preparation of injections.
All materials to be injected were sterilised by autoclaving at 121°C 
for 15 minutes, ensuring that the solutions or suspensions were not 
adulterated by the sterilisation process. Using methods documented in 
the British Pharmacopeia, Volume II, 1988, 10% of each injection was 
tested for sterility and pyrogenicity (see appendices 3 and 4 
respectively). Products which gave positive results, i.e. microbial 
growth or gelation of the Limulus amoebocyte lysate, were rejected as 
false information would be derived from such products.
2.4.2.2. Histological studies.
Injection procedure.
0.3ml of each test material was injected intramuscularly into the
gastrocnemius muscle of male Wistar rats (200g, 10 weeks old), using
a single injection per rat. After 7 or 14 days the animals were
killed by dislocation of the neck, the injection sites located and a
gross macroscopic evaluation carried out by visual inspection. The
%
tissue at the injection sites was carefully excised and then fixed in 
10% phosphate buffered formalin prior to preparation for histological 
evaluation.
Histological preparation.
The fixed muscle tissues were embedded in epoxy resin, sectioned, 
mounted then stained with haematoxylin and eosin. Each tissue section 
was examined under high and low power using a Weiss microscope. This 
procedure was kindly carried out by Dr McCleod at the Royal United 
Hospital.
2.4.2.3.Assessment of increased vascular permeability.
Male Wistar rats, 100-150g in weight, were lightly anaesthetised with 
ether and their tails warmed in water at 45-50°C to dilate the tail 
vessel. Intravenous injections (0.4ml) of Evan’s Blue (25mg/5ml) were 
introduced into a lateral tail vein. Intradermal injections (0.2ml) 
of the polymer suspensions (20mg polymer/ml) and monomer solutions 
(10 and lOOmg/ml) in PBS were introduced into the abdominal skin 
previously shaved with commercial animal clippers. The concious 
animals were left for 2,3 or 4 hours at room temperature before 
killing by stretching the neck. After killing, the area of dye 
leakage was excised and extracted over 24 hours with a mixture of 7ml 
acetone and 3ml 0.5% sodium sulphate solution. After this period the 
tissue was removed and, following centrifugation to remove debris, 
the concentration of dye in the supernatent was determined by UV 
absorbance at 620nm using a Perkin-Elmer 550S spectrophotometer. To 
allow for variations in background ’'blueing” of the rats, a reference 
blank was obtained from each rat by excision and extraction of a 
piece of abdominal skin taken from outside the locality of the 
injection. The absorbances measured were converted to concentration 
with the use of Beer-Lambert calibration curve. Known irritants, 5HT 
(ImM), histamine (ImM), 1M HC1 and 0.1M NaOH were also injected 
intradermally and the resulting degree of increased vascular 
permeability assessed as above for use as comparative indices.
2.2.2.4. Assay of cellular activities.
Animal treatment
A lOmg/ml injection of PHB microspheres (approximate diamter 40um) 
was prepared using a 1% methvlcellulose and 0.9% saline injection 
vehicle. The injection mixture was sterilised in an autoclave at
121°C for 15 minutes. On cooling the injection mixture was sonicated 
to redisperse the microspheres and prevent further aggregation. A 
control injection mixture of vehicle only was also prepared as above.
Male Wistar rats, 150-200g in weight, were fed on Labsure 
pellets with water ad libertum. Into the right thigh muscle of each 
rat 0.3ml of the polymer suspension was injected using a 25 gauge 
needle. Other rats were similarly treated with lOmg/ml suspensions of 
P(HB-HV) and 10 or lOOmg/ml solutions of either monomer (HB or HV) as 
its sodium salt. The left thigh of each animal was used as the 
control by injection of the vehicle alone.
At intervals post injection (1,2,4,6,8,10 or 40 days) the rats 
were anaesthetised with ether, cardiac bled then immediately killed. 
5ml of blood from each rat was collected, centrifuged for 10 minutes 
at 3000rpm and stored on cracked ice ready to be assayed. The right 
and left thigh muscles were immediately removed, separately weighed 
and stored in 0.9% saline solution on cracked ice. Each muscle was 
homogenised thoroughly, the homogenate centrifuged for 10 minutes at 
3000rpm and the clear tissue extract removed for assay. The procedure 
was repeated with known inflammatory materials; zymosan (lOOmg/ml), 
polyacrylic acid (PAA) (lOOmg/ml), and a known biocompatible polymer 
polymethylmethacrylate (PMMA) (lOOmg/ml), which is used extensively 
for the manufacture of contact lens. These positive and negative 
control injections were presented to the tissue as solutions (PAA) or 
suspensions of the powder (zymosan and PMMA). Films of PHB and 
P(HB-HV) (2cm x 1cm) were also used in this study to evaluate the 
effect of the physical form of the implant on the intensity and 
duration of the inflammatory response. The films were sterilised by 
autoclaving and implanted into the muscle tissue using sterile blunt 
forceps to create a pocket between the muscle fibres. The wound was
sealed with sterile animal clips. PMMA films were used as the control 
in this experiment.
Enzyme assay
The extracellular enzyme activities of exudate samples were 
determined using a colorimetric method. Both assays involved enzyme 
reaction with p-nitrophenylphosphate as the substrate. A 
2-amino-2-methyl-l-propanol buffer at pH 10.3 was used for assay of 
alkaline activity and a citrate buffer at pH 4.8 was appropriate for 
the acid phosphatase activities (figure 3.1). The absorbance of the 
degradation product p-nitrophenol, was measured at 398nm using a 
Perkin-Elmer 550S spectrophotometer.
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CHAPTER 3. The preliminary assessment of the biocompatibility of PHB. 
P(HB-HV) and their monomers using cell culture.
3.1 Introduction
Many in vitro systems have become available for use as primary 
toxicological screens for new biomaterials in relation to their 
potential use in medicine and dentistry. The history of the 
application of in vitro screening programmes has been the subject of 
a number of comprehensive reviews (Pomerat, 1954; Schindler, 1969; 
Tardiff, 1978; Rees, 1980 and Ekwall, 1980). Cell culture assays are 
currently the most popular in vitro tests for acute toxicity 
evaluation on the basis that an observed in vitro event may also 
occur in vivo. Cultured mammalian cells offer a number of advantages 
over in vivo systems for the assessment of the biomaterial toxicity. 
These include sensitivity and rapidity of response, reproducibilty of 
observations (as the cells are from a phenotypically and genetically 
uniform stock maintained in a precisely defined and highly 
controllable enviroment), ease of experimentation and also relative 
inexpense in comparison to animal experiments, (Grisham and'Smith, 
1984).
The experimental protocol used in cell culture toxicity 
testing depends on the choice of cell line. Important considerations 
when choosing the cell line include the time span-of the project. A 
project that is to be run over several months requires the use of a 
finite cell line, and since different cells have differing abilities 
to multiply, some element of choice is given. Human cells in culture 
for biomaterial toxicity testing have been used by a number of 
investigators (Rae, 1986), however due to the limited life span of 
these cells it was impossible to complete a set of experiments on
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cells from a single source. It is also important to decide whether 
the cells will be grown in monolayers (and, if so, to ensure that the 
cell line selected does not show a tendency to overgrow), or whether 
the cells will be grown in suspension. Cells which are derived from 
dissociated tumours will grow and divide when maintained in 
suspension, but cultures of this type have had a limited application 
in biocompatibilty testing. With the above considerations in mind an 
established cell line was chosen for this work. CH0-K1, isolated from 
Chinese Hamster Ovary (Puck et a_Z., 1958), have been used by Levis 
and Majone (1979) in toxicity testing and is the cell line of choice 
in this study.
Most toxicity testing is performed on a soluble extract of the 
material under investigation, (Grasso et al., 1973; British Standards 
5736, 1981 and United States Pharmacopeia, 1975) or on the material 
itself with its components coming into direct contact with with the 
cells in monolayer culture. Hornsey (1970) exposed a number of 
polymers in a pseudoextracellular fluid for 62hr at 115°C and then 
used aliquot portions of this to prepare the nutrient medium for 
newborn mouse heart tissue. Using this method it was shown that 
certain polymers such as polyacrylic acid exhibited a moderate degree 
of cytotoxicity. Some investigators have used the biomaterial itself 
as the substratum for cell attachment, (Campbell et al. , 1941). 
However the growth of cells directly on a surface will not be a 
suitable technique for the investigation of all biomaterials as in 
some cases e.g. materials used in blood pumps and indwelling 
catheters, it is not desirable for the cells to become attached to 
the surface. Other investigators, Rosenbluth et al., (1965) and Lydon 
et al. (1985) allowed polymers to come into direct contact with cell 
monolayers. However, polymeric materials which have a density less
than that of the tissue culture medium tend to float and do not come 
into direct contact with the cells. This problem can be overcome by 
growing cells on a solid substratum under growth medium which 
contains a gelling agent. The test material is placed on top of the 
solid gel and the cytotoxic effects measured as the components of the 
material diffuse through the solid media to the monolayer of cells 
beneath, this is known as the agar overlay technique first used by 
Guess et al. (1965) and since by Grasso et al., 1973, Peling et al., 
1973 and Chawla et al., 1982. However there are problems with the
agar overlay technique, since the agar may impede diffusion of the 
soluble products and/or moieties of the test material thereby 
decreasing the sensitivity of the assay. Wennberg et al., (1979) 
attempted to overcome this problem by growing cells as a monolayer on 
one side of a membrane filter placed on top of an agar overlay and 
then the test biomaterial was placed on the other side of the filter. 
This technique altered the growth of the cells in monolayer due to 
the pores in the filter. Because of these potential problems it was 
decided to use in this study a direct contact method to study the 
cytotoxicity of PHB, P(HB-HV) and their degradation products.
End points that can be quantified as cellular manifestations 
of toxicity vary in degrees of precision and sensitivity. The 
appropriate technique is normally governed by choice of cell line. A 
major class of methods involve the measurement of cellular integrity, 
either by dye exclusion, (Phillips, 1973) or by the retention of 
radioactive chromium, (Ronai, 1969). However, permeability of the 
cell membrane to such markers does not unambiguously demonstrate cell 
death, as some cells are able to repair the underlying damage to the 
cell membrane or ion pumps and re establish volume control (Castellot 
et al., 1978; Kucera and Paulus, 1982). Changes in the cellular
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morphology and histology have also been used, (Grasso, 1973) however, 
such methods can only be used to obtain a qualitative end point since 
the interpretation of results is often subjective. Biochemical assays 
e.g. the release of lysosomal enzymes such as lactate dehydrogenase 
(LDH) and the measurement of cellular respiration have also been used 
to quantify manifestations of cellular toxicity (Rae, 1975 and 1981). 
However, a major disadvantage of biochemical testing for LDH 
activity is that calf serum contains appreciable amounts of LDH which 
will vary for different batches of sera used in multiple experiments. 
A more accurate method of determining cell death/toxicity is that of 
scoring the cell population either by direct cell count using a 
haemocytometer or indirectly by assay of cellular protein or DNA. 
Direct cell counts were used by Pappas and Cohen (1968) and Mital and 
Cohen (1968) when studying the toxicity of metal particles in tissue 
culture. A direct cell count method was one of the methods used in 
this present study to determine the cellular toxicity of PHB, 
P(HB-HV) and their degradation products.
The following chapter decribes the estimation of cellular 
toxicity caused by the polymers and their degradation products in 
direct contact with a monolayer of CH0-K1 cells using:
1) a direct cell count method with construction of growth curves,
2) a replica plating method using a colony formation assay.
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3.2 Results
3.2.1. The effect of PHB, P(HB-HV) and their monomers on the growth 
parameters of CH0-K1 cells.
For each of the treated cultures the lag and population doubling time 
(ti/2) was calculated to enable a direct comparison between control and 
treated cultures. The lag time was calculated by extrapolation of the 
exponential portion of the curve back to the axis of the original 
seeding density. The population doubling time determined from the 
exponential part of the curve was calculated from the following 
equation:
Log Nt = Log No + kt Log 2 
where Nt is the number of cells at time t, No is the number of cells 
at time 0, t is the time in hours, k is the exponential growth rate 
constant and 1/k gives the population doubling time. The effect on 
the growth parameters of CHO-K1 cells grown in the physical 
presence of PHB, P(HB-HV), PMMA and PAA over a 60 hr period is shown 
in figure 3.1. From these growth curves the lag time and population 
doubling time were calculated (table 3.1). Statistical analysis 
between groups was performed using Student’s *t* test in all cases.
The growth parameters indicated that the PHB treated cultures 
did not differ ( p>0.05) from the control culture, indicating good 
cell biocompatibilty. The lag and population doubling times of the 
CHO-K1 cells grown in the presence of P(HB-HV) polymer films were 
greater when compared to the control growth parameters, but were not 
significantly different. PMMA treated cultures showed a significant 
difference (p<0.02) in the lag time of the PMMA treated cultures, 
however no significant difference in ti/2 was found between treated 
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Figure 3.1. Growth curves of CHO-K1 cells grown in Hams F10 + 
5% FCS in the presence of polymer films (4%w/v), PHB (V), 
PAA ( O ), P(HB-HV) { ■ ) or PMMA ( A ). The growth curve of 
cells grown in the absence of any polymer is also shown I • ). 
Each point represents the mean of 3 experiments. The s.d. in 
each case was < 5% of the mean.
Treatment Lag time (hr) Mean (s.d.) T 1/2 (hr) Mean (s.d) r
__________________________________ n = 3____________________________________n = 3_____________
Control 7.34 9.93 0.96
11.39 8.33 (2.21) 9.10 10.48 (1.40) 0.96






























Table 3.1. The effect of polymer films (4%w/v) on the growth characteristics of CHO-Kl cells grown 
in Ham’s F10 and 5% FCS.
T 1/2 = Population doubling time, 
r = Correlation coefficient.
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inhibit cell growth and a degree of cytotoxicity was observed after 
only lOhr culture. Following a 48 hr pre-treatment with each of the 
polymer films the effect on the growth of CHO-Kl cells is shown in 
figure 4.2. and the calculated growth parameters given in table 4.2.
These results indicate good cell biocompatibilty of both the 
homopolymer copolymer and PMMA following 48hr pre-treatment, as the 
growth parameters displayed no significant difference (p>0.05) 
between the test polymers and the control culture. This suggests that
the effect of the physical presence of copolymer and PMMA films on
the growth of CHO-Kl cells caused the increase in lag time when
cells were cultured in their continual presence. Predictably, as PAA
induced cell death after 10 hr of culture then after 48hr 
pre-treatment no cell growth occurred.
The effect of the monomers, HB and HV as their sodium salts on 
the growth of CHO-Kl cells is shown in figures 3.3 - 3.5
and the calculated growth parameters presented in tables 3.3 and
3.4. The effect of the monomers on the growth of CHO-Kl cells 
indicated that at concentrations above lQmg/ml (HB) and 15mg/ml (HV) 
moderate to severe cytotoxicity occured as the lag time and ti/2 
increased. To establish whether the pH or osmolarity of these 
monomers at certain concentrations had any effect on the 
cytotoxicity, sucrose and sodium chloride were used at concentrations 
that gave similar pH and osmolarity readings to the monomers i.e. 
cell compatible concentrations (<lQmg/ml HB and <15mg/ml HV) and 
cytotoxic concentrations (>10mg/ml HB and >15mg/ml HV). Figure 3.6. 
shows the calibration curve for osmolarity used to determine the 
concentrations of sucrose and sodium chloride to be used. From this 
concentrations of sucrose and sodium chloride that gave similar 
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Figure 3.2. Growth curves of CHO-Kl cells grown in Hams F10 + 
5% FCS following a 48 hour exposure to polymer films (4%w/v), 
PHB ( V ), P(HB-HV) ( A ) , or PMMA ( ■ ) . A regression line for
control cells {----- ) is included for comparative purposes.
Each point represents the mean of 3 experiments. The s.d. in
each case was < 5% of the mean.
Treatment Lag time (hr) Mean (s.d.) T1/2 (hr) Mean (s.d.) r








11.39 8.33 (2.21) 9.10 10.48 (1.40) 0.96
6.25 12.40 0.96
6.74 11.16 0.99
6.65 6.80 (0.15) 8.65 9.38 (1.27) 0.99
7.00 8.32 0.98
8.06 11.26 0.99
6.25 7.79 (1.16) 11.44 11.32 (0.08) 0.98
9.05 11.26 0.98
6.50 7.64 0.99
7.50 7.50 (1.00) 12.49 9.19 (2.34) 0.99
6.50 7.43 0.99
no growth/ cell death cell death
cell death
The effect of 48 hrs pre-treatment with polymer films (4%w/v) on the growth 
characteristics of CHO-Kl cells grown in Ham’s F10 and 5% PCS.
T1/2 = Population doubling time, 
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Figure 3.3. Growth curves of CHO-Kl cells grown in Hams F10 + 
5% PCS in the presence of hydroxybutyric acid. Cells were 
grown with 3 mg/ml or 5 mg/ml hydroxybutyric acid ( ■ , □ , 
respectively). Each point represents the mean of 3 
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Figure 3.4. Growth curves of CHO-Kl cells grown in Hams F10 + 
5% FCS in the presence of 10, 15 or 20 mg/ml hydroxybutyric 
acid ( V , A , □ ). The growth curve of cells grown in the 
absence of hydroxybutyric acid is also shown ( • ). Each point 
represents the mean of 3 experiments. The s.d. in each case 
was < 5% of the mean.
Treatment Lag time (hr) Mean (s.d)
_____________________________ n= 3
T1/2 (hr) Mean (s.d)











11.34 8.33 (2.21) 9.10 10.48 (1.40) 0.96
6.25 12.40 0.96
9.10 8.23 0.96
10.02 9.90 (0.61) 7.43 7.59 (0.47) 0.96
10.57 7.11 0.96
12.60 7.60 0.98
12.20 12.18 (0.36) 7.49 7.41 (0.19) 0.97
11.73 7.15 0.98
13.05 -* 7.53 0.98
11.55 12.05 (0.71) 7.63 7.60 (0.10) 0.99
11.55 7.63 0.99
15.28 10.75 0.98
14.14 14.08 (1.00) 11.30 10.92 (0.30) 0.98
12.82 10.70 0.99
22.96 14.33 0.97
19.84 20.23 (2.10) 17.37 17.07 (2.10) 0.98
17.90 19.52 0.96
36.47 20.46 0.99
31.60 34.04 (2.40) 18.73 22.88 (4.70) 0.99
30.40 , 29.45 0.98
cell death cell death ---
Table 3.3. The effect of 3 -Ilydroxybutyrate (as sodium salt) on the growth characteristics of CHO-Kl 
cells grown in Ham’s F10 and 5% PCS.
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Figure 3.5. Growth curve of CHO-Kl cells grown in Hams F10 + 
5% FCS in the presence of 10, 15, 20, or 20 mg/ml 
hydroxyvaleric acid ( ▼ , A , • , ■ ). A regression line for
control cells (-----) is included for comparative purposes.
Each point represents the mean of 3 experiments. The s.d. in 
each case was < 5% of the mean.






















Table 3.4. The effect of 3 -Hydroxyvalerate (as 
cells grown in Ham’s F10 and 5% FCS. 
Ti/2 = Population doubling time, 
r = Correlation coefficient.
Ti/2 (hr) Mean (s.d.) r
_____________________n= 3________
9.93 0.96
9.10 10.48 (1.40) 0.96
12.40 0.96
10.75 0.96
9.41 9.70 (0.60) 0.97
9.41 0.95
9.40 0.96
9.40 9.40 (0.00) 0.96
9.40 0.96
9.70 0.96
9.40 9.50 (0.14) 0.96
9.40 0.96
6.50 0.98
6.70 6.65 (0.05) 0.98
6.70 0.98
9.70 0.96
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Figure 3.6. Jso-osmolaritv estimation of sucrose ( T ), 
hydroxybutyric acid ( A ) and hydroxyvaleric acid ( □ ) 
solutions. Determinations were carried out using a calibrated 
CamJab freezing point osmometer ( ref. section 2.1.16.). Each 
point represents the mean of 3 experiments. The s.d. in each 
























Figure 3.7. Growth curves of CHO-Kl cells grown in Hams F10 + 
5% FCS in the presence of 12.5 mg/ml NaCl ( • ) and 60 mg/ml 
or 100 mg/ml sucrose ( ▼ , A ) . A regression line for control
cells (-----) is included for comparative purposes. Each
point represents the mean of 3 experiments. The s.d. in each 
case ws < 5% of the mean.
Treatment Lag time (hr) Mean (s.d) T1/2 (hr) Mean (s.d) r
____________________________ -n = 3_____________________________ n = 3__________
Table
Control 7.34 9.93 0.96
11.39 8.33 (2.20) 9.10 10.48 (1.40) 0.96
6.25 12.40 0.96
Sucrose 5.85 14.28 0.90
60mg/ml 3.36 4.11 (1.20) 15.16 14.76 (0.40) 0.90
3.12 14.85 0.90
lOOmg/ml cell death cell death ---
NaCl 8.70 10.03 0.99
12.5mg/ml 7.20 7.67 (0.70) 10.11 10.00 (0.10) 0.96
7.10 9.87 0.96
25mg/ml cell death cell death ---
3.5. The effect of NaCl and sucrose of equivalent osmolarities to 10 and 15mg/ml of HB and HV on the 
growth characteristics of CHO-Kl cells grown in Ham’s F10 and 5% PCS.
T1/2 = Population doubling time, 




monomers are 60mg/ml sucrose and 12.5mg/ml NaCl (= lOmg/ml HB and 
15mg/ml HV) and lOOmg/ml sucrose and 25mg/ml NaCl ( =15mg/ml HB and 
20mg/ml HV) respectively. The growth curves were constructed as 
before (figure 3.7) and the growth parameters calculated (table 3.5).
Sucrose and NaCl at concentrations of equivalent osmolarity to 
the cytotoxic concentrations of HB and HV were seen to exhibit 
cytotoxic effects on CHO-Kl cells. The treatment of the cells with 
equivalent osmolarity to concentrations which were cell compatible, 
had similar calculated population doubling times, however there was a 
significantly shorter lag time (p<0.05) required for the cells grown 
in 60mg/ml sucrose. This could be due to the surplus sugar and energy 
provided by a culture medium rich in sucrose, which would have 
enabled the cells to recover from trypsinization and allow attachment 
to the culture flasks more rapidly. These results indicate that 
osmolarity does affect the growth of CHO-Kl cells in monolayer 
culture.
3.2.2.Replica Plating
Transfer efficiencies from plate to polyester cloth:
CHO-Kl cell lines were seen to have a basal colony-forming efficiency 
of 60-70%. Three or four high resolution copies could be generated 
from a single master plate, with 100% transfer efficiencies from the 
plastic culture dishes to the overlays. At this stage the CHO 
colonies were 2-4mm in diameter.
Effect of homopolymer, copolymer and monomers on the replica plates 
of colonies of CHO-Kl cells.
Table 3.6. shows the effect of the polymers and their monomers on the 
replicate CHO colonies over 72 hr s. After 72 hours contact with the
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Table 3.6 The percentage survival of CHO-Kl colonies following exposure to
either the polymers or monomers.
% survival = no of colonies on treated replica plates
no of colonies on untreated master replica plate (control)
Treatment Percentage survival (S.D.) n=3
24 hr exposure 48 hr exposure 72 hr exposure
PHB film 98.9 (0.46) 95.2 (0.69) 94.7 (0.81)
P(HB-HV) film 94.9 (0.29) 89.9 (1.16) 89.5 (1.56)
PMMA film 93.8 (0.58) ** 60.5 (1.62) **57.8 (0.66)
PAA film ** 18.9 (1.97) ** 0.00 (0.00) ** 0.00 (0.00)
HB lmg/ml 100 (0.00) 98.6 (0.66) 99.1 (0.76)
2mg/ml 100 (0.00) 100 (0.00) 98.3 (0.78)
3mg/ml 97.9 (1.16) 97.5 (0.80) 97.5 (0.80)
5mg/ml 98.5 (0.70) 98.0 (1.05) 97.4 (1.08)
lOmg/ml 99.3 (0.52) 97.0 (0.81) 96.7 (0.69)
15mg/ml 89.7 (0.23) 88.3 (1.21) *84.3 (1.56)
20mg/ml *80.1 (1.16) **75.4 (0.69) **49.5 (1.56)
25mg/ml **48.7 (1.79) **0.00 (0.00) **0.00 (0.00)
35mg/ml **0•00 (0.00) **0.00 (0.00) **0.00 (0.00)
HV lmg/ml 98.6 (0.90) 98.1 (1.00) 98.1 (0.35)
2mg/ml 98.9 (0.90) 98.9 (0.44) 98.9 (0.44)
3mg/ml 98.2 (0.34) 98.7 (0.61) 98.7 (0.64)
5mg/ml 97.6 (0.69) 98.9 (0.31) 98.4 (1.06)
lOmg/ml 97.4 (0.64) 97.9 (0.87) 98.8 (0.69)
15mg/ml 97.7 (0.52) 95.7 (0.69) 94.0 (0.48)
20mg/ml *80.1 (1.16) **75.4 (0.69) **49.5 (1.56)
25mg/ml **0.00 (0.00) **0.00 (0.00) **0.00 (0.00)
3 5 mg'/ml **0.00 (0.00) **0.00 (0.00) **0.00 (0.00)
Sucrose
60mg/ml 97.5 (0.42) 95.5 (0.03) 95.4 (0.77)
lOOmg/ml 94.6 (1.54) 89.6 (1.01) . 88.6 (0.63)
NaCl
12.5mg/ml 95.4 (0.46) 89.1 (0.69) *75.8 (0.33)
25mg/ml **0.00 (0.00) **0.00 (0.00) **0.00 (0.00)
*p <0.01 Statistically significant at the 99% confidence interval when 
compared to the mean control value.
**p <0.001 Statistically significant at the 99.9% confidence interval when 
compared to the mean control value. Student’s t test for paired samples.
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colonies PHB induced only a 5.3% colony death, whereas P(HB-HV) 
induced 10% colony death in the same period. 24 and 48hr exposure of 
these two polymers induced insignificant (p>0.05) colony death when 
compared to the master replica disc. PMMA, of reported
biocompatibilty, induced significant (p<0.001) colony death after 48 
and 72 hrs exposure. PAA of reported cytotoxicity induced total 
colony death, i.e. cell death between 24 and 48hr exposure. The 
monomer, HB, was well tolerated at concentrations <15mg/ml however at 
concentrations above this significant (p<0.001) colony death was 
seen. Similiarly, HV caused significant (p<0.001) colony death at 
concentrations above 20mg/ml and this was thought to be an osmolarity 
effect. However, lOOmg/ml sucrose did not produce colony death as 
would be expected from the growth curve data, suggesting the
possibilty that colonies of cells require a greater source of sugar 
and therefore energy requirement to maintain growth than single cells 
in monolayer.
3.3. Discussion
Comparison of the population doubling times of treated cells with 
control cells can be used to estimate induced toxicity (Pappas and
Cohen, 1968; Mital and Cohen, 1968; Rae, 1975, 1977, 1981).
Population growth parameters give an indication of the rate of 
doubling of reproductively competent cells within that population and 
is a function of the number of cycling cells and their cycle time. 
Defective cellular reproduction is manifested by impaired growth and
maintenance of the population of affected cells. It is known that
defective population growth may be due to: 1) reproductive arrest 2) 
slowed cell cycling 3) unregulated cell cycling. A cell in
reproductive arrest is one that has incurred damage resulting from
perminant blockage of cell cycle transit. The blockage can occur in
various phases of the cell cycle, indicating that defects of
different cellular processes may be responsible (Mauro and
Madoc-Jones, 1970). However, it is important to realise the cell is
not necessarily dead. Slowed population growth may be produced by 
temporary blockage of the cell cycle or by permanent slowing of cell 
cycle transit. Both responses often result from cellular defects that 
affect a specific event during one cycle phase. Unregulated 
proliferation i.e cycling may also occur and this has been equated 
to neoplastic transformation (Monat and Loeb, 1983). Reproductive 
arrest, slowed cell cycling and unregulated cycling can all occur 
through the toxic effects of chemicals and/or physical injury which 
may be imparted to the tissue by the implanted polymer.
The calculation of population doubling times obtained from the 
construction of growth curves for the copolymer, PMMA and monomer 
treated cultures compared to untreated cultures of CHO-K1 cells, 
suggested slowed cell cycling had occurred. Divergent slopes, seen 
with P(HB-HV) and PMMA (fig. 3.1.) and increasing concentrations of 
the monomers (fig. 3.4. and 3.5.) in the culture medium, when
compared to the slope of the control culture has been suggested to 
indicate reversible toxicity which merely slows or transiently blocks 
cell proliferation (Painter, 1977). As both the soluble monomer and 
polymer films appeared to cause slowed cell cycling, it was believed 
that their physical presence (i.e as expected with the films) did not 
impede cell growth. The slowed cell cycling observed with the 
increasing concentrations of both monomers was believed to be due at 
least in part to an osmotic effect. Experiments to determine whether 
osmolarity affected the cell cycling of CHO-K1 cells indicated that 
high osmolarity of culture medium (>280mmol) increased the population
culture medium cell death occurred. At no time was pH seen to affect 
cell growth as the sodium bicarbonate buffering system in the culture 
media maintained the pH between 7.2 and 7.6 even with increasing 
concentrations of the monomers. Further to interpretation of the 
growth curve data it has been proposed that parallel slopes of 
treated cells and control cells indicate that a fraction of cells 
have been permanently prevented from cycling either by cell death or 
reproductive arrest (Grisham and Smith, 1984). The fraction of dead 
or reproductively sterilized cells can be roughly estimated by
extrapolation of the exponential portion of the curve to the cell 
axis. Parallelism of slopes was observed between P(HB-HV) treated 
CHO-Kl cells and PMMA treated CH0-K1 cells. Hie cells grown in the 
continued presence of copolymer and PMMA films show increased 
population doubling times, which could be due to the physical 
presence of the films or more probably, as the presence of PHB films 
did not similarity affect population growth, leaching of cytoxic 
chemicals such as additives, plastisicers or their monomers. The 
deprivation of 02 or nutrients was also unlikely to occur in the
presence of the polymers films as the total area occupied at any one
time was 36%. If osmolarity was not the cause of increased lag and 
population doubling times then to establish the critical adducts or 
the mechanism of cellular toxic response more sophisticated
techniques would be required. However for the purpose of a rapid 
toxicological screening programme for biomaterials this would not be 
necessary.
Rae (1975, 1977, 1981), assessesd the toxicity of particulate 
metals of orthopedic interest, using counts of cells in the lag phase 
of growth and in the replication phase of growth. It was thought the 
particulate presentation of the biomaterial would produce more
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particulate presentation of the biomaterial would produce more 
sensitive results in cell culture due to the large surface area 
presented to the cells in monolayer. However problems of 
sedimentation, nonuniformity and problems of dispersion lead to 
difficulties in the exposure of the cells or colonies to identical 
doses. Therefore growth curve assessment of CHO cells was performed 
with their exposure to films of the polymers or solutions of their 
monomers.
The replica plating experiments measured the ability of 
colonies of cells to maintain growth i.e. the ability of the attached 
cells to proliferate and double with the required speed. If no toxic 
response occurs the established colony formation on the master 
replica disc should exactly match those of the treated discs. The 
cytotoxicity observed with the PMMA and PAA treated replica plates 
was believed to be chemically related. Leaching of cytotoxic 
materials used in the polymer preparation or its monomers was thought 
to induce colony death. The deprivation of O2 and/or nutrients 
inducing colony death was not believed to occur as both polymers have 
a large number of cross-links in the structure allowing access of the 
O2 and nutrients to the colonies.
The two cell culture methods have shown that PHB and its 
copolymer have good biocompatibilty and that both the monomer 
products at 10-15 mg/ml concentrations are non toxic. This was in 
agreement with the data produced by Korsatko et al. (1984), where in 
vitro cellular growth and metabolism was measured for mice 
fibroblasts exposed to tablets of PHB.
The sensitivity of cell culture has allowed a rapid picture to 
be formed of a biomaterials acute toxic reaction and probable in vivo 
biocompatibilty. However, there are disadvantages in relying solely
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on the results from in vitro toxicity testing as in vivo cells rarely 
act in isolation since the tissue reaction to implanted materials is 
likely to be a series of complex, integrated responses which may take 
place over many months. Therefore the conditions reproduced in vitro 
are a very simplified part of what may occur in vivo. One other major 
disadvantage of cell culture is that toxicity in vitro may be an 
overestimate of the toxicity in vivo due to the relatively stagnant 
conditions of the system. Cells in culture are also isolated from 
important detoxification and excretion pathways. Futhermore the 
metabolism of the cells in culture is abnormal. A solution to this 
problem has been suggested by the use of liver homogenate 
preparations, such as the mammalian microsomal ’S9’ mix (Styles, 
1981). However this does not necessarily represent metabolism in 
non-hepatic tissues. These disadvantages do not preclude the use of 
in vitro cell culture as a toxicological screen, but used in 
conjunction with in vivo animal experiments the biocompatibilty of 
new materials may be established with greater efficiency and 
sensitivity.
Tissue culture methods employed for mutagenicity testing and 
carcinogenicity testing in the assessment of polymer toxicity are 
also desirable but are beyond the scope of this present work.
3.4. Conclusions.
1) No significant difference (p>0.05) in the lag or T1/2 growth 
parameters of CHO-K1 cells grown in the continuous presence of PHB or 
P(HB-HV) films.
2) No significant difference (p>0.05) in the lag or T1/2 growth 
parameters of CHO-K1 cells pretreated for 48 hours with PHB or 
P(HB-HV).
3) At concentrations greater than lOmg/ml, HB caused an increase 
in both the lag time and T1/2 when compared to control cultures, and 
at concentrations greater than 25mg/ml cell death occurred.
4) At concentrations greater than 15mg/ml, HV also increased lag 
time and Ti / 2 .
5) Increase in osmolarity was thought to be the cause of the 
cytotoxicity as shown with experiments using NaCl and sucrose.
6) The second cell culture method to determine cytoxicity and 
therefore biocompatibility gave results that agreed with the growth 
curve method, indicating the reproducibility of in vitro cell culture 
methods.
3.4. Conclusions.
1) No significant difference (p>0.05) in the lag or T1/2 growth 
parameters of CHO-K1 cells grown in the continuous presence of PHB or 
P(HB-HV) films.
2) No significant difference (p>0.05) in the lag or T1/2 growth 
parameters of CH0-K1 cells pretreated for 48 hours with PHB or 
P(HB-HV).
3) At concentrations greater than lOmg/ml, HB caused an increase 
in both the lag time and Ti/2 when compared to control cultures, and 
at concentrations greater than 25mg/ml cell death occurred.
4) At concentrations greater than 15mg/ml, HV also increased lag 
time and T1/2 .
5) Increase in osmolarity was thought to be the cause of the 
cytotoxicity as shown with experiments using NaCl and sucrose.
6) The second cell culture method to determine cytoxicity and
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therefore biocompatibility gave results that agreed with the growth 
curve method, indicating the reproducibility of in vitro cell culture 
methods.
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CHAPTER 4. The effect of PHB, P(HB-HV) and their degradation products 
on activation of the macrophage.
4.1. Introduction
Over the past decade a number of investigators have examined the 
effects of biomedical materials on macrophage accumulation in vivo 
and macrophage activation in vitro with regard to prediction of the 
material’s biocompatibility (Miller et al., 1989; Spilizewski et al. , 
1987; Miller and Anderson, 1988; Marchant et al., 1984 and Bakker et 
al. , 1988). Emphasis has been put on macrophage activation in
biocompatibility studies as it plays a crucial part in the 
pathophysiology of inflammation, (Baggiolini, 1985) by virtue of its 
phagocytic capabilities and release of factors into the extracellular 
inflammatory exudate, (Schorlemmer et al., 1977; Rae, 1975, 1981;
Reiko et al., 1984; Nathan, 1987). Dependent upon the concentration
of macrophage accumulation and then release of these mediators, 
inflammation may be exacerbated or resolved (Ziats et al, 1988). .An 
understanding of the interaction between macrophages and the foreign 
material may lead to a prediction of the reaction of tissues to the 
implantation of biomaterials.
Macrophage activation has been defined by a number of workers 
(Petty, 1978; Lasser, 1983; Davies et al., 1974) as an increase in
functional activity induced by a given stimulus when compared to the 
resident macrophages which are present at any given site in the 
absence of an exogenous or endogenous inflammatory stimulus. In many 
instances macrophage activation has been said to accompany or precede 
the process of phagocytosis and also the subsequent release of 
inflammatory mediators into the area of stimulus (Henson, 1980; 
Anderson et al., 1984; Synderman et al., 1971).
During macrophage activation the macrophage undergoes many
changes with production and release of a myriad of substances 
including oxidised products of arachidonic acid through the
cyclooxygenase cycle, of which prostaglandin E 2 (PGE2 ) is the major 
end product (Davies et al. , 1980; Scott et al., 1980; Passwell et
al. , 1979 and Humes et al., 1977; Artursson et al., 1987). PGE2 has
therefore been used as an index of phagocytic activation by many 
investigators in the assessment of biomaterial toxicity (Miller et 
al., 1989; Elliott et al., 1987).
Macrophage activation has been investigated in vitro using 
cultures of freshly isolated mouse peritoneal macrophages, 
(Parwaressch et al. , 1981; Schorlemmer et al., 1976,1977;
Pizzoferrato et al., 1987 and Raz et al. , 1977). A variety of
different biological endpoints/parameters have been determined
including the production and release of PGE2 and lysosomal enzymes 
(Cohn et al. , 1963; Cardella et al. , 1974; Allison et al. , 1975;
Axiline et al. , 1970 and Weissman, 1971). Lactate dehydrogenase (LDH) 
release has been used as a marker of cytotoxicity of these cells by a 
number of workers, (Chambers, 1981; Weissman et al. , 1971) and may
also be used in the evaluation of the biocompatibilty of implant 
materials. Changes in cellular morphology have also been used as an 
indicator of macrophage activation (Leake et al. , 1975, 1979; Rasp et 
al., 1979 and Raz et al., 1977; Becker et al., 1986; Miller et al., 
1989). The latter include the measurement of the amount of membrane 
ruffles and the extent of cell attachment and spreading as compared 
to the same parameters in non-activated cells.
In the following chapter work will be presented showing the effect of 
PHB, P(HB-HV) and their degradation products on the kinetics and 
accumulation of macrophages in vivo and the extent of activation of 
resident and elicited macrophages in vitro. A known macrophage
activator, opsonized zymosan, (Schnyder and Baggiolini, 1978; Bonney
et al., 1978; Henson, 1980 and Humes et al., 1977) was used as a
positive control in this study. Macrophage activation was assessed 
in vitro by the release of prostaglandin E2 (PGE2) in culture. 
Cytotoxicity was assessed by7 LDH production and release.
Morphological changes and the extent of phagocytosis shown by
macrophages in culture, when activated by certain materials, were 
observed using a scanning electron microscope.
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4.2. Results
According to the sterility assay (B.P. 1988 Vol. II, appendix XVI)
and the Limulus amoebocyte lysate (LAL) assay for endotoxins (B.P. 
1988 Vol. II, appendix XIV and using Sigma procedure 210-2) 
supensions of polymers and solutions of their monomers were 
determined to be essentially free of bacterial contaminants and 
endotoxins thereby ensuring any macrophage activation was due to the 
biomaterials.
Four days following intra-peritoneal injection (as described 
in 2.2.2), the number of cells classified as macrophages when 
examined by light microscopy after staining with Giesma stain was 
found to be ~ 85%. Typical characteristics of macrophages observed
after treatment with Giesma included staining of a kidney-shaped or 
bi-lobed nucleus surrounded by a relatively large volume of 
cytoplasm which remained uncoloured. Their typical diameters ranged 
from 15 to 20 urn compared to the smaller PMN’s 8 um. Following the 
period of 3 hrs allowed for adherence to the culture plates or glass 
coverslips then subsequent washing off of nonadherent cells, the 
macrophage population was determined to be >95%. The viability as 
indicated by phase contrast microscopy after 24 hrs culture was > 
90%.
4.2.1. Quantification kinetics of macrophage accumulation in vivo. 
Table 4.1. shows the macrophage number accumulated in the
peritoneal cavity following injection with the test materials. 
To provide a comparative index for macrophage accumulation and
activation, thioglycollate media, a known eliciting agent of
macrophages, and opsonized zymosan, a known macrophage activator,













PHB 2.10 0.31) 4.55 (0.26) 12.75 (0.84) 11.30 (2.10) 4.51 (0.62) 1.40 (0.10)
P(HB-HV) 2.55 0.20) 3.35 (0.53) 4.12 (0.53) 4.20 (1.50) 3.03 (0.48) 1.30 (0.11)
HB 1.04 0.03) 0.91 (0.09) 2.27 (0.25) 2.89 (0.25) 2.23 (0.2) 1.46 (0.08)
HV 1.39 0.03) 1.57 (0.17) 2.40 (0.14) 2.82 (0.30) 2.43 (0.20) 1.34 (0.11)
PBS
(negative control)
0.90 0.00) 0.85 (0.20) 2.37 (0.21) 1.66 (0.21) 2.18 (0.25) 1.20 (0.11)
PMMA
(negative control)
1.13 0.09) 1.39 (0.12) 2.25 (0.17) 2.52 (0.39) 1.77 (0.25) 1.40 (0.24)
Chalk 
(positive control)
3.47 0.49) 3.08 (0.09) 2.42 (0.17) 2.43 (0.16) 4.83 (0.18) 1.72 (0.12)
Thioglycollate 
(positive control)
2.20 0.24) 1.74 (0.12)
*
4.20 (0.24) 2.94 (0.12) 2.56 (0.21) 1.30 (0.12)
Zymosan (lOOug/ml) 
(positive control)
2.50 0.28) 5.10 (0.18) 14.8 (1.00) 18.00 (0.32) 11.4 (0.69) 5.20 (0.33)
Table 4.1. :Quantification of the kinetics and magnitude of macrophage accumulation in vivo 




= 7.3) with 1% methylcellulose, the injection vehicle, was used as 
the negative control. The results showed good reproducibility for 
macrophage accumulation for all materials tested (s.d. <15%) between 
animals.
Injection of PHB particles into the peritoneal cavity of CLFP 
mice resulted in an increase of macrophage accumulation over an 8 day 
period which gradually decreased to vehicle control macrophage 
levels. At day 4 there was a significant increase in macrophage 
number (p<0.01) when compared to the vehicle, and at days 6 - 8 a 
highly significant increase (p<0.001) in macrophage number was seen. 
Zymosan resulted in a highly significant increase (p<0.001) in 
macrophage numbers from days 4 - 2 8  when compared to vehicle control 
groups. Thioglycollate induced a significant increase (p<0.01) in 
macrophage numbers at days 6 and 8 only and the counts were 
considerably lower than those produced by PHB or zymosan particles.
P(HB-HV) resulted in a significant increase (p<0.01) in 
macrophage number when compared to the vehicle control on day 6, 
followed by a decrease to vehicle control macrophage numbers by day 
28. The degradation products of the two polymers, HB and HV, resulted 
in significant increases (p< 0.01) in macrophage number at day 8.
Significant increases were thought to be indicative either of 
inflammation and toxicity or macrophage activation and release of 
factors which attracted more macrophages to the site of injection.
In summary, when compared to the resident macrophage 
population in freshly killed CLFP mice of 0.95 x 106 +/-0.12, PBS 
with 1% methylcellulose causes little increased accumulation 
following peritoneal injection. HB, HV, PMMA and chalk had no 
significant effect on macrophage accumulation. Thioglycollate, a 
known eliciter of macrophages, and P(HB-HV) showed only a slight 
increase in macrophage accumulation number following their respective
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injections. PHB and zymosan had a significant effect on macrophage 
accumulation on days 4-10.
4.2.2. Effect of particulate concentration on macrophage 
accumulation.
Table 4.2. shows that over the ten day period the number of 
macrophages attracted to the peritoneal cavity after injection with 
PHB microspheres was significantly greater (p<0.01) for the lOOmg/ml 
injection when compared to the 50 mg/ml injection. This suggested a 
dose response to the materials in terms of the numbers of elicited 
macrophages. This could be explained by : i) a greater inflammatory 
stimulus therefore attracting more macrophages to the area or ii) a 
greater number of particles liable to be phagocytosed thereby 
attracting more macrophages at the intra-peritoneal site. It was 
interesting to note that the number of macrophages attracted to the 
site of PHB injection (lOOmg/ml) was ~ x6 greater on day 6 and x4 
greater on day 8 than numbers attracted by the equivalent
concentration of chalk powder. This effect may only in part be due to 
differences in the surface characteristics of the materials since at 
50mg/ml the PHB microspheres and chalk powder did not significantly 
differ in the number of macrophages attracted to the site of 
injection. P(HB-HV) (lOOmg/ml) caused an approximate doubling in 
macrophage numbers on days 6 - 8 when compared to the equivalent
concentration of chalk powder, but at 50mg/ml the P(HB-HV) 
microspheres and chalk powder did not significantly differ in the 
number of macrophages attracted to the site of injection.
4.2.3. Effect of bicmaterials on the activation of the macrophages 
in vitro.
Table 4.3. shows the mean concentration of prostaglandin E2 (PGE2 )
Days
Test material 2 4 6 8 10
macrophage accumulation xlO6 mean (S.D.) n=4
PHB 50mg/ml 1.37 (0.20) 2.39 (0.23) 5.30 (0.33) 1.98 (0.37) 3.02 (0.27)
lOOmg/ml 2.10 (0.35) 5.04 (0.42) 13.80 (0.59) 9.15 (0.37) 4.67 (0.45)
P(HB-HV) 50mg/ml 1.82 (0.12) 2.49 (0.31) 2.40 (0.21) 2.31 (0.19) 1.79 (0.14)
lOOmg/ml 2.30 (0.22) 3.57 (0.21) 4.30 (0.29) 4.10 (0.31) 3.13 (0.27)
Chalk 50mg/ml 1.66 (0.18) 2.25 (0.19) 1.89 (0.15) 1.80 (0.19) 0.96 (0.09)
powder
lOOmg/ml 2.77 (0.24) 3.37 (0.27) 2.31 (0.2) 2.37 (0.11) 4.78 (0.22)
Table 4.2.:- The effect of particulate concentration on the extent of in vivo macrophage accumulation.
Figures are mean (S.D.) of 4 experiments.
Time












HB (lOOmg/ml) 544 984 1027 990 540 410 557 130 178 207
(33) (71) (43) (9) (36) (50) (93) (74) (23) (33)
HV (lOOmg/ml) 917 1010 1000 1035 532 350 485 567 347 282
(62) (12) (87) (21) (36) (71) (29) (119) (29) (21)
P(HB-HV) (10mg/ml) 583 560 680 703 580 603 795 737 240 187
(164) (57) (152) (104) (73) (156) (138) (21) (29) (54)
P (HB-HV) (lOOmg/ml) 857 983 1023 907 637 622 727 410 463 157
(47) (132) (29) (137) (90) (170) (35) (121) (159) (31)
PHB (lOmg/ml) 648 1010 1130 1030 220 526 590 528 466 102
(74) (31) (128) (16) (62) (47) (38) (24) (114) (14)
PHB (lOOmg/ml) 583 855 887 1050 517 737 798 737 536 188
(123) (74) (126) (42) (78) (47) (157) (97) (45) (24)
Control media 95 88 93 105 75 68 85 65 107 85
(16) (19) (26) (5) (16) (19) (26) (24) (17) (10)
Zymosan (1OOug/ml) 797 1150 1350 1050 683 960 860 838 748 683
(38) (107) (254) (45) (81) (69) (57) (36) (43) (67)
Table 4.3. : The effect of biomaterials on the production of PGE2 in macrophages in vitro. 
Figures are mean (S.D.) of 3 experiments.
Time
Test material 1 3 5 10 15 1 2 3 5 24
<;----------------mins  } ^-----------------hrs--------  — - ----^
HB (lOOmg/ml) 5.83 11.14 11.00 9.43 7.20 6.00 6.55 2.00 1.67 2.43
HV (lOOmg/ml) 9.65 11.44 10.72 9.86 7.08 5.12 5.71 8.72 3.25 3.31
P(HB-HV) lOOmg/ml) 9.02 11.14 10.96 8.63 8.49 9.10 8.55 6.31 4.34 1.84
PHB (lOOmg/ml) 6.14 9.68 9.50 10.00 6.89 10.79 9.39 11.33 5.03 2.22
Zymosan (100^g/ml) 8.38 13.02 14.50 10.00 9.10 14.06 10.12 12.90 7.01 8.03
Table 4.4. : Ratio of test PGE2 production for macrophages in vitro.
control
The control value was taken as the amount of PGE2 measured in the media of control cultured 
macrophages at specific time intervals.
The ratio was calculated using mean of 3 values.
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released from macrophages following incubation with each of the test 
polymers or their monomers. The culture medium and tissue culture 
grade plastic dish was used as the negative control and the opsonized 
zymosan as the positive control.
There was a highly significant increase (p< 0.001) in PGE2 
production in the first 15 minutes of culture following treatment 
with all polymers and monomers compared to the negative control. From 
1 hr to 24 hrs in culture there was a gradual decrease in PGEz 
production with all polymers and monomers. The opsonized zymosan 
showed a significant increase (p<0.001) in PGE2 production and 
release throughout all time intervals in the 24 hr culture with only 
a small decrease in activation after 24 hrs.
The results are summarized in table 4.4. which expresses the 
extent of macrophage activation as a ratio of PGE2 production from 
test material treated macrophage cultures and untreated macrophage 
cultures.
4.2.4. Cytotoxicity as shown by the LDH assay.
An increase in LDH release into culture media occurs on lysis of 
macrophages and this phenomenan has been used to measure cellular 
toxicity and hence predict the material’s biocompatibilty. Table 4.5. 
shows significant increases in LEW concentration in the media for 
both HB and HV treated cultures, but only a small insignificant 
increase (p>0.05) at the end of the 24hr culture period for the other 
materials. It was assumed that macrophage lysis and therefore 
cellular incompatibilty occurs only at high concentrations of 
degradation products and that the polymers do not therefore 
adversely affect macrophages.










Table 4.5. The effect
10 15 30 1 2 3 5 24
--------------mins > £ ------------------ hrs-----------------   ^
LDH production in D/D per ml mean (S.D.) n=3
380 430 380 1168 657 1113 1419 1483
(51) (43) (37) (241) (95) (471) (578) (346)
460 530 1865 1868 2273 1970 2120 1593
(56) (86) (149) (149) (117) (110) (36) (624)
0.0 0.0 74 276 487 627 857 2140
(105) (39) (114) (95) (91) (110)
0.0 0.0 0.0 0.0 213 558 1163 2033
(26) (48) (144) (343)
0.0 0.0 0.0 487 637 710 767 870
(135) (76) (123) (99) (104)
1283 550 357 644 720 707 783 1510
(284) (51) (63) (300) (173) (164) (237) (387)
355 563 617 1057 531 682 704 597
(23) (120) (246) (107) (106) (71) (110) (113)
387 303 303 317 327 300 336 497
(24) (66) (21) (50) (56) (24) (47) (86)
of biomaterials on LDH production in in vitro macrophage cultures.
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Studies using scanning electron microscopy revealed that the surfaces 
of the macrophage population cultivated with lOOmg/ml of PHB 
suspended in RPMI 1640 media, possessed a large number of ridges or 
ruffles. ( Figures 4.1. and 4.2.). The electron micrographs show
little cellular spreading at the membrane periphery i.e. few 
filopodia, however the cells themselves had adopted an elongated 
profile. The large numbers of ruffles and elongation of the 
macrophages were thought to be indicative of activation.
P(HB-HV) caused similar morphological effects in the 
macrophages (figures 4.3. and 4.4.), but monomer (lOOmg/ml) treated macrophage 
slight elongation in morphology but with little evidence of membrane 
ruffles. The majority of the monomer treated macrophages appeared to 
be attached to the glass coverslip by long thin filopodia at one end 
of the cell (figure 4.5.).
Normal macrophages showed little ruffling of the membrane, a 
smooth peripheral membrane with little filopodia at the periphery and 
little cellular spreading (figures 4.6.).
Figures 4.1 and 4.2. Scanning electron micrographs of macrophage 
cultures treated with PHB(lOOmg/ml) cultivated for 15 hours in RPMI 
1640 medium containing 10% v/v heat inactivated foetal calf serum.
4.1) x 750 20KV
4.2) x 3500 20KV
2 0 K U 0041921X 3 , 5 9 0  5Hro
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Figures 4 3 and 4.4. Scanning electron micrographs of macrophage 
S s  t r e a S  With P(HB-HV) lOOmg/ml, cultivated for 15 hours in 
RPMI 1640 medium containing 10%v/v heat inactivated oe a 
serum. X 3500 _ 20KV
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Figure 4.5. Scanning electron micrograph of cu^ V r®
treated with lOOmg/ml HB, cultured for 15 hours m  RPMI 1640 medium
containing lOXv/v heat inactivated foetal calf serum. x3500 20KV.




The mononuclear phagocytic system is a line of cells that originate 
in the bone marrow, are transported by the blood stream and localize 
in the tissues where they differentiate to form macrophages. 
Macrophages have globulin receptors, complement C3 receptors and 
receptors for the Fc portion of IgG with three different Fc 
expressions on their surfaces, (Rabinovitch 1970 and Lasser et al., 
1982; Gordon and Rabinowitz, 1989). During inflammation the 
mononuclear phagocytes are chemotactically attracted to the 
inflammatory focus by a number of mediators including complement 
components (Boyden, 1972 and Schorlemmer et al., 1976; Mellman et
al., 1988) and antigen antibody complexes (Walker, 1977 and Steinman, 
1974; Steinman et al., 1983). The number of macrophages attracted to 
the site of inflammation is dependent on the size of the inflammatory 
stimulus, (Scott et al., 1980 and Petty, 1978). In this study the
greatest polymer induced accumulation of macrophages occured on days 
6-8 after mice were injected intraperitoneally with PHB 
microspheres. This could be explained either by toxicity o'f the 
material which would be reflected in the magnitude and duration of 
the inflammatory response (see chapter 8 for a discussion of the role 
of macrophages in inflammation), or an attempted phagocytosis of PHB 
without any toxicity to the tissues. The latter conclusion was 
favoured as no necrosis or chronic inflammation was obvious at the 
site of injection, as verified by the histology, vascular 
permeability and enzyme histochemistry work described in chapter 6.
Thioglycollate is a known macrophage ’eliciter* (Gordon, 1976 
and Conrad, 1977) and was used as a positive control in the in vivo 
studies of accumulation of macrophages after intraperitoneal 
injection. The effect of thioglycollate was to cause a doubling of 
the count on day 6 when compared to the vehicle control and. slightly
raised counts on other days. Zymosan also a positive control, and at 
a tenth (lOOug/ml) of the concentration of polymers injected in this 
experiment, was seen to induce a much greater increase in 
accumulation throughout the study, reaching a peak on day 8 which was 
sustained until day 28. PHB caused a comparable accumulation on day 6 
but the levels had returned to normal by day 28. Clearly the effect 
of PHB was short-lived in comparison with zymosan. This could be 
explained in part by ongoing phagocytosis of the zymosan particles 
(~3um in diameter) and therefore the subsequent attraction of more 
macrophages to this inflammatory stimulus. PHB however, initially 
attracts the macrophages to its site of injection in order to be 
phagocytosed, but because the particle size is 40 urn in diameter, 
(~x3 bigger than the actual macrophage) ’frustrated’ phagocytosis may 
occur. As the polymer is non-toxic to the tissues the macrophage 
number decreases. The accumulation of macrophages after injection of 
P(HB-HV) was similar to the accumulation after injection of 
thioglycollate (table 4.1.), the macrophage accumulation number only 
significantly greater (p<0.01) at day 6 when compared to the vehicle 
control. The differences in macrophage accumulation number of PHB and 
P(HB-HV) were believed to be due in part to the difference in surface 
chemistry of the two polymers. The dissolved monomers had little 
effect on macrophage activation in vivo which was expected as the 
monomers would be cleared rapidly from the peritoneal cavity.
Following chemotaxis to the inflammatory stimulus, depending 
on the material (solution or particulate), phagocytosis or 
pinocytosis (fluid-phase endocytosis) can occur. Pinocytosis of small 
volumes of fluid is likely to be constitutive whereas phagocytosis in 
many cases requires activation of the macrophage: i.e. the macrophage 
undergoes several morphological, biochemical and functional changes 
when expressing enhanced resistance to foreign material and
inflammatory stimuli (Nathan, 1987; Mackanass, 1964, 1970; Macmonie 
et al., 1968 and Humes et al., 1977).
Over 50 structural and biochemical alterations have been shown 
to occur in activated macrophages, some of which are listed in table 
4.6. The measurement of the production and release of PGE2 from 
activated macrophages is particularly useful as PGE2 plays a key role 
in mediating inflammatory reactions and also participates in the 
regulation of immune functions (Passwell et al., 1979). The critical 
role of PGE2 in the inflammatory process is suggested by the fact 
that the tissue concentration of prostaglandin E2 correlates with the 
local accumulation of the inflammatory exudate and inhibitors of 
prostaglandin synthesis decrease the intensity and duration of 
inflammation (Vane, 1971,1976 and Flower, 1976). In vitro studies 
have shown that PGE2 also inhibits immune function in general (Bray 
et al., 1978) and inhibits macrophage inhibitory factor production 
(Gordon et al., 1976) thereby exacerbating the inflammatory process.
During macrophage phagocytosis and activation the magnitude of 
prostaglandin synthesis and duration of production is determined by 
the p h a g o c y t i c  stimulus. As shown in this study the greatest increase 
in PGE2 synthesis was induced by opsonized zymosan, a known 
macrophage activator. Both PHB and P(HB/HV) induced immediate 
production and release of PGE2 within the first 15 minutes of 
culture indicating an initial macrophage activation , however this 
production and release decreased steadily over the 24 hr culture 
period whereas the activation caused by the zymosan was potentiated. 
This pattern of events could be explained by : 1) an initial
macrophage activation and release of PGE2 associated with attempted 
phagocytosis of the particles, and 2) followed by an inhibition 
feedback system caused by down-regulation of the stimulation of
Table 4.6. Characteristics of activated macrophages.
Morphological increases in: 
Size
adhesiveness and spreading 






Calcium ion influx 
Glucose oxidation











Intracellular microbicidal activity 
Cytotoxic effects on tumour cells
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PGE2 on macrophage activation resulting in less subsequent release of 
prostaglandin. This has been described by some investigators, 
(Baggiolini, 1985 and Passwell et al., 1979; Elliott et al., 1987). 
Schnyder et al., 1978, 1980 and 1981 suggested that PGE2 may 
counteract other activating agents and the amounts of PGE2 produced 
in response to other activators determine the degree of macrophage 
activation. The down-regulation of activation was less pronounced 
after injection of zymosan particles.
Lactate dehydrogenase production is increased during 
macrophage activation, but LDH is only released when cell lysis 
occurs, (Henson, 1980; Chambers, 1981). LDH measurement was therefore 
used as an indication of the cytotoxicity of the biomaterials and 
their degradation products. In most cases the release of LDH from 
macrophages innoculated with the test samples was no different to the 
LDH measured in the media of control cultures. Significant (p<0.01) 
amounts of LDH were measured after the cultures were treated with HB 
and HV, particularly those treated with HV at lOOmg/ml, indicating 
that the degradation products were cytotoxic at these concentrations. 
This cytotoxicity was comparable to that observed during cell 
culture work with CHO-K1 cells, and was thought to be a function of 
the osmolarity of the injection. The secretion of this enzyme by the 
macrophage indicates cytotoxicity and at the same time may exacerbate 
tissue damage leading to chronic inflammation as generation of 
inflammatory mediators then recruit more inflammatory cells to the 
focus. However, as described in chapter 6, when high concentrations 
of monomer (lOOmg/ml) were injected i.m. into rats no chronic 
inf lamination was seen; this was probably due to the rapid clearance 
of the soluble monomers away from the site of injection, whereas m  
vitro the conditions are stagnant and therefore an artificial measure
of the monomer’s toxicity is obtained.
SEM of cultured normal and polymer /monomer treated macrophage 
cultures revealed that the surface morphology of the latter appeared 
to differ significantly when compared to the former. The 
morphological features of the PHB and monomer treated macrophages 
were characterised by active cellular spreading indicated by the 
extension of long, thin filopodia and in the case of the polymer 
particles a highly ridged/ruffled membrane. It is generally believed 
that increases in the adherence of macrophages as indicated by active 
cellular spreading facilitate phagocytosis (Rabinovitch, 1970; Miller 
and Anderson, 1988). As no particle uptake was observed by light or 
scanning electron microscopy, this appearance of activation could be 
due to attempted or "frustrated" phagocytosis. Attempted 
phagocytosis has been described by a number of workers as a function 
of the size of particle or substrate (Lord, 1986) or the surface 
charge and hydrophobicity of the particulates or substrates, (Jones, 
1975 and Wilkinson, 1974). Pizzoferrato et al. 1987 observed that the 
finer the particle size the greater the amount phagocytosed and 
transported. Surface charge is important in determining the 
acceptability of particles for ingestion. A particle with a strong 
net charge either positive or negative is ingested more avidly than 
an uncharged or weakly charged particle (Hench, 1982). Nishimura et 
al., (1986) looked at macrophage activation with beads prepared from 
deacetylated chitin (a potential biodegradable drug delivery system). 
He postulated that before activation could take place contact with 
the surface of the material has to be made. This contact would occur 
with hydrophillic surfaces but not hydrophobic. As PHB and P(HB-HV) 
are more hydrophobic than zymosan particles , then the surface 
hydrophobicity could therefore partly explain why zymosan 1)
attracted more macrophages to the site of i.p. injection and 2) 
induced greater activation in vitro.
The parallelism between the capacity of various agents to 
induce chronic inflammation in vivo and the selective release of 
lysosomal enzymes and PGE2 of peritoneal macrophages in culture is 
further discussed in chapter 8.
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4.4. Conclusions
1) Injection of PHB particles into the peritoneal cavity of CLFP mice 
resulted in highly significant increases (p<0.001) in macrophage 
accumulation number on days 6-8, which was comparable to injection of 
zymosan (a known macrophage eliciter) over 28 days. P(HB-HV), HB, and 
HV resulted in significant increases (p<0.01) in macrophage 
accumulation number on days 6 and 8, the numbers comparable to 
injection of thioglycollate media (another macrophage eliciter).
2) There appeared to be a dose response to the polymer materials in 
terms of numbers of elicited macrophages.
3) Macrophage activation, as indicated by PGE2 production and release 
appeared to increase significantly (p<0.001) in the first 15 minutes 
of macrophage culture following treatment with PHB, P(HB-HV) and 
their monomers when compared to the control macrophage culture.
4) Macrophage cytotoxicity, as indicated by significant increases 
(p<0.01) in LDH production and release, occurred at high 
concentrations of both monomers (lOOmg/ml). The effect was believed 
to osmotic.
5) Scanning electron microscopy revealed highly ruffled surfaces 
indicative of macrophage activation for polymer treated cultures 
only.
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CHAPTER 5. In vitro plasma protein and platelet interactions with 
PHB and P(HB-HV) in assessment of their blood compatibility.
5.1 Introduction
The performance of a bioraaterial within the cardiovascular system is 
dependent on the manner in which the material interacts with the 
blood. An obvious requirement for such a biomaterial in contact with 
blood is its blood compatibility. Blood compatible materials have 
been broadly defined as those which do not cause thrombosis, 
destruction of the formed elements of the blood, alterations of 
plasma proteins, destruction of enzymes, or depletion of electrolytes 
(Williams, 1986).
For the design of experimental protocols to evaluate the blood 
compatibility of biomaterials, an understanding of the events 
preceeding thrombosis formation is required. Many investigators have 
found that when a foreign surface comes into contact with blood, one 
of the first events which occurs is the adsorption of plasma proteins 
(Baier, 1971,1977; Vroman, 1971; Lyman and Kim, 1971, Lyman, 1974). 
After this very rapid event some conformational and compositional 
rearrangement of the protein layer occurs which may be followed by 
platelet adhesion (Ito et al, 1989; Andrade, 1985; Morrissey, 1977; 
Lyman, 1975). At this stage the platelets may become activated, 
releasing a myriad of raetabolically active products such as ADP and 
platelet factor 4, which cause further adhesion and aggregation of 
platelets, (Wintrobe, 1981; Fass et al., 1978 and Weinstein, 1979). 
Accumulation of platelets can lead to a mural thrombus formation, 
which may be accompanied by fibrin formation following surface 
activation of the coagulation system. A summary of the events 
occuring at the blood-biomaterial interface is given in figure 5.1.
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Instantaneous 
adsorption of some plasma proteins 
water and small ionic components.
I
Time-dependent 
desorption and enzymatic modification 





Adhesion, release, aggregation 
red and white cells.
chiefly red cells 
in fibrin






Figure 5.1. Behavior of synthetic materials in flowing blood.
(Reproduced from Bruck, S.D., Biomater., Med. Dev., Artif. Organs, 6, 341, 1978)
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The character of the adsorbed protein layer has been shown to 
influence the subsequent fate of the biomaterial surface. Almost 
exclusively, fibrinogen and gammaglobulin have been found to enhance 
the adhesion of platelets to the surface (Whicher and Brash, 1978; 
Kim and Lee, 1979) while albumin passivates the surface and retards 
extensive thrombosis, (Young et al., 1982; Ishikawa et al., 1984). 
The blood however does not dictate the whole reaction; the physical, 
chemical and morphological properties of the biomaterial surface play 
an important part in the reaction. The most researched properties of 
the biomaterial surface in this respect are surface charge (Salzman, 
1972 and Nossel et al., 1969) surface tension and wettability of the 
surface (Jayakumari, 1985; Absolom et al, 1987; Steinberg et al, 
1989).
The most common method of investigating blood or blood 
component interactions with biomaterials is in vitro. These 
experiments are often much easier, faster and less expensive to 
perform than in vivo tests. The test parameters are easier to control 
and the results more quantifiable. These advantages have resulted in 
widespread use of in vitro techniques to establish biomaterial blood 
compatibility although a main disadvantage is that the blood is 
usually anticoagulated and not tested under conditions resembling 
clinical situations.
The pivotal role of plasma proteins, in the interaction of 
blood with artificial surfaces, has prompted many investigators to 
devise techniques to measure the adsorption of certain plasma 
proteins to materials. Earlier techniques used to study the kinetics 
of protein-material interactions included circular dichroism 
(McMillan and Walton, 1974), electron microscopy (Valantine, 1959), 
infrared internal reflection microscopy (Brash and Lyman, 1969),
ellipsometry (Vroman, 1964), and in situ radioiodination of adsorbed 
protein followed by electrophoresis (Horbett and Weathersby, 1981). 
In more recent years radiometric methods such as the iodination of
protein have become the methods of choice mainly because of their
high sensitivity; as little as lng of protein adsorbed onto 1cm2 of 
material can be detected (Lee et al., 1974; Chuang et al., 1978).
This chapter reports an assessment of the blood compatibilty 
of PHB and P(HB-HV) using radiolabeled albumin, fibrinogen and
gammaglobulin. Adsorption isotherms have been determined and 
competitive adsorption has been investigated using binary protein 
solutions. The extent of platelet adsorption was also assessed using 
a 51Cr radiometric method. Two primary reference materials (as
defined by the National Heart Lung and Blood Institute) low density 
polyethylene (PEE) and polydimethylsiloxane (PDS), were used to 
provide a comparative index in the determination of the blood 
compatibility of PHB and P(HB-HV). In general PDS tends to be good 
materials for blood-material interaction whereas PEE is recognised to 




All experiments were carried out with labeled protein solutions in 
which the free iodine did not exceed 5%. If free 125I was found to be 
greater than 5% the solution was discarded as free iodine was found 
to preferentially adsorb onto the polymer surfaces thereby 
invalidating the data. The usual value of free 125I ranged between 
2-5%. The percentage efficiency of the radioiodination process ranged 
between 60-70% and the amount of protein recovered from the column 
ranged between 96-98% according to the Lowry assay.
5.2. Preferential adsorption tests.
The results of preferential adsorption of the three radiolabeled 
proteins onto PHB and P(HB-HV) film surfaces are shown in table 5.1. 
At low ratios of labeled protein to unlabeled protein, the amount of 
protein adsorbed onto the polymer surfaces appeared constant for each 
of the three plasma proteins. However at high ratios of labeled to 
unlabeled protein (i.e. >50%) the labeled protein appeared 'to be 
preferentially adsorbed to the polymer surfaces. PEE and PDS were 
also seen to preferentially adsorb the labeled protein at a ratio 
>50% of labeled : unlabeled protein. This suggested that some
conformational change in protein structure had occured during 
radiolabeling, which enabled protein adsorption to occur to a greater 
extent.
5.3. Adsorption isotherms.
Figures 5.2-5.4 represent the adsorption isotherms obtained for 
albumin, fibrinogen and gammaglobulin onto each of the polymer 
surfaces. The data is summarized in table 5.2 where the slopes and
Table 5.1 Preferential adsorption of the radiolabeled proteins to PHB and P(HB-HV.
PHB
Protein % Gammaglobulin Fibrinogen Albumin
1 2 3 1 2 3 1 2 3
1 0.16 0.32 Q.32 0.11 0.16 0.10 0.26 0.22 0.19
5 0.27 0.26 0.18 0.13 0.17 0.11 0.21 0.25 0.25
10 0.24 0.26 0.24 0.16 0.14 0.14 0.24 0.27 0.24
20 0.19 0.58 0.30 0.23 0.18 0.17 0.27 0.30 0.31
50 0.53 0.48 0.37 0.20 0.26 0.25 0.64 0.58 0.55
100 0.92 0.91 1.16 0.36 0.39 0.31 0.84 1.10 0.94
P(HB-HV)
1 0.25 0.29 0.25 0.10 0.15 0.12 0.19 0.16 0.15
5 0.25 0.21 0.31 0.18 0.16 0.16 0.12 0.21 0.18
10 0.22 0.33 0.20 0.12 0.15 0.17 0.17 0.15 0.16
20 0.37 0.36 0.30 0.21 0.13 0.18 0.24 0.21 0.26
50 0.38 0.34 0.36 0.20 0.19 0.16 0.23 0.31 0.27
100 1.20 0.45 1.03 0.22 0.27 0.27 0.59 0.64 0.66
Figures represent amount of labeled protein adsorbed to the each polymer surface in ug/cm2. 
Total concentration of protein in solution in each case is 2mg/ml.





















Figure 5.2. Adsorption isotherm for ^-globulin onto PHB ( •  ), 
P(HB-HV) ( O  ), PDS ( A ) and PEE ( ■ ). The data were obtained from 
films adsorbed for 2 hours at 37°C following thorough rinsing. Each 
point represents the mean of 3 experiments. The s.d. in each case was 




















Figure 5.4. Adsorption isotherm for albumin onto PHB (•), PDS (A) 
PEE ( ■ ) and P(HB-HV) ( V ). The data were obtained from films 
adsorbed for 2 hours at 37°C following thorough rinsing. Each point 





















Figure 5.3. Adsorption isotherm for fibrinogen onto PHB ( •), 
P(HB-HV) ( O  ) i PDS ( A ) and PEE ( ■ ). The data were obtained from 
films adsorbed for 2 hours at 37°C following thorough rinsing. Each 
point represents the mean of 3 experiments. The s.d. in each case was 
< 5% of the mean.
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5.2. Freundlich analysis of the plasma protein adsorption to polymers.
Protein Slope Intercept
~b +b~ ~K
PHB Albumin 0.59 (0.01) -0.16 (0.03)
Fibrinogen 0.25 (0.02) -0.60 (0.02)
globulin 0.68 (0.02) -0.05 (0.01)
P(HB-HV) Albumin 0.73 (0.03) -0.03 (0.01)
Fibrinogen 0.53 (0.01) -0.12 (0.02)
globulin 0.68 (0.01) -0.06 (0.02)
PEE Albumin 0.68 (0.02) -0.25 (0.05)
Fibrinogen 0.29 (0.02) -0.43 (0.13)
globulin 0.70 (0.04) -0.06 (0.03)
PDS Albumin 0.69 (0.01) -0.10 (0.01)
Fibrinogen 0.29 (0.01) -0.46 (0.07)
globulin 0.67 (0.03) -0.06 (0.01)
n = 3
Analysis of the isotherms was done according to the Freundlich isotherm: 
log A = b log C + K, where A is the adsorption (ug/cm2) and C is the 
bulk protein concentration (mg/ml), b and K are the slope and the 
intercept of the line through the log A vs log C data.
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intercepts for the regression lines which best fit the data are 
documented. Each adsorption isotherm showed that the protein 
adsorption was characteristic of a Freundlich plot over the 
concentration range studied. No saturation of protein adsorption was 
seen at high concentrations, and therefore the adsorption profile was 
unlike a Langmuir adsorption isotherm. However it is possible that at 
very high protein concentrations saturation would have been reached, 
langmuir analysis may then have been appropriate.
Analysis of the Freundlich isotherm can be used to measure the 
strength or affinity of the adsorbate for the surface by calculation 
of the slope. Comparison of the slope values allow one to speculate 
which protein is most likely to be adsorbed when the polymer is 
exposed to whole blood or plasma. The results of the adsorption 
isotherm show that the rank order of affinities of the three proteins 
for each polymer is as follows;
PHB: gammaglobulin > albumin >> fibrinogen 
P(HB-HV): albumin = gammaglobulin > fibrinogen 
PEE: albumin = gammaglobulin >> fibrinogen 
PDS: albumin > gammaglobulin >> fibrinogen
5.4. Competitive adsorption.
Figures 5.5-5.7 show representative competition curves for various 
competing protein pairs. The concentration of unlabeled protein (I) 
which caused a reduction to 50% of maximal labeled protein (II) 
adsorption provides a convenient summary of the entire set of data. 
It is at this concentration that the two proteins compete equally for 
the adsorption sites, therefore if the two proteins were equally 


































10*3 10*2 10*1 10° 101 102 weight/weight
Fibrinogen / Albumin 
Figure 5.5. Competitive adsorption of plasma 
proteins to P(HB-HV). The percent of maximum 
adsorption of 125I-fibrinogen in the presence of 
decreasing amounts of albumin is plotted. The 
ratio of fibrinogen/albumin at which 50% maximal 
adsorption of labelled protein occurs is derived 
from this plot, (a) and (b) represent the 
results presented on Table 5.3,of experiments 2 
and 3, respectively. Each point represents the 






























10-3 10-2 10-1 10° 101 102 weight/weight
""/-globulin / Albumin
Figure 5.6. Competitive adsorption of plasma proteins onto P(HB-HV). The 
percent of maximum adsorption of 125j_ J -globulin in the presence of 
decreasing amounts of albumin is plotted. The ratio of J-gJobulin/albumin 
at which 50% maximum adsorption of label l**d protein occurs is derived 
from this plot, (a) and (b) represent the results presented on Table 5 3 
of experiments 1 and 2, respectively. Kach r>oint represents the mean of 






































10*3 10-2 10'1 10° 101 102 weigh t/weight
^/-globulin / Albumin
Figure 5.7. Competitive adsorption of plasma 
proteins onto PHB. The percent of maximum 
adsorption of 125I-J -globulin in the presence of 
decreasing amounts of albumin is plotted. The 
ratio of J-globulin/albumin at which 50% of 
maximum adsorption occurs is derived from this 
plot, (a) and (b) represent the results presented 
on Table5.3.of experiments 2 and 3, respectively. 
Each point represents the mean of 3 experiments. 



























10-3 10"2 10-1 10° 101 102 weight/weight
Fibrinogen / Albumin
10"3 10"2 10-1 10° 101 102 weight/weight
Fibrinogen / Albumin
Figure 5.8. Competitive adsorption of plasma 
proteins onto PHB. The percent of maximum
adsorption of 125I-fibrinogen in the presence of 
decreasing amounts of albumin is plotted. The 
ratio of fibrinogen/albumin at which 50% maximal 
adsorption of labelled protein occurs is derived
from this plot, (a) and (b) represent the results
presented on Table5.3of experiments 1 and 2,
respectively. Each point represents the mean of 3 
experiments. The s.d. in each case was < 5% of 
the mean.
Polymer Experiment no. BF : BSA BG : BSA BG : BF
PHB 1 5 : 95 60 : 40 48 I 52
2 3 : 97 50 : 50 40 : 60
3 8 : 92 35 ; 65 38 j 62
P(IIB-HV) 1 75 : 25 5 : 95 36 : 64
2 80 ; 20 10 : 90 30 : 70
3 60 ; 40 20 ; 80 35 • 65
PEE 1 10 : 90 70 : 30 95 ; 5
2 15 : 85 65 : 35 97 : 3
3 10 i 90 75 i 25 95 j 5
PDS 1 10 : 90 60 : 40 90 : 10
2 15 : 85 50 : 50 95 : 5
3 7 : 93 45 : 55 92 * 8
Table 5.3 The ratio of labeled protein : unlabeled protein at which a reduction to 50% maximal 
adsorption of labeled protein occured in binary competitive adsorption experiments.
BF = bovine plasma fibrinogen 
BSA = bovine serum albumin 
BG = bovine gamma globulin
occur at equal concentrations of the two proteins. If the 50% 
reduction point is reached at a lower concentration of the competing 
protein (I) than the labeled protein (II), the competing protein is 
considered to have a greater affinity for the polymer surface than 
the labeled protein.
The information obtained from the competition curves for each 
polymer is summarised in table 5.3. The concentration ratio of 
labeled (II) to nonlabeled protein (I) which causes a 50% reduction 
of maximal labeled protein (II) adsorption is stated. Fibrinogen 
adsorption to PHB surfaces was reduced to 50% of maxiraumal adsorption 
by albumin at a protein ratio of fibrinogen to albumin 5 : 95, this 
implied that affinity of fibrinogen for PHB was 19 times greater than 
that of albumin. Gammaglobulin adsorption was reduced to 50% of its 
maximum by albumin at a mass ratio 48 : 52, which indicated that the 
affinities of gammaglobulin and albumin to PHB were approximately 
equal. Similarly gammaglobulin adsorption was reduced to 50% of its 
maximum by equal concentrations of fibrinogen. This competitive 
adsorption data for PHB indicated that fibrinogen equally adsorbs 
gammaglobulin when in competition with each other. The extent of 
protein adsorption as determined by the adsorption isotherms 
determines which plasma protein will be preferentially adsorbed and 
therefore whether PHB is likely to be thrombogenic. P(HB-HV) 
adsorbed 2.57 times more albumin than fibrinogen, 7.3 times more 
gammaglobulin than albumin and 1.94 times more gammaglobulin than 
fibrinogen. The competitive adsorption profile for P(HB-HV) was 
therefore, gammaglobulin > albumin > fibrinogen.
The primary reference material PEE adsorbed 7.3 times more 
fibrinogen than albumin, 2.33 times more albumin than gammaglobulin 
and 24 times more fibrinogen than gammaglobulin, therefore is
adsorption sequence is likely to be fibrinogen > albumin > 
gammaglobulin. PDS however adsorbed at equal concentrations of 
gammaglobulin and albumin, but 7.4 times and 11.5 times more 
fibrinogen than albumin or gammaglobulin respectively.
5.4. Platelet adsorption:
The kinetic adhesion of platelets to the four biomaterial surfaces 
is shown in figure 5.8. For all polymers maximum platelet adhesion 
occured within 10 minutes and thereafter a plateau effect was seen.
Table 5.4 illustrates the number of platelets which adsorbed from PRP 
onto untreated polymer surfaces and surfaces coated with a single 
plasma protein. As expected coating polymers with albumin prior to 
the adhesion experiments brought about a reduction in the number of 
platelets that adhered to the surface. PHB coated with fibrinogen did 
not incur an increase in the number of adsorbed platelets when 
compared to the uncoated polymer surface. However when PHB was 
coated with gammaglobulin a greater number of platelets adhered to 
its surface.
Platelet adhesion to PEE and P(HB-HV) was unaffected by 
coating with gammaglobulin or fibrinogen. PDS however did show an 
increase in platelet adhesion when coated with fibrinogen, although 
coating with gammaglobulin appeared to have no effect. Platelet 
adsorption to P(HB-HV) was considerably greater than to other 
polymers both in untreated polymer and protein-coated polymer 




















Figure 5.9. Platelet adhesion rate onto P(HD-HV) (O), PHB (•), PDS (▲) 
and PEE <■). Incubations were carried out at. 37°(' and the degree of 
adhesion assessed by J-counting. Each |>oint represents the mean of 9
experiments. The s.d. in each case was < 5% of the mean. —
CJO
cn
Table 5.4 : Adhesion of platelets from PRP onto single protein coated or uncoated polymers surfaces.
Polymer No. of adhered platelets/104um2 mean (S.D)
Uncoated BSA BG BF
FHB 148.9 (22.0) 160.3 (16.6) 434.5 (114.7) 155.6 (25.5)
192.2 (32.5) 197.8 (45.8) 270.9 (68.8) 207.3 (34.7)




























PDS 320.5 (16.9) 











n = 9 in each of the three separate experiments.




Investigations into the thrombogenicity of biomaterials have shown 
that the composition of the surface protein layer adsorbed onto 
biomaterials, will greatly affect its thrombogenic character (Young 
et al., 1982). This adsorbed protein layer will affect the adherence 
of platelets and their subsequent activation (Adams and Feuerstein, 
1981; Young et al., 1982). Much research has been directed towards 
establising the pattern of adsorption of three plasma proteins, 
albumin, gammaglobulin and fibrinogen and their modification of 
surface properties and therefore their subsequent influence on cell 
surface interactions. In more recent years trace plasma proteins, 
such as fibronectin and von Willebrand factor, in addition to the 
main plasma proteins have been studied to establish their role in 
thrombogenicity (Vroman et al., 1980 and Kochwa et al., 1977). It is 
generally accepted that on natural surfaces, plasma proteins remain 
in their natural state and are reversibly adsorbed (Iorclanskii and 
Zaikov, 1983). Conversely, plasma proteins which adsorb and 
accumulate onto polymer surfaces may exhibit changes in their 
conformation and orientation, and subsequent thrombotic events such 
as platelet adhesion may be influenced greatly by the nature of this 
protein layer (Morrisey, 1977; Packman, 1969 and Baier, 1977).
An important consideration in such studies is the effect of 
radiolabeling the protein on its affinity for a polymer surface. In 
this study the results of preferential adsorption studies indicated 
that denaturation of labeled protein had an effect on adsorption at 
high mole ratios of labeled protein. This supports the findings of 
Grant et al. (1977). However, Bomzin and Miller, (1982) found that 
the measured adsorption of albumin and fibrinogen on two different
surfaces was independent of the mole fraction of labeled protein, 
indicating no effect of radiolabel ing.
Adsorption isotherm data suggested that P(HB-HV) had a 
significantly greater (p<0.01) affinity for fibrinogen proteins when 
compared to the primary reference materials and its homopolymer and a 
significantly greater (p<0.01) amount of the protein was adsorbed to 
its surface at any one concentration when compared to the other 
polymers. PHB, P(HB-HV), PEE and PDS had equal affinity for 
gammaglobulin. All polymers as indicated by the slope value appeared 
to have similar affinities for albumin, again P(HB-HV) adsorbing 
significantly more (p<0.01) when compared to the other polymers over 
the concentration range used. . Protein adsorption affinities for 
each of the polymer surfaces can be summarised as gammaglobulin = 
albumin > fibrinogen as indicated by the slope values for each 
polymer surface. The affinity of the polymer surfaces for 
gammaglobulin implied that all polymers could be potentially 
thrombogenic. However, McCoy et al., (1989) reported that PEE and 
PDS were relatively benign in their interaction with blood an^ could 
be assumed nonthrombogenic. The degree of thrombogenicity must 
therefore be determined by factors other than the adsorption
affinity from the single protein solutions.
Hanson et al., (1986) suggested that it was the amount of 
plasma protein irreversibly adsorbed to the polymer surface, and its 
competition with other plasma proteins which determined the pattern 
of plasma protein adsorption and therefore subsequent adhesion and 
activation of platelets.
The competition adsorption data for the polymers from binary 
protein solutions show the two primary reference materials adsorbed 
in the pattern of fibrinogen > albumin > gammaglobulin, and as seen
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from the adsorption isotherm data the amount adsorbed in terms of 
concentration was greatest for fibrinogen > albumin > gammaglobulin. 
These results indicate that platelets are likely to adsorb to the 
polymer-protein surfaces when in contact with whole blood, but the 
extent of which can only be determined by platelet adhesion 
experiments. PHB appeared to adsorb gammaglobulin and albumin to the 
same extent when in competition in a binary solution. Gammaglobulin 
was adsorbed to a slightly greater, but insignificant (p>0.05), 
extent when in competition with fibrinogen in binary solution. 
However fibrinogen was significantly adsorbed (P<0.01) to PHB when in 
competition with albumin. These results suggest that when all three 
plasma proteins are in solution then gammaglobulin and fibrinogen 
would preferentially adsorb. P(HB-HV) competitively adsorbed the 
proteins in the order gammaglobulin > fibrinogen > albumin. The 
overall plasma protein adsorption profile indicates that platelets 
are likely to adhere to all polymer surfaces when in contact with 
blood but the extent of which can only be determined by platelet 
adhesion experiments
It is agreed by most investigators in the field of blood 
compatibilty that adsorbed fibrinogen and gammaglobulin facilitate 
and enhance platelet adsorption, whereas albumin behaves as a 
passivating agent (Kim et al. , 1977 and Mosher, 1981). This can be
explained by the following platelet adhesion mechanism: following
protein adsorption platelets approach the proteinated surface and 
react with glycoprotein receptors to form a complex which is 
catalysed by a glycosyl transferase enzyme (Bosmann, 1971,1972 and 
Lee et al., 1974, 1979). The stabilty of the complex determines the
strength and duration of the reaction and therefore the formation of 
a thrombus. Only fibrinogen and gammaglobulins contain these
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glycoprotein receptors and are therefore capable of forming a 
platelet protein complex. Albumin does not contain any glycoprotein 
receptors and therefore does not have the capacity to form such 
complexes, which may be the reason for its nonthrombogenicity.
The results of the platelet adhesion experiments onto protein 
coated polymers agreed with the above hypothesis in that all polymers 
precoated with albumin decreased the number of platelets adhering to 
the polymer surface. However fibrinogen and gammaglobulin coated 
polymer surfaces appeared to adsorb platelets to the same extent as 
the noncoated polymer (p>0.05), except for gammaglobulin coated PHB 
surface when adsorption was significantly greater (p<0.01) than that 
for the uncoated polymer. The adsorption of platelets therefore also 
appears to be due to a surface property of the polymer. Platelet 
adhesion to coated or uncoated P(HB-HV) was greater (p<0.01) than 
adhesion to all other polymers. Whereas uncoated and albumin or 
fibrinogen coated PHB adhered the least number of platelets when 
compared to the other polymers. Where gammaglobulin coated PHB showed 
an increase in platelet adherence numbers this was comparable to the 
uncoated primary reference materials, indicating good blood
compatibility of this polymer.
In summary, the results of both plasma protein and platelet 
adsorption to the polymer surfaces in vitro, gave a thrombogenicity 
index of P(HB-HV) > PEE > PDS > PHB. The relation of PEE to PDS in 
this index agreed with other research carried out on these reference 
materials (Neumann et al., 1980, 1983; Lelah et al., 1983; Mason et
al., 1983 and Pelzer and Heimberger., 1986). McCoy et al., (1989)
also showed PDS to be less thrombogenic than PEE in vitro and ex 
vivo, however PDS in long term experimentation adhered a greater 
number of platelets and therfore the formation of a mural thrombus
increased. Hanson et al,, (1980) showed little difference in the
blood compatibility of the two primary reference materials and 
therefore both were pronounced blood compatible. However, Lelah et 
al,, (1983) and Mohammed et al,, (1976) showed significant platelet 
reactivity and adsorption on PEE. Contradictory literature reports 
emphasises the need for other primary reference materials to be used 
in blood compatibility assessment so that interlaboratory comparisons 
and compatibility index can be made. The similarity in surface 
properties and blood compatibility of these reference materials and 
their commercial counterparts indicates the need for less
thromboresistant as well as more polar reference materials. However, 
as many extracorporeal devices and pumps are made from PDS (Silastic) 
tubing (Neumann et alt 1983; Lelah et al, 1983) any material with a 
lower thrombogenicity index to this material can be considered to 
have good blood compatibility.
The question arises, why do certain polymer surfaces 
preferentially adsorb albumin and are therefore nonthrombogenic while 
others adsorb fibrinogen or gammaglobulin „ and are potentially 
thrombogenic. Many investigators believe that surface hydrophobicity/ 
hydrophillicity plays an important part in plasma protein adsorption 
and subsequent platelet adherence. Lyman et al (1965) established a 
relationship between surface free energy of uncharged, hydrophobic 
polymers and coagulation time of the plasma or blood in contact with 
them. The more hydrophobic the polymer the less thrombogenic it 
appeared. Therefore in theory a prediction of the thrombogenicity of 
a material could be predicted by its surface wettability i.e. 
hydrophobicity (Absolom et al, 1987; Steinberg et al, 1989). The 
greater the value of contact angle the greater the hydrophobicity of 
the material.
Table 5.5 lists contact angle data for P(HB-HV) and PHB, and 
the primary reference materials. The data showed that the sequence of 
hydrophobicity of these polymers was:
PDS > PEE > PHB > P(HB-HV)
Of the polymers studied, P(HB-HV) had the lowest contact angle and 
therefore appeared to be the most hydrophilic material studied.
Hydrophilicity has been reported to equate with potential
thrombogenicity, (Baier, 1984) this was borne out in the experiments 
where high fibrinogen and gammaglobulin adsorption and the greatest 
platelet adhesion occured to P(HB-HV). The fact that the uncoated 
polymer surface adhered platelets equally as well as the surfaces 
coated with gammaglobulin and fibrinogen suggested a different 
mechanism of adherence was involved. A second hypothesis for control 
of platelet adhesion has been reviewed by Neumann et al, (1983). The 
minimum interfacial free energy theory states that as interfacial 
free energy (solid/water) approaches zero, the driving force for 
protein and platelet adsorption decreases (Coleman et al, 1982). 
Surfaces with low interfacial free energy are said to be hydrophobic 
and those with high interfacial energy are hydrophilic. This theory 
reasons that hydrophobic surfaces present less driving force for 
spreading and attachment. In agreement with this, surfaces with lower 
interfacial free energy adsorb fewer platelets than the more 
hydrophilic surfaces (Lindsay et al, 1980; Neumann et al, 1978,1980.)
Brash (1969) reported that the most important general binding 
mechanism of protein to polymer surface, is that of hydrophobic 
interaction, i.e. the interaction of nonpolar groups in aqueous 
media. Proteins are known to contain hydrophobic domains in their 
surface which would be available to interact with hydrophobic 
contacting surfaces, typified by PDS, PEE and PHB. The degree to
Table 5.5.  Contact angle . data for polymers: ' Air/water from sessile drop measurement.
Surface Cpntac t I j Ref.
PRM-SR 90 McCoy et. al (1989)
PRM-PE H9 McCoy et al (1989)
Silastic SR 80 McCoy et. a.l (1989)
Intramedic PIC 93 McCoy et a I (1989)
PHB (380K) 85 (smooth) 83 (rough) Akhtar (1989)
P(HB-HV) 12.6% mole hv 67 (smooth) 71 (rough) Akhtar (1989)
Mw 76OK
which any particular protein is adsorbed to the polymer surface 
depends on whether the surface is hydrophilic or hydrophobic, charged 
or neutral and polar or apolar. Plasma proteins in general have been 
reported to have a greater affinity for hydrophobic surfaces than 
hydrophilic surfaces (Neumann et al., 1983). Albumin is a protein 
which has hydrophobic domains used for transporting low molecular 
weight molecules in the blood; adsorbing albumin to the surface could 
expose the hydrophobic domains and would therefore increase the 
hydrophobicity of the surface. Since highly hydrophobic domains are 
thought to be blood compatible, an explanation of the protective 
effect of albumin coating may be due to exposure of its hydrophobic 
domains (Kotte-Marchant et al. , 1989). Pre-coating of polymer
surfaces with albumin has been used to improve the blood 
compatibility of many prosthetic devices. Other methods to improve 
the blood compatibilty of polymers include heparinisation (Chokalis 
and Sefton, 1989). However, contradictory evidence in the use of 
albumin pre-coating or heparinisation (Wilson, 1981; Ito et al, 1986) 
has lead investigators to elaborate on the mechanisms of blood 
compatibility and therefore work on other methods to achieve better 
blood compatibility of polymers.
To date no synthetic material has been found to be entirely 
passive to blood. In 1978 Mansfield and Wechezak and Burkel et al 
(1978) lined both synthetic and natural materials with cultured 
epithelial cells in an attempt to produce a nonthrobogenic blood 
compatible surface, however difficulty arose in developing a 
continous lining and the great length of time required to prepare the 
prosthesis. Over the past 25 years, much research has been directed 
towards finding biomaterials for use as blood contacting surfaces in 
cardiovascular devices, heart valves, large diameter vascular grafts
and in equipment for blood storage and in devices used in renal 
dialysis. Biodegradable materials are among newer concepts emerging 
in the development of biocompatible small caliber vascular 
prostheses, in that they could function as scaffolds for the 
regeneration of an intimised wall. Bowald et al., (1980) studied the 
implantation of a double layer of absorbable polyglactin 910 mesh 
tubes in the descending aorta of young pigs, and found that within 
40-60 days this had become completely replaced by a new endothelium. 
Lauritzen (1983) used polyglycolic acid as an absorbable vascular 
prosthesis in the femoral arteries and veins of rats. Four months 
after implantation 50% of the veins became patent, the polyglycolic 
acid hardly detectable after 4 weeks. Lei et al., (1985 and 1986) 
tested microporous compliant biodegradable vascular grafts prepared 
from mixtures of poly lactic acid and polyurethane in the abdominal 
aorta of rats. The in vitro studies on plasma protein and platelet 
adsorption to the biodegradable polymers PHB and P(HB-HV), has shown 
that PHB exhibits many characteristics indicative of a 
thromboresistant material. As PHB is also biodegradable there is 
great potential in the use of this material in vascular grafts.
5.4. Conclusions,
1) There was preferential adsorption of radiolabeled protein at 
high labeled :unlabeled protein ratios to both polymer surfaces, 
indicating that some conformational change in protein structure had 
occurred during radiolabeling which enabled protein adsorption to 
occur to a greater extent.
2) Adsorption of plasma proteins from single protein solutions was 
characteristically of the Freundlich isotherm.
3) Competitive adsorption of proteins in binary solution showed 
that the primary reference materials adsorbed in the pattern,
fibrinogen> albumin> globulin; PHB adsorbed proteins in the pattern, 
globulin= albumin> fibrinogen; P(HB-HV) adsorbed in the4 pattern
globulin > fibrinogen >albumin.
4) P(HB-HV) adsorbed the greatest number of platelets, but PHB 
adsorbed platelets to the same extent as the primary reference
materials.
*
5) Fibrinogen coated polymer surfaces adsorbed a greater number of 
platelets than the uncoated surface.
6) PHB, PEE and PDS have the potential of good blood
compatibility, whereas P(HB-HV) showed signs of poor blood 
compatibility.
CHAPTER 6. In vivo biocompatibility studies. Assessment of the soft
tissue inflammatory response.
6.1 Introduction
Many techniques employed for the evaluation of biomaterials cover an
assessment of the inflammatory reaction caused by the materials
(Callis et al. , 1988; Marion et al., 1980). The stimulus necessary to
initiate an inflammatory response can vary greatly, but it is the
continued presence or absence of the stimulus that dictates the
inflammatory response. Attempts to neutralise or eliminate the
inflammatory stimuli either by macrophage uptake or formation of a
fibrous capsule around the stimuli can lead to eventual problems with
the implanted material such as formation of necrotic lesions or
tissue reaction (Coleman et al., 1974).
Surgery involved in implantation or even simple injection may
induce the initial reactions which include a series of interdependent
events that begin with haemodynamic changes, (Joon Du Park, 1984)
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followed by alterations in the vascular permeability (Wilhem, 1977). 
The increased permeability of the adjacent vasculature promotes the 
transport of protein rich inflammatory fluid or exudate into the 
extravascular tissues and wound site (Meachim and Pedley, 1981). 
Simultaneously circulating leucocytes interact with the stimulatory 
factors, adhere to the blood vessels endothelia and pass through the 
vessel wall and into the vascular tissue around the implant.
The intensity and duration of the response is controlled by a 
variety of mediators, including histamine and prostaglandins, and 
determined by the size and nature of the implanted material (Rigdon, 
1974; Stokes and Cobian, 1982; Turner et al., 1973; Meachim et al., 
1982). The dynamic variation of the components of the inflammatory
and healing responses determine the biocompatibility of the material. 
A brief cellular response of low intensity is indicative of tissue 
compatibility (Marchant and Anderson, 1986). Interactions at the 
polymer interface is important particularly in relation to cellular 
function and organisation. The majority of studies on the effects of 
polymer implants on cellular organisation and function have been 
based on histological observations and morphological evaluations
(Clarke et al., 1974; Thomsen and Ericson, 1985; Williams and
Blayney, 1987; Tamargo et al. , 1989). Using these techniques
information on the post implantation changes occurring within 
specific cell populations can be gained, but little is gained
regarding changes in cell function.
The acute phase of inflammation is characterised by the 
preferential migration of PMN’s (the neutrophil), peak migration 
occurring within the first 72 hrs following injury (Dickinson and 
Hiltner, 1981). Macrophages and lymphocytes predominate at later 
stages of the inflammatory process (Salthouse et al., 1973,1975). The 
cellular response evoked by implantation of a foreign object is
accompanied by a variety of enzyme patterns. These are characteristic 
and indicative of the functional capacity of these cell populations 
adjacent to the implants and can therefore be used as markers in 
assessment of the inflammatory response and also the biocompatibility 
of implanted material. An enzyme histochemical approach .to the 
assessment of biomaterial’s tissue compatibility, founded by 
Salthouse and coworkers (1972, 1973 and 1976), is now an established 
technique.
The most important enzymes associated with the PMN’s and 
macrophages of the inflammatory response are the lysosomal 
hydrolases, alkaline and acid phosphatase respectively. Alkaline
phosphatase is usually only observed at the implant site from 1-7 
days in association with the PMN’s. This enzyme is located in the 
specific granule of the PMNs and its release is through exocytosis 
resulting from activation (Salthouse and Williams, 1969). The level 
of activity of this enzyme will indicate the severity of the initial 
acute inflammatory response induced at the implant site by the 
implanted material. Acid phosphatase is the most prevalent hydrolase 
resulting from the presence of macrophages at implant sites. In 
general, but depending on the implant material, reactivity is 
noticeable at 4 days and reaches a maximum at ~14 days, activity then 
declines until fibrosis at the site is complete. With highly 
irritating polymer implants acid phosphatase activity is very greatly 
increased (Black, 1981). Thus acid phosphatase is particularly useful 
as an indicator of macrophage phagocytic activity at the site of 
implantation, the significance of which was discussed in chapter 4.
Raekallio (1970) showed the value of enzyme histochemistry for 
the assessment of biocompatibility of polymeric materials in wound 
healing studies and Salthouse and Williams (1969) used similar 
techniques to evaluate the tissue reaction to surgical sutures. Since 
then the use of enzyme histochemistry has continued to be used as an 
indicator of biocompatibility by a number of scientists (Salthouse 
and Willigan, 1972; Marchant et al., 1983, 1984, 1987; Spilizewski et 
al., 1987).
In this study three methods were used to assess the in vivo 
soft tissue inflammatory response of the rat to PHB, P(HB-HV) and 
their degradation products:
1) Histological studies to allow an overall assessment of the tissue 
reaction,
2) Changes in vascular permeability.
3) Changes in enzyme activity.
6.2. Results♦
The uninjected, dry microspheres prepared as described in appendix 1, 
appeared uniformly spherical in shape when examined using light 
microscopy. When examined using scanning electron microscopy smaller 
particles were found adhering to the surface of each microsphere so 
that their surfaces appeared rough. The average diameter of the 
microspheres was 40 urn. These were injected into the hind thigh of 
male Wistar rats and left 1-40 days when the muscle was examined.
6.2.1. Macroscopic observations.
Macroscopically, the injection sites of PHB and P(HB-HV) microspheres 
appeared as pockets of microspheres between muscle fibres at the 
proximal area of injection. There was a localised slight reddening in 
the muscle tissue surrounding these injection sites. No dependence on 
time of implantation could be observed by visual inspection. The 
injection sites following injection of the monomers also showed 
slight reddening in the muscle tissue, no suppuration or necrosis was 
evident.
Film implants were prepared as described in appendix 1 and 
inserted into rat thigh for 1-40 days. On inspection of the film 
implant sites for PHB and P(HB-HV), a mild acute inflammatory 
response characterized by reddening and oedema was seen during the 
first 10 days. At day 40 both films were encapsulated by a thin 
fibrous capsule, unaccompanied by chronic inflammation or necrosis. 
On removal of the capsule the films were seen to remain intact. The 
PMMA film evoked a similar response, however the fibrous capsule 
around PMMA film appeared to be of greater density and thickness.
6.2.2. Histological observations.
The sites of sham injections and vehicle injections (1%
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methylcellulose in 0.9% saline) appeared to be "normal" 
histologically (see figs G.l and 6.2 respectively), i.e. cellular 
organisation proximal to the injection site did not differ to the 
cellular organisation seen in normal muscle tissue of the rat. On 
examination of the tissue proximal to the injection site of PHB 
microspheres, after 7 days a majority of normal cells with a few 
round cells and giant cells were evident, which were still apparent 
after 14 days (see figs 6.3 and 6.4 respectively). The site of 
monomer HB (lOOmg/ml) injection, after 7 and 14 days, appeared normal 
histologically.
Seven days following the injection of P(HB-HV) microspheres 
severe inflammation was evident as characterised by muscle fibrosis 
and abcess formation (see fig. 6.5). After 14 days this inflammatory 
response had resolved and was characterized by the presence of 
"foamy" cells and giant cells, (see fig. 6.6). The corresponding 
monomer HV (lOOmg/ml) 7 days after injection indicated a minor 
inflammatory response as shown by infiltration of a few PMN1s into 
the injection site (see figure 6.7). 14 days after HV injection the 
tissue appeared histologically normal. The positive control, PAA, at 
both 7 and 14 days following its injection, showed a vast number of 
round cells in the viscinitv of the injection site (see figures 6.8 
and 6.9).
The above results indicated a different response to injection 
of PHB and P(HB-HY) microspheres. The histological examination of 
P(HB-HV) injection into rat muscle tissue was therefore repeated 
using 3 separate batches of injection on different occassions. In 
each case the histologist performed the assessment without knowledge 
of the identity of the formulation. The results were the same for 
each batch of P(HB-HV); this polymer therefore appeared to evoke a
Table_6_.„1 _Histological examination of tissue after intramuscular in.iection of test materials.
 ^ —  7 days-------------- £--------------- 14 days- — -------------------------- ^
PMN’s Macrophages FBGC Muscle Necrosis PMN’s Macrophages FBGC Muscle Necrosis
Fibrosis Fibrosis
PHB 10 - + ++ - - - ++ ++ - -
100 - + ++ - - - ++ ++ - -
P (HB-HV1 10 - ++ ++ + + - + ++ _ _
100 - ++ ++ +++ +++ - + +++ - -
HB 10 + + - - — - + — _ —
100 + + - - - - + - - -
HV 10 + ++ - - - - + - - -
100 + ++ - - - - + - - -
PAA 100 - ++ +++_ + + - + + - -
Zymosan 100 
j.ig/ml
+ +++ ++ + ++ - +++ + + ++
Vehicle + + — — — — + — - -
Sham + + _ _ _ _ + _ _ _
+++ severe response 
++ moderate 
+ mild
Vehicle = 1% methylcellulose in 0.9% saline.
Observations are made on histological sections taken from 4 rats with each treatment.
Polymer
mg/m]
more severe inflammatory response than PHB. The results of the 
histology assessment are summarized in table 6.1.
6.2.3. Effect on vascular permeability
Changes in vascular permeability were assessed by the extent of 
extravasation of Evans Blue in the vicinity of the site of injection. 
The dye was assayed by spectrophotometry at 612nm. Table 6.2 shows 
the amount of Evans Blue recovered from the injection site after 
administration of various agents. Irritants (HC1 and NaOH) produced 
highly significant increases (p<0.001) in the vascular permeability 
when compared to changes produced by injection of the control vehicle 
(1% methylcellulose in 0.9% saline). However intradermal injection of 
5HT and histamine, known mediators of the inflammatory response, did 
not significantly increase the vascular permeability. Zymosan 
(lOOul/ml) also resulted in highly significant increases (p<0.001) in 
vascular permeability, but PHB and P(HB-HV) caused no significant 
changes in vascular permeabilty over a 4 hour period. Both monomers, 
HB and HV, resulted in significant increases (p<0.01) in vascular 
permeabilty at lOmg/ml and lOOmg/ml, however sucrose injection 
(500mg/ml) also significantly increased vascular permeability 
suggesting that osmotic effects were responsible. The effect of sham 
injections on the vascular permeability was lower than all other 
injections including vehicle injection suggesting that injection of 
0.1ml vehicle has an effect and invokes its own inflammatory 
response.
Table 6.2 Degree of extravasation as a consequence of intradermal administration of various mediators.
Evans Blue (ug) recovered in the skin after i.d. injection (0.1ml)
Hrs after injection 
2 4
Mediator (M; pH )
NaOH (0.1M; 12.84) ** 74.20 (2.06) ** 79.10 (7.21)
HC1 (1.OM; 0.45 ) 96.90 (2.89) ** 74.00 (5.33)
Histamine (lmM ; 9.37 ) 31 .40 (16.22) 14.80 (4.21)
5-HT (O.lmM; 6.32) .13.60 (4.95) 14.00 (2.89)
HB (lOmg/ml; 7.G1) 26.40 (4.23) * 35.40 (4.95)
HB (lOOmg/ml; 7.82) 40.60 (9.26) * 38.80 (2.81)
HV (lOmg/ml; 7.24) 36.30 (4.95) * 24.00 (2.89)
HV (100mg/ml;7.18) ** 61 .10 (4.38) * 41.50 (7.21)
PHB (20mg/ml; 7.26) 9.10 (4.57) 10.40 (1.20)
PHB/HV (20mg/ml; 7.30) 13.00 (1.00) 12.20 (4.95)
Polymer vehicle (7.36) 11.80 (1.59) 12.20 (1.94)
Sucrose (500mg/ml; 7.46) 14.60 (1.59) 12.30 (2.81)
Zymosan (lOOug/ml 7.35) ** 89.63 (6.60) * 85.11 (3.55)
Sham 5.84 (2.58) 5.12 (1.75)
Polymer vehicle = 1% methylcellulose in 0.9% NaCl
Sham = penetration of tissue with needle without injection of fluid 
Figures represent the mean (s.d.) of three experiments
^^Statistically different at the 99.9% confidence level (p<0.001) compared to the vehicle control.
^Statistically different at the 99% confidence level (p< 0.01) compared to the vehicle control. 
Students t test for unpaired samples.
6.2.4. Effect on alkaline and acid phosphatase enzyme activity. 
Alkaline and acid phosphatase enzyme levels in untreated tissue was 
highly varied (p<0.01) between groups of rats. Within groups of rats 
the enzyme activities in untreated tissue did not vary. In PHB and 
P(HB-HV) treated tissue the enzyme activities appeared to 
significantly differ between groups. This was thought to be due to
the actual injection technique of different animal technichans. Thus
absolute enzyme levels were difficult to compare between experiments 
and are best compared to the vehicle controls and untreated tissues 
within each experiment and the mean value was used as the basis of 
comparison for the test.
Effect on tissue alkaline phosphatase activity.
The activities of tissue alkaline phosphatase after intramuscular 
injection of the polymers, monomers, the injection vehicle and the 
sham controls are given in table 6.3 and then presented in table 6.4 
as the mean percentage change in enzyme activity when compared to the 
injection vehicle enzyme activity at any one time after injection.
The test was sensitive even to the sham injection i.e. when no 
material ‘ was injected. However the enzyme activities due to 
penetration of muscle with the needle were not significantly higher
than the levels in untreated muscle on any day due to the large
standard deviation within both groups. Injection of vehicle caused a 
larger but not significant response with respect to sham injected
tissue throughout the 1.0 days and at day 40 there was no difference
in enzyme activities between vehicle injected tissue, sham injected
tissue or untreated tissue.
Following the injection of the positive control, zymosan 
(lOOjil/ml), into the muscle tissue, highly significant increases 
(p<0.001) in the alkaline phosphatase activity throughout the 10 day
Table 6.3 Tissue alkaline phosphatase activities following intramuscular injection with test materials.
Alkaline phosphatase activity in IU mean (S.D.)
Test Time in days
1 2 4 6 8 10
PHB lOmg/ml 67 (10) 309 (60) 72 (26) 128 (28) 115 (32) 87 (0.5)
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1056 (212) 854 (126)
845 (238) 655 (74)
Untreated rat control 211 (46)
**1113 (262) **780 (148)
73 (22) 61 (26)
Untreated rat control 137 (24)
206 (18, 214. (56)
211 (20) 177 (16)
Untreated rat control 163 (8)
204 (24) 227 (86)
239 (86) 175 (90)

























* Statistically significant at the 99% confidence level (p <0.01) when compared to vehicle treated tissue.
** Statistically significant at the 99.9% confidence level (p <0.001) when compared to vehicle treated tissue. 
Student’s t test for paired samples, n= 4
n = 14 for untreated tissue (mean value (S.D.) given over whole time period)
Table 6.4 Alkaline phosphatase activity for each biomaterial expressed as mean % change from vehicle.
Time in days
1 2  4
PHB lOmg/ml 65.12 37.70 22.43
P(HB-HV) lOmg/ml 12.10 14.96 5.80
HB 1 Orng'/ml 11.09 38.59 39.25
HB lOOmg/ml 74.95 1.40 49.35
HV lOmg'/ml -4.25 -10;60 -8.80
HV lOOmg'/ml 91.47 40.67 24-90
Zymosan lOOug/ml 826.68 1145.50 1420.70
P M  lOmg/ml -3.53 7.20 -2.30













Table 6.5 Tissue acid phosphatase activities following intramuscular injection of test materials..
Acid phosphatase activity in IU mean (S.D.)
Test Time in days
1 2 4 6 8 10
PHB 1 Omg'/ml 499 (102) 433 (62) 695 (170) 612 (114) 428 (24) 497 (44)






389 (26) 542 (56)
P(HB-HV) 1 Omg'/ml 165 (32) 139 (20) 275 (108) 200 (20) 179 (62) 170 (22)






145 (12) 156 (20)
HB lOmg/ml 297 (68) 262 (30) 315 (24) 227 (16) 270 (4) 246 (2)






242 (56) 219 (10)
HB lOOmg'/ml 289 (54) 188 (50) 387 (74) 106 (24) 221 (26) 246 (16)






164 (32) 156 (16)
HV 1 Omg'/ml 98 (22) 93 (28) 57 (6) 61 (32) 120 (28) 71 (16)






89 (38) 80 (24)






















233 (50) 238 (62)
257 (34) 182 (54)
Untreated rat control 114 (16)
*502 (82 *626 (110)
272 (39) 316 (37)
Untreated rat control 221 (30)
*113 (54) *100 (30)
48 (18) 42 (10)
Untreated rat control 55 (4)
74 (14) 191 (42)
78 (22) 114 (16)









* Statistically significant at the 99% confidence level (p <0.01) when compared to the vehicle 
Student’s t test for paired samples, n = 4.










Table 6.6 Acid phosphatase activity of each biomaterial expressed as mean % change from vehicle.
1 2
PHB10mg/ml 49.10 31.50
P(HB-HV) lOmg/ml 10.50 -4.90
HB lOmg/ml 62.50 28.10
HB lOOmg'/ml 49.70 20.00
HV lOmg/ml -14.80 1.36
HV lOOmg/ml 64.16 46.40
Zymosan lOOmg/ml 30.40 57.30

























period of examination when compared to the enzyme activities of the 
vehicle and untreated muscle were evident. PAA (lOOmg/ml) showed a 
significant increase in alkaline phosphatase activity at day 8 
(p<0.05) and 10 (pCO.OOl) when compared to the vehicle injected 
muscle. By day 40 the activity had decreased to control (untreated 
muscle) levels for both the zymosan and PAA treated muscles.
The PHB treated muscles showed an elevation in enzyme activity 
two days after injection, this was significantly different (p<0.01) 
to the enzyme activity in the muscle of untreated rats. A similar 
significant increase was seen for the vehicle treated muscles 
although there was no significant difference between polymer and 
vehicle treatments at this point. From day four to forty there were 
no significant increases (p> 0.05) in the alkaline phophatase
activity in polymer treated muscles when compared to untreated 
muscle, although the activities tended to be significantly (p<0.01) 
higher in both cases when compared to untreated muscle. When 10 mg/ml 
and lOOmg/ml solutions of HB were injected no significant increases 
in alkaline phophatase activity when compared to vehicle treated rat 
muscle were seen over a 40 day period. P(HB-HV) injections produced 
transient acute increases in the alkaline phosphatase activity-which 
were not significantly different from the activity seen in the 
untreated muscle, but levels remained higher for longer and at day 10 
a highly significant increase (p<0.001), in alkaline phosphatase 
activity was evident. By day 40 this effect had resolved to levels of 
enzyme activity comparable to the untreated muscle. In common with HB 
no significant increase in alkaline phosphatase activity were seen 
when a lOmg/ml solution of HV was injected, when compared to the 
vehicle treated muscle. When the concentration of HV was raised to 
lOOmg/ml, highly significant increases (p< 0.001) in alkaline
phosphatase activity when compared to both vehicle treated and 
untreated rat muscle were recorded during the first two days 
following its injection into the muscle.
Effect on tissue acid phosphatase activity.
The activities of tissue acid phosphatase after intramuscular 
injection of identical materials and controls are given in table 
6.5 and presented in table 6.6 as the mean percentage change in 
enzyme activity when compared to the injection vehicle enzyme 
activity at any one time after injection.
Tissue acid phosphatase activity significantly increased 
(p<0.01) on days 4-6 after injection of suspensions of PHB 
microspheres when compared to untreated muscles enzyme activities. 
Levels of enzyme activity remained higher but not significant when 
compared to untreated tissues over a 10 day period due to the 
considerable variation between animals. The mean values of enzyme 
activity of PHB treated tissue were not significantly different from 
vehicle injected tissues when examined using a t-test. At both 
concentrations of the monomer, HB, a highly significant increase 
(p<0.001) in the tissue acid phosphatase activity on day 4 when 
compared to vehicle injected tissue and untreated tissue was evident, 
these elevated levels of enzyme activity were then seen to reduce to 
the baseline level of activity of untreated tissue during days 6-10.
The copolymer P(HB-HV), did not significantly increase acid 
phosphatase activity at any time period studied during the experiment 
when compared to both untreated tissue enzyme activities and injected 
vehicle tissue enzyme activities. Following injection of the 
monomer HV (lOOmg/ml) a significant increase (p<0.01) in acid 
phosphatase activity when compared to vehicle treated and untreated 
tissue at day 1 was seen. The lOmg/ml HV solution did not evoke any
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significant increases in the acid phosphatase acivity during the time 
course of the experiment. The two positive controls, zymosan and PAA, 
both produced a significant increase (p<0.01) in acid phosphatase 
activity from days 4 - 1 0  when compared to untreated tissue and
vehicle injected tissue which was resolved by day 40 in both cases.
Serum alkaline and acid phosphatase enzyme activities.
When serum was assayed for increases in the alkaline phosphatase and 
acid phosphatase activities compared to untreated rats no significant 
increases were found for any of the treatments, as shown in tables 
6.7 and 6.8.
Effect on enzyme activity following implantation of films.
Tables 6.9 and 6.10 give the activities of alklaine and acid
phosphatase found in the muscle tissue following implantation with
polymer films. The results indicate a significant increase (p<0.01)
in alkaline phosphatase activity for the control film PMMA at days
6-10 when compared to the sham operated sites, which decreased to
sham control levels by day 40. PHB, evoked a significant increase
(p<0.01) in alkaline phosphatase activity on days 4 and 10 which had 
resolved by day 40. The copolymer showed similar significant
increases on days 4 and 8 only. Significant increases (p<0.01) in
tissue acid phosphatase activity was seen on days 2 and 4 for PHB,
days 1,4 and 6 for P(HB-HV) and days 4, 8 and 10 for PMMA films.
Tables 6.11 and 6.12 show no differences in serum enzyme levels for 
any of the implanted films indicating no serious toxicity or 
inflammation is due to the polymers.
Data obtained for serum levels of enzymes were unambiguous but 
the tissue enzyme data were conclusive only for inflammatory
Table 6.8 Serum acid phosphatase activities following intramuscular in.iection with test materials.
Acid phosphatase activity in IU mean (S.D.)
Time in days
1 2 . 4  6 8 10
Test
PHB/Vehicle 52 (24) 61 (12) 71 (10) 64 (16) 44 (2) 33 (12)
Control rat 45 (4)
P(HB-HV)/ 37 (18) 33 (6) 65 (16) 37 (14) 34 (8) 36 (10)
Vehicle
Control rat 26 (16)
62 (12) 55 (32) 51 (28) 21 (10) 50 (20)
Control rat 60 (22)
HB 100mg/ml/ 41 (C) 61 (8) 32 (6) 64 (10) 14 (4) 46 (10)
Vehi cle
Control rat 60 (22)
HB 10mg/ml / 64 (16)
Vehicle
HV 10mg/ml/ 15 (2) 15 (4) li (2) 16 (6) 14 (4) 12 (8)
Vehicle
Control rat 20 (4)
37 (2) 156 (22) 26 (10) 25 (2) 54 (14)
Control rat 20 (2)
50 (2) 63 (12) 73 (20) 76 (14) 70 (6)
Control rat 53 (22)
PAA / 14 (1) 12 (2) 20 (20) 30 (18) 20 (5)
Vehicle
Control rat 17 (4)
Vehicle / Sham 17 (6) 15 (10) 11 (2) 11 (12) 10 (20)
(Control rat 12 +/- 10)
Figures represent mean of 4 samples.











Table 6.7 Serum alkaline phosphatase activities following in.iection with test materials
Alkaline phosphatase in IU mean (95% C.I.) n=4
Test








HB lOmg/ml 222 (17) 
Vehicle
HB lOOmg/ml 250 (31)
118 (10) 150 (5)





116 (14) 178 (21)
(Control rat 143 +/- 6)
108 (10) 94 (12)
(Control rat 66 +/- 1)
274 (6) 254 (4)
(Control rat 265 +/- 25)
256 (16) 292 (11)





HV lOmg/ml / 53 (2)
Vehicle
40 (6) 50 (8) 52 (1)
(Control rat 25 +/- 4)
37 (1)
HV 100mg/ml/ 157 (6) 146 (14
Vehicle
Zymosan/ 198 (16) 202 (6)
Vehicle
PAA/ 49 (2) 41 (2)
Vehicle
Vehicle/ Sham 52 (11) 49 (12)
*'=4 for each time point per experiment 





61 (6) 159 (4) 80 (17)
(Control rat 25 +/- 4)
232 (15) 217 (10) 201 (4)
(Control rat 113 +/- 10)
51 (9) 67 (2) 58 (6)
(Control rat 49 +/- 6)
53 (21) 48 (8) 40 (19)
(Control rat 38 +/- 9)
• J l
Cjrr
Table 6.9 Tissue alkaline phosphatase activities following film implantation.










































Figures represent the mean (S.D.) of 4 experiments.
* Significant at the 99% confidence level (p<0.01) when compared to sham sites. 
Student’s t test for paired samples.
Table 6.10 Tissue acid phosphatase activities following implantation of films.
Acid phosphatase in IU (mean +/- S.D)
<;---------- — ------------ Time in days -----------------— — — ----------------------^
1 2 4 6 8 10
Test
PHB 273 (70) 223 (13) *387 (29) 233 (18) 173 (14) 111 (4)
Sham 225 (81) 160 (18) 198 (53) 247 (64) 143 (27) 109 14)
P(HB-HV) 121 (19) 168 (26) *167 (8) *196 (27) 163 (26) 163 (10)
Sham 171 (12) 196 (20) 102 (16) 112 (15) 132 (33) 113 (36)
PMMA 213 (34) 211 (12) *263 (9) 173 (12) *237 (23) *215 (21.)
Sham 171 (23) 255 (30) 207 (14) 144 (21) 140 (10) 109 (33)
Figures represent the mean (S.D.) of 4 experiments.
* Statistically significant at the 99% confidence level (p<0.01) when compared to sham sites. 
Student’s t, test for paired samples.
Table 6.11 Serum alkaline phosphatase activities following implantation with films.
Alkaline phosphatase in IU mean (S.D.)
<:---------------------Time in days-
1 2 4 6 8 10
Test
PHB/Sham 31 (21) 55 (8) 59 (10) 30 (6) 62 (4) 53 (8)
P(HB-HV)/ 41 (7) 63 (3) 38 (22) 31 (22) 35 (7) 39 (7)
Sham
PMMA/ 36 (3) 45 (9) 57 (16) 44 (6) 73 (4) 97 (3)
Sham
Figures represent the mean (S.D.) of 4 samples.
Table 6.12 Serum acid phosphatase activities following film implantation.
Test
Acid phosphatase in IU mean (S.D.)




24 (2) 25 (4) 21 (4) 19 (2) 28 (11) 28 (2)
P(HB-HV)/ 24 (3)
Sham
26 (5) 16 (2) 20 (6 ) 27 (4) 17 (2)
PMMA/
Sham
30 (4) 14 (2) 23 (5) 16 (4) 27 (2) 31 (4)
Vi cfi ires ■ represent mean (S.D.) of 4 samples
materials such as zymosan. The interpretation of data relevant to the 
implantation of PHB and P(HB-HV) was difficult due to inherant 
variability of the animal study, rather than the sensitivity of the 
assay. For this reason a second study was conducted with the aim of 
testing the effects of PHB and P(HB-HV) microsphere injections using 
a series of different batches of each polymer. Great care was taken 
during this study to ensure that the injections were performed in as 
reproducible a manner as possible. The results of this study are 
given in tables 6.13 -6.14.
The injection of two different batches of PHB microspheres 
into rat muscle tissue produced similar patterns in enzyme activities 
(table 6.13), to those seen in the initial experiments. Significant 
increases (p<0.01) in alkaline phosphatase activity were seen on days 
1-2 when compared to untreated muscle tissue, but no significant 
increase was seen when compared to the vehicle treated muscle. Acid 
phosphatase activity was significantly increased (P<0.01) on day 6 in 
PHB injected muscle when compared to the vehicle injected muscle. As 
indicated by a large S.D. from the mean in this second set of 
experiments there still appears to be an inherant variability of the 
study.
\
The three separate batches of P(HB-HV) also produced similar 
increases in enzyme activities over the test period. However the 
results of this experiment differed slightly to those obtained in the 
first set of experiments. Significant (p<0.01) increases in alkaline 
phosphatase when compared to vehicle treated muscle were seen on days 
6-14 whereas a significant increase in activity was seen on day 10 
only in the first set of experiments. Acid phosphatase was also 
significantly increased (p<0.01) on days 8-14 when compared to 
untreated muscle, whereas no significant increases were detected in
Table 6.14. Tissue acid/alkaline phosphatase activities following i.m. injection of various batches of P(HB-HV).
Alkaline Phosphatase activity mean (S.D) n=4 
Time in days













































































































Acid phosphatase activity mean (S.D) n=4
1 2 4 6 8 10 14 21 40
Batch 1 334 (6) 362 (41) 325 (27) 442 (47) *642 (53) *760 (21) *660 (36) 370 (18) 298 (24)
Vehicle 332 (21) 288 (20) 308 (20) 362 (31) 266 (19) 216 (37) 285 (10) 321 (16) 206 (45)
Batch 2 300 (26) 361 (15) 376 (72) 497 (55) *762 (46) *759 (30) *702 (68) 319 (31) 287 (31)
Vehicle 271 (27) 294 (18) 301 (37) 392 (41) 229 (35) 233 (21) 207 (19) 242 (14) 215 (17)
Batch 3 337 (26) 370 (37) 339 (44) 436 (20) *695 (32) *732 (33) *694 (16) 287 (29) 306 (29)
Vehicle 287 (13) 264 (58) 272 (25) 320 (19) 343 (15) 360 (15) 224 (29) 194 (40) 263 (17)
* Statistically significant at the 99% confidence interval (p<0.01) using a student’s t test for paired samples 1
Table 6.13 Tissue alkaline/acid phosphatase activities following i.m. injection of two batches of PHB.
Alkaline phosphatase activity mean (S.D) n==4

























































Acid phosphatase activity mean (S.D) n:=4

























































* Statistically significant at the 99% confidence interval (p<0.01) using a student’s t test for paired samples.
the first set of experiments. The results of this second set of 
experiments appear to more closely correlate with the findings of the 
histologly of P(HB-HV), where a florid reaction was observed 7 days 
after injection, however large S.D. also indicate an inherant 
variability in the study.
6.3. Discussion.
Stimulation of the inflammatory response is often the first response 
to tissue damage or to the presence of foreign material, which can 
then develop to involve the immune system. Implantation of any 
material, (inert, naturally occurring, or foreign) is likely to 
stimulate a response due initially to its physical presence. Whether 
the response develops into a significant inflammatory reaction or 
results in toxicity will depend on the material in question - the 
biocompatibility of the implant being a function of the tissue 
response. The polymers under study were not believed to be acutely 
toxic, with reference to their compatibilty with cells in culture 
(chapter 3) and previous work (Korsatko et al, 1983), but should 
significant or prolonged inflammation result from their use, they 
would be unacceptable for use in clinical practice. This study set 
out to assess their biocompatibility in vivo.
The magnitude and duration of the inflammatory response has 
been used, for a number of years by many workers in the establishment 
of a materials biocompatibilty, (Turner et al., 1973; Marchant et 
al., 1983,1984). The most common methods of assessment have been 
qualitative histological studies. Histology is an essential component 
in the evaluation of tissue compatibilty and the implanted material. 
Such techniques have been particularly useful initial evaluation of 
the material. A number of implantation sites have been used to assess 
material biocompatibility. Langer et al., (1981) studied the
biocompatibility of a number of polymeric delivery systems for 
macromolecular drugs using the cornea as the implantation site. 
However this site has the disadvantage of avascularitv and therefore 
the haemodynamic changes that occur with tissue damage cannot be
seen, perhaps leading to false conclusions of the materials 
biocompatibility. Other sites for implantation used in the study of 
in vivo biocompatibilty include the rat middle ear as used by 
Williams and Blayney (1986) and Bakker et al., (1988) and the bone, 
as used by Mattie and Bajpai (1988) for assessment of materials for
use in bone grafting. Subcutaneous implantation sites have also been
■>
used (Leong et al., 1986; Marion et al., 1980) but again this tissue 
is not ideal for histology or enzyme histochemical studies as it is 
poorly vascularized and is extremely fatty. Perhaps the best mode of 
implantation for assessment of biocompatibilty is intramuscularly 
into the gluteal or gastrocemius muscle of the rat or rabbit. This 
has been used by many workers including Marchant et al (1983, 1984, 
1985, 1988) who used a cage implant system. This intramuscular site
of implanation is suggested in the British Standards for testing of 
Biocompatibilty (BS 5736 Part 2, 1981) by the ATMS (F763-82, 1982) 
and the U.S. Pharmacopeia (section 661, 1980).
Histological assay of tissue adjacent to an implant demands 
particular attention to implantation and biopsy techniques and 
although such evaluations are necessary they remain subjective to a 
degree and difficult to quantitate. The histological evaluation of 
PHB, P(HB-HV) and their degradation products revealed that only the 
copolymer gave rise to continued inflammation over 14 days. Why 
P(HB-HV) resulted in a florid reaction when PHB did not cannot as yet 
be explained. Korsatko et al. , (1984) assessed the degree of
inflammation caused by tablets of PHB implanted subcutaneously into 
the neck crease of mice. Assessment was carried out by histological 
examination. A mild foreign-body reaction in the form of inflammatory 
processes in the region of the implant lasted throughout the 20 week 
implantation period. A cell rich connective tissue capsule which was
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highly vascularised developed after five weeks implantation. These 
results are not unlike our own, as only a transient inflammatory 
reaction was seen with the injected PHB microspheres, suggesting that 
the physical form of the PHB tablet had caused prolonged 
inflammation. However in this study PHB films were not seen to 
prolong the initial inflammatory reaction associated with the 
surgical trauma of implantation. It is believed that subcutaneous 
implantation into the neck crease of mice used by Korsatko and his 
coworkers to assess the tissue reaction to PHB would not give enough 
information to the actual inflammatory potential of the material as 
this is a fatty and poorly vascularised tissue. PAA has been used in 
other histology assessments (Langer et al., 1981) where it was found 
as in this work to produce significant inflammation. This may be 
explained by the leaching of monomers, methacrylamide, or initiators 
of polymerisation which are potentially toxic. The PHB and P(HB-HV) 
films were well tolerated by the soft tissue and all indications were 
of good biocompatibilty exemplified by an intact local blood supply, 
thin fibrous capsule and good cellularity, the features as defined by 
Coleman et al., (1974) for-good biocompatibilty.
Damage to a vascularized tissue leads to increased 
permeability, an outpouring of exudate fluid, blood cells and plasma 
cells from the vessels and into the extravascular territory. Vascular 
permeabilty and exudate changes are mediated by the local release of 
active endogenous chemical substances including histamine, 
prostaglandins, kinins, complement derivatives and some lysosomal 
derivatives, (Bult and Herman, 1985). Vascular permeabilty changes 
were assessed by Evans Blue leakage. The responses to the polymers 
used in this study were negligible (Table 6.2.) suggesting that these 
materials may be suitable for in vivo use. Raised permeability was
observed after injection of HB and HV and was thought to be related 
to an osmotic effect as the results were not significantly different 
to sucrose on a molar basis. Zymosan used as a positive marker for 
measurement of vascular permeabilty changes (Williams, 1979; Wedmore 
and Williams, 1981) caused substantial vascular permeabilty which was 
not due to pH effects caused by the irritants HC1 and NaQH (pH 0.45 
and 12.84 respectively). However histamine and 5HT, both commonly 
used to induce increases in the permeability of the surrounding 
vasculature (Arvier et al, 1977; Coughlin et al, 1981), did not
significantly increase vascular permeability when compared to the
vehicle of polymer injection suggesting the inflammatory potential of 
the vehicle itself.
The quantitative study of cellular dynamics in relation to 
implant toxicity has certain definite advantages over procedures
relying solely on observed macroscopic or microscopic observations 
for histocompatibilty. The results are not subjective and are based 
on cellular function and behaviour and not merely on cell population 
or morphology. The PMN alkaline phosphatase and macrophage acid 
phosphatase lysosomal activity adjacent to the tissue appears to be 
related to the toxicity of the implant components. These enzymes can 
be measured quantitatively therefore giving an objective parameter 
for application to the study of cellular toxicity of materials 
implanted in vivo. Salthouse and his coworkers (1969, 1970, 1975)have 
extensively reviewed enzyme histochemistry in the study of
biocompatibilty and these techniques have since be used by many 
workers (Goldman and Raz, 1975; Allison et al., 1969; Morland and 
Morland, 1978; McNamara and Williams, 1984).
The results of this study suggest that intramuscular injection 
of PHB or P(HB-HV) provoke a mild acute inflammatory response which
is characterized by the influx of PMN’s into the vicinity of the 
implant and hence an increase in alkaline phosphatase activity. 
Alkaline phosphatase is located within the specific granule of the 
PMN’s and its presence in the exudate denotes its release either by 
the death of the PMN with lytic release or through an exocytosis 
mechanism that involves non-cytolytic extracellular release of this 
enzyme from the granules, usually occurring during phagocytosis. This 
acute inflammatory response did not differ significantly from the 
vehicle injected rats and was only transient. There were some 
differences in the duration of the acute inflammatory effect, 
particularly in P(HB-HV) injected rat muscle as indicated by 
significant increases in alkaline phosphatase activity on days 6-14 
seen in the second set of experiments. It is not clear at present how 
important these effects may be. A sustained PMN concentration as 
shown by the zymosan test which produced continued elevation of the 
enzyme was an indication of continued PMN migration from the
vasculature to the injection/implantation site and suggested that
inflammatory mediators were being maintained at relatively high 
concentrations in the inflammatory exudate. The subsequent attraction 
of macrophages into the inflammatory site through the chemotactic 
factors released by the PMN’s and other blood cells in the vicinity, 
was indicated by a clear increase in acid phosphatase activity after 
injection of zymosan. As the macrophages attempt to phagocytose 
foreign material, exocytosis of lysosmal enzymes, of which acid
phosphatase is the most abundant, occurs. Significant increases in 
acid phosphatase activity was also seen on days 8-14 in P(HB-HV) 
treated muscle, this correlated well with the increased PMN
concentration and alkaline phosphatase activity seen at this time, 
when macrophage attraction through the chemotactic factors released
by PMNs probably occurred.
Salthouse equated high acid phosphatase activity with cell 
lysis and tissue destruction. The intensity and duration of the 
inflammatory response measured through these enzymes is controlled by 
the mediators determined by the injected material, site of injection 
and the reactive capabilty of the host. As indicated by the 
experiments conducted in this study inflammation caused by PHB or
P(HB-HV) was transient and was also observed after injection of
vehicle and, to some extent, by simple penetration of the needle.
Thus it may be that the observed inflammation was due to the trauma 
of injection and not to the polymers or monomers themselves. The 
short interaction shown by the macrophages representative of later 
stages of inflammation, indicated that the tissue’s responses to the 
polymers and monomers were simply those of short duration 
inflammatory reaction followed by normal wound healing. Highly
irritating implants greatly increase acid phosphatase activity, as 
seen with PVC samples containing organtin stabilizers and phthalate 
ester plastiszers, (Salthouse et al., 1973; Salthouse and Matlaga; 
1975) cat gut suture (Newcombe, 1972), and many metals used in 
implants. Biocompatible polymers eg. high density medical grade 
polyethylene and polypropylene evoke only minimal levels of enzyme 
activity which diminish to undetectable levels after the third or 
fourth week following implantation, (Spilizewski et al., 1987). The 
effects of PHB and P(HB-HV) were comparable to those of the latter 
polymers.
Formulation, geometry and surface characteristics can affect 
both the tissue reaction and enzyme activity associated with the 
sample as shown by many workers (Van Oss and Gillaman, 1972; Andrade, 
1973; Matlaga et al., 1975; Taylor and Gibbons, 1983; Schakenraad et
al,, 1987). As suggested by Henson (1980) the inflammatory response 
is also dependent upon the size of the implant and whether a material 
is in particulate or bulk form.The former may allow phagocytosis 
which may provoke a different degree of inflammation than the same 
material in a non-phagocytosable form such as a film, where 
frustrated phagocytosis and exocytosis will probably prevail. PHB and 
P(HB-HV) films, when compared to a biocompatible material, PMMA, did 
not significantly differ in the enzyme activity produced and any 
significant inflammation appeared to be due to the surgical procedure 
of implantation and not the polymers.
In conclusion this study has shown that PHB and P(HB-HV) are 
biocompatible in the sense that implantation in / adjacent to the rat 
thigh results in no significant chronic inflammation. On degradation 
to the monomers, both HB and HV are probably removed and enter the 
bloodstream prior to excretion. Hence no significant accumulation of 
breakdown products would be expected. Should the monomers remain at 
the polymer site this study has suggested that no chronic
inflammatory response would result. These polymers are therefore 
biocompatible within soft muscle tissues.
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6.4. Conclusions.
1) The tests were sensitive as trauma due to injection was 
detectable.
2) Inflammatory materials such as zymosan produced significant 
increases in the vascular permeability and clearly raised enzyme 
levels over a 10 day period.
3) There was considerable variability in enzyme activities between 
animals in both sets of experiments. Often raised levels of enzyme 
were determined but the S.D. was large leading to the conclusion that 
there were no significant differences in enzyme activities between 
polymer treated and vehicle treated rat muscle. Generally an acute 
effect was evident which had subsided after a few days and certainly 
after 40 days.
4) Rats were found to tolerate large quantities of HB and HV, far 
more than would be expected at the site of implantation of PHB or 
P(HB-HV).
CHAPTER 7. Evaluation in vitro and in vivo of PHB as a biodegradable
drug delivery system.
7.1. Introduction.
Interest in controlled-release technology has increased steadily over 
the last twenty years. Recently major advances in genetic engineering 
have enabled large quantities of potent polypeptides and proteins to 
be produced. Practical and effective formulations are now required 
for their delivery. Polypeptides e.g. insulin and growth hormones are 
normally administered parenterally, as they are rapidly degraded and 
deactivated by proteolytic enzymes in the gastro-intestinal tract. 
However problems are encountered with parenteral administration in 
that polypeptides have short half-lives and therefore fhequent 
injections are usually required to produce effective plasma 
concentration (Hutchinson and Furr, 1987; Tice et al., 1989). To 
overcome this problem drug delivery devices which degrade within the 
body, have pre-determined life spans and which protect the labile 
drug during its lifetime are now being developed. Such delivery 
devices must meet requirements in mechanical properties, 
biodegradation kinetics, tissue compatibility, drug compatibility and 
ease of manufacture.
Biodegradable polymers have been used in the development of 
drug delivery systems for a number of drugs including narcotics, 
antimalarials and antibiotics, and their applications have been 
reviewed (Wood, 1980; Heller, 1980; Heller, 1984, Heller et al., 
1985; Holland et al., 1986; Davis and Ilium; 1986). Early designs 
based on biodegradable polymers have made use of homo and copolymers 
of lactic and glycolic acid. The first demonstration of the'utility 
of polylactide, as a biodegradable implant capable of sustained 
release of a therapeutic agent, was described about 20 years ago
(Yolles et al., 1970). Since then many publications have described 
the sustained release of pharmaceuticals from P(LA-GA) systems 
(Woodland et al., 1973; Yolles et al., 1975; Wise et al., 1979; 
Gilding and Reed, 1979; Wakiyama et al., 1981, 1982; Juni et al., 
1985). More recently P(LA-GA) systems have been used for the 
sustained drug delivery of peptides (Sanders et al., 1984, 1986, 
1988; Hutchinson and Furr, 1987). Previous work on these polymers as 
suture materials has shown that they are inert and biocompatible 
within the physiological environment after implantation (Kulkarni et 
al., 1966, 1971; Frazza and Schmitt, 1971; Cutright and Hunsuck, 
1971; Gourlay et al., 1978). P(LA-GA) systems degrade to 
toxicologically acceptable products which are already present in the 
body, i.e. glycolic acid and lactic acid. Such polymeric carriers are 
expected to be ideal for formulation of controlled drug delivery 
systems.
The release of the therapeutic agent from a degradable 
delivery system will be influenced by the mechanism and rate of 
degradation of the polymeric carrier. The majority of reports 
relating to such drug delivery systems concentrate’on the degradation 
of the polymeric carrier by hydrolysis in the absence of enzymes. 
Heller (1984) classified two extreme types of hydrolysis, bulk 
hydrolysis and surface hydrolysis. In bulk hydrolysis, chain cleavage 
takes place throughout the bulk of the material while in surface 
hydrolysis the reaction is confined to the outer surface of the solid 
device.
Research has shown that polymers of lactate and glycolate 
degrade by bulk hydrolysis (Heller, 1986). Monolithic devices which 
undergo a bulk erosion process often exhibit complex drug release 
kinetics because release rate is determined by drug diffusion
phenomena and polymer hydrolysis. In general the initial kinetics of 
release are comparable with those resulting from diffusion from
non-erodable monolithic devices; release rate is often proportional 
to the square root of time as described by Higuchi * s equation 
(Higuchi, 1961). However, sis bulk hydrolysis proceeds, the
permeability of the polymer increases and thus the rate of diffusion 
of the drug increases (Heller, 1986; Hadgraft and Guy, 1987).
The kinetics of drug release from monolithic devices which
undergo surface hydrolysis are more predictable. Release additional 
to that expected by matrix diffusion would only occur from the
surface of the polymeric carrier as surface erosion of the carrier 
proceeded. Such devices should be capable of providing zero-order 
drug release if the drug is entrapped in the polymer matrix and the 
surface area of the device remains constant. In practice the rate of 
drug release is likely to decrease with reduction of the total 
surface area of the device, which will be a consequence of the 
erosion process. However in principle, by controlling the geometry of 
the device one could determine its lifetime. For instance, for a 
laminate the lifetime of the device would be directly proportional to 
its thickness. Much research is therefore directed towards finding a 
biocompatible, biodegradable polymer which degrades by surface 
erosion only. Heller and his collegues (1985) have developed 
bioerodible polymers that do undergo surface erosion and are capable 
of releasing drugs by zero-order kinetics; namely, polyorthoesters. 
Polymers from this group have been prepared synthetically by the Alza 
corporation (USA) and are marketted under the trade name Alzamer. 
Recent work at the university of Bath has shown that the polyesters 
PHB and P(HB-HV) degrade by surface erosion. (Majid, 1988). The rate 
of hydrolysis was very slow but could be enhanced by making the
hydrolytic medium more alkaline.
The controlled delivery of a model drug from PHB, P(HB-HV), 
PLA and P(LA-GA) matrices, produced by melt extrusion, has been 
investigated. Delivery of proteins and peptides was of particular 
interest. However proteins degrade to amino acids and are recycled 
into other body proteins. Neither the original protein nor its 
metabolites are excreted and it is therefore difficult to measure the 
absolute release rates of such macromolecules in vivo {Brown et al., 
1983). Indirect measurement of release rates in vivo could be 
determined by assaying the mass of protein remaining in the implants 
at various time points, but this would require a large number of 
animals and expenditure for each investigation. Inulin, a 
polysaccharide (Mw 5200) was chosen as a model macromolecular drug as 
it is totally excreted (Smith, 1956; Gutman, 1965) allowing its 
release kinetics from polymers to be studied in vivo (Langer et al, 
1981). Release of inulin was determined both in vitro and in vivo to 
allow comparison of the respective release kinetics.
Release was studied in vitro in both accelerating conditions 
and physiological conditions. The effect of drug loading on the 
kinetics of release was studied in vivo and in vitro and the effect 
of tempertaure and pH on kinetics of release was studied in vitro.
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7.2.Materials
Inulin; Sigma Chemicals Co, Poole, Dorset.
14C Inulin; Sigma Chemicals Co, Poole, Dorset.
Dulbecco’s PBS, Qxoid Ltd, England.
Sodium hydroxide pellets; Aldrich Laboratories, Gillingham, Dorset. 
Phenol; Aldrich Laboratories, Gillingham, Dorset.
Concentrated sulphuric acid, Fisons Ltd., Loughborough, Leicester.
LKB Optiphase Liquid Scintillation cocktail; FSA Laboratory supplies, 
Loughborough, Leicester.
LKB Wallac Internal Standard Kit for liquid scintillation counting; 
FSA Laboratory Supplies, Loughborough, Leicester.
PHB, Mwt 23,000; Marlborough Biopolymers, Teeside.
P(HB-HV), Mw 760,000, 12.6 mole%, Marlborough Biopolymers, Teeside. 
Poly (L-lactide) Resomer* L206; Boeringher Ingleheim, West Germany. 
Poly D,L-lactide-co-glycolide 50:50, Resomer* RG 505; Boeringher 
Ingleheim , West Germany.
* Trade name.-
Equipment
LKB Wallac 1215 Rackbeta Liquid Scintillation Counter, Wallac Oy, 
Finland.
Pye Unichem pu8610 uv/vis kinetics spectrophotometer; Philips, 
Fisons, Loughborough, Leicester.
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7.3 In vitro release experiments.
7.3.1. Matrix preparation.
Appropriate amounts of PHB and inulin powders were mixed thoroughly 
using a pestle and mortar to achieve homogeneity. lOOmg of the 
powder blend was carefully poured into a thermostatically controlled 
pre-heated die. The mix was melted at 180°C +/” 5°C (PHB blends) for 
approximately 4 minutes and the melt allowed to cool by ~20°C when 
the melt could easily be extruded from the die. The extruded rod was 
cut into sections to give final dimensions 1cm x 0.3mm (length x 
diameter). P(LA-GA) 50:50 and PLA systems were prepared in 
essentially the same way but the temperature of melt differed. PLA 
was sucessfully extruded at 130°C and P(LA-GA) copolymer at 115°C. 
P(HB-HV) matrices could not be fabricated with the high molecular 
weight copolymer using the melt extrusion technique as it was too 
viscous at melt temperature.
7.3.2. Experimental.
Three 1cm x 0.3mm sections of polymer/inulin extrudate were placed 
into 20ml closed screw-capped vials with 10ml of sterile -release 
medium; either PBS (pH 7.4) or 0.1M NaQH (pH 12.9). The vials were 
agitated in a shaking water bath at 37°C or 70°C. 200ul of the buffer 
solution was removed daily, assayed.for inulin content and replaced 
by 200ul of fresh sterile release media. Sink conditions were 
ensured due to the large volume of release media relative to the 
small amount of inulin incorporated into the melts.
At the end of a selected release period, typically 14 days, 
the extrudate was carefully removed to prevent splintering or 
disintegration, dried and weighed. Finally the extrudates were 
examined using scanning electron microscopy.
7.3.3. Inulin assay
The assay of inulin used a phenol-sulphuric acid assay commonly used 
for determination of polysaccharides. This is a non-specific method 
for detection of neutral carbohydrates and has sufficient sensitivity 
to measure l-60ug glucose in 200ul solution (~30uM-2mM).
200ul samples of release media (containing up to 60ug of 
carbohydrate) were mixed with 200ul of 5% w/v phenol solution in 
water. 1.0ml of concentrated sulphuric acid was added rapidly and 
directly to the solution surface without touching the sides of the 
tube. The solutions were left undisturbed for 10 minutes before 
vortexing for one minute. A highly coloured product was formed which 
was assayed spectrophotometrically at 490nm ater 30 minutes. The 
readings were converted to concentration of inulin using calibration 
curves of inulin in PBS (pH 7.4) or 0.1M NaOH (pH 12.9).
7.4. In vivo release experiments.
7.4.1. Matrix preparation.
14C labeled inulin powder was mixed with unlabeled inulin powder and 
then blended with polymer powder to give drug loadings of 20%w/w in 
PHB/inulin extrudates and 10%w/w in PLA, P(LA-GA)/inulin extrudates. 
The polymer/inulin matrix was then extruded through a pre-heated die 
as described in 7.3.1. PHB/inulin extrudates were steam sterilised 
at 121 °C for 15 minutes before implantation and PLA, P(LA-GA) 
extrudates sterilised by alcohol washes prior to implantation into 
the thigh muscle of rats.
7.4.2. Implantation technique.
Three polymer/14C inulin extrudates, 1cm x 0.3mm were implanted into 
the thigh muscle of each male Wistar rat (weight 200g) by making a
2cm incision in the gluteal muscle. A pair of sterile round edged 
scissors was used to create a pocket in the intra-muscular tissue and 
the sterile extrudates placed into the pocket with sterile forceps. 
The wound was closed with animal clips. The rats were individually- 
housed in metabolic cages for the duration of the experiment (28
days) after a post-operative recovery period of 3 hours. Urine was
collected daily in 15ml graduated collection tubes, allowing urine 
volumes to be read directly.
7.4.3. Inulin assay for determination of release kinetics in vivo.
A 500ul aliquct of the urine collected daily from each rat was added 
to 500ul of distilled water and 10ml of scintillation fluor in a 
glass scintillation vial. The radioactivity present was measured 
using a liquid scintillation counter the cocktail being counted for 
120 seconds. A quench correction curve was constructed using a series 
of 14C quench standards and this curve was used to' correct all
counts. Cumulative % release was plotted versus time. After 4 weeks 
the experiment was terminated and the rats killed. The implants were 
removed and each site examined visually for host response. Recovered 
implants were inspected for deterioration weighed and surface
erosion/porosity was examined using SEM.
7.5. Results.
7.5.1. In vitro release kinetics.
Figures 7.1-7.6 show the effects of temperature, pH and drug 
loadings on the release kinetics of inulin from the drug/polymer 
matrices. The % cumulative release of inulin is plotted against time. 
Data plotted is the mean of 15 replicate release studies from each 
extrudate, standard deviation being < 5% of the mean. The studies 
were conducted for up to 14 days. Table 7.1 summarises the total
percent polymer weight loss and total percent drug loss over 14 days 
for each variable examined.
Each study exhibited two phases of release. There was an 
initial burst seen on day 1 in which 5-10% of the incorporated inulin 
was released. The burst effect was followed by a second phase when 
approximate zero-order release kinetics were seen for the PHB/inulin 
extrudates under release conditions of ^  7.4 and temperatures of
37°C and 70°C. Approximate zero-order release kinetics were seen over 
the first 7 days for the PHB/inulin extrudates under release
conditions of pH 12.9 and both temperatures. First order release
kinetics were observed for all PLA and P(GA-LA)/inulin extrudates 
under pH 12.9 and 37°C and 70°C release conditions.
The release of 10% and 15% inulin loaded PHB (Mw 23,000) at
37°C and 7.4 is compared in figure 7.1. Over the 14 day release 
period, both the 10% and 15% inulin loaded PHB extrudates, delivered 
12% of the total incorporated inulin. The burst effect occurred on 
day 1 for both matrix systems delivering 5-6% inulin which was 
probably due to surface inulin and inulin at the cut edges of the 
extrudate. The second release phase showed a lower release rate but 
of approximate zero order kinetics. Figure 7.2. shows the release of 














Figure 7.1. Cumulative percent release of 10% and 15% loaded inulin/FHB matrices versus time in days into
phosphate buffered saline, pH 7.4 at temperature 37°C.
Points represent the mean release of 15 samples, S.D. <5% of the mean.
■ 10% inulin loading.














Figure 7.2. Cumulative percent release of 10% and 15% loaded inulin/PHB matrices versus time in days into phosphate 
buffered saline, pH 7.4 at temperature 70°C.
Points represent the mean releast* of 15 samples, S.D. <5% of the mean.
■ 10% inulin loading.
□  15% inulin loading.
effect was seen on day 1 where 7.5-9.5% of inulin was released. From 
day 2 to 14 a further 8.5% and 13.5% inulin was released following 
approximate zero-order release kinetics from the 10% and 15% loaded 
PHB matrices respectively. As was expected at higher temperatures the 
amount of inulin released from both the 10% and 15% loaded PHB 
matrices increased.
The release of inulin from PHB matrices at pH 12.9 and 37°C is 
shown in figure 7.3. Over the 14 day release period 33.5% and 28% of 
inulin from the 10% and 15% inulin loaded matrices respectively had 
been released. An initial burst effect was seen on day 1 when 7% of 
the total incorporated inulin was released. Over the first week the 
release of inulin was minimal (< 10%). This was followed by a rapid 
increase in release from day 7 to day 14, following approximate first 
order kinetics.
Figure 7.4. shows the release at pH 12.9 and 70°C. Over the 14 
day release period 32% and 33% of inulin were released from the 10% 
and 15% inulin loaded matrices. No obvious burst effect was seen and 
the release of inulin under these conditions appeared to follow first 
order kinetics .-
Table 7.1 shows the polymer weight loss which had occured 
through degradation of the polymer matrix and the amount of drug that 
was released after 14 days. Polymer degradation at pH 12.9 and 70°C 
was ~ 50% and the drug release was '*32%. This suggests that in order 
for drug release to occur polymer degradation had to occur. However 
in all other cases examined the % polymer loss through degradation 
was less than the % drug release suggesting that release of the drug 
did not exclusively rely on polymer degradation.
Release rates from PLA and P(LA-GA)/inulin extrudates at pH 


















Cumulative percent release of 10% and 15% loaded inulin/PHB matrices versus Lime in days into (0.1M) NaOII 
release media pH 12.9 at temperature 37°C.
Points represent the mean release of 15 samples, S.D. <5% of the mean.
■ 10% inulin loading.

















I. Cumulative percent release of 10%,and 15% loaded inulin/PHB matrices versus time in days into (0.1M) NaOH 
release media pH 12.9 at temperature 70°C.
Points represent the, mean release of 15 samples, S.D. <5% of the mean.
■ 10%- inulin loading.
□ 15% inulin loading.
c=>
CJ1
Drug loading Original weight 
(g +/- s.d.)
Weight after 








10% 0.1149 +/-0.03 0.0858 +/-0.02 29 25% 34% 3.8 25.2
l
15% 0.1098 +/-0.03 0.0947 +/-0.02 15 14% 28% 3.1 11.9
10%
o
0.1177 +/-0.01 0.0542 +/-0.01 63 54% 32% 3.8 59.7
Ci
15% 0.1098 +/-0.01 0.0527 +/-0.02 ' 57 52% 33% 3.6 53.5
10%
o
0.1205 +/-0.02 0.1102 +/-0.02 10 9% 16% 1.9 8.4
O
15% 0.1055 +/-0.01 0.0929 +/-0.01 13 12% 23% 2.4 . 10.3
10%
A
0.1163 +/-0.01 0.1098 +/-0.01 7 6% 12% 1.4 5.1
4
15% 0.1247 +/-0.01 0.1103 +/-0.00 14 12% 12% 1.5 12.9
Table 7.1. The effect of pH, drug loading and temperature on PHB (23K)/inulin melt extrudate release in vitro.
1 = pH 12.9; temperature 37°C
2 = 12.9; temperature 70°C
3 = pH 7.4; temperature 70°C






5. Cumulative percent release of 10% and 15% ioaded inulin/PLA and inulin/P(LA-*GA) 50:50 matrices versus time 
in days into (0.1M) NaOH release media, pH 12.9 at temperature 37°C.
Points represent the mean release of 15 samples, S.D. <5% of the mean.
10% inulin loading.
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G. Cumulative percent release of 10% and 15% loaded inulin/PLA and inulin/P{LA-GA) 50:50 matrices versus time 
in days into (0.1M) NaOH release media, pH 12.9 at temperature 70°C.
Points represent the mean release of 15 samples, S.D. <5% of the mean.
O ,A 1 0 %  inulin loading.
• , A 1 5 %  i n u  I i ri l o a d i n g .
OO
a O ’
2 0 K U
Figure 7.7. Scanning electron micrograph of inulin/PHB melt extrusion
containing 15% by weight inulin, before release experiments.
a) Cut section of extrusion. x750 20KY.
b) Surface view. x500 20KV.
Figure 7.8. Scanning electron micrograph of inulin/ PHB melt extrusion 
containing 15% by weight inulin after 14d in (0.1M) NaOH, 
pH 12.9 and temperature 70°C.
a) Cut section of extrusion. xlOO 20KY
b) Surface view. x500 20KY
respectively. The release of both 10% and 15% inulin loaded PLA, 
P(LA-GA) matrix systems at both temperatures appeared to be linear 
with time. The rate of inulin release from PLA appeared to be greater 
than from the P(LA-GA) matrices at both drug loadings and both 
temperatures. Total degradation and drug release from these PLA, 
P(LA/GA) matrices had occured by day 5.
At the end of the release study SEM suggested that PHB
extrudates degraded by erosion as no internal pores were observed
(figures 7.7-7.8).
7.5.2. In vivo release .
Figure 7.9 compares the release kinetics of 10% loaded 14C
inulin-P(LA-GA) matrices and 20% loaded 14C inulin-PHB matrices in
vivo over a 28 day implantation period. Cumulative percent release of
labeled inulin is plotted against time and each graph illustrates
the releases kinetics from implanted extrudates for individual
animals. The release rate of 14C inulin from PHB matrices was between
3-5% over the 28 day period. The P(LA-GA) systems however released%
between 25-40% of the total incorporated drug. P(LA-GA) systems 
exhibited two phases of release. The initial phase of release was
slow and steady over the first 10 days. In the second phase of 
release a . burst of release occured over two days which then became 
steady, giving near zero order release kinetics over 12-28 days. The 
PHB loaded systems released inulin steadily over 28 days. At the end 
of the studied release period the implants were removed, dried and 
weighed. The PHB/drug matrices had lost very little weight, P4%) 
whereas the P(GA-LA) matrices lost ~20% of their initial weight. SEM 
revealed no porosity within the PHB/drug matrix and very little 










Figure 7.9. The release kinetics of 14C inuiin from PHD and P(GA-LA) extrusions in vivo.
■ 20% drug loading in PHD (n=3; S.D <5% of mean).
□ 10% drug loading in P(GA-LA) extrusions (n = 1). ^
▲ i' i. /• . r “ *
Figure 7.10. Scanning electron micrograph of inulin/PHB melt extrusion 
containing 20% by weight inulin, after 28d implantation 
into rat gluteal muscle.
a) Cut section of extrusion. x500 20KY.
b) Surfce view. xlOO 20K\.
P(LA-GA) systems were porous and pitted at the surface which was 
probably explained by drug release via diffusion and homogenous 
(bulk) erosion (figure 7.11).
Figure 7.11. Scanning electron micrograph of inulin/P(LA-GA) 50:50 melt 
extrusion containing 10% by weight inulin, after 28d 
implantation into rat gluteal muscle.
a) Cut section. xlOO 20KY
b) Surface view. x200 20KY
7.6, Discussion.
In vitro degradation of PHB and subsequent inulin release has shown 
the influence of temperature and pH on the rate of matrix buffer 
hydrolysis and drug release.The rate of drug release and extent of 
overall polymer degradation in aqueous buffer solutions, one at 
physiological pH (7.4) and one in alkali conditions (pH 12.9) 
increased with temperature in accordance with the proposed ester 
hydrolysis mechanism (equation 1). The enhancement of overall polymer 
degradation and drug release in alkaline hydrolytic medium was also 
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Degradation of polyesters in basic solutions. (Schnabel, 1981)
A change in drug loading between 10 and 15%w/w did not appear 
to influence greatly the overall drug release from PHB matrices or
the overall extent of polymer degradation. This suggested that the 
polymer degraded at the surface and that drug was released only when 
exposed by polymer degradation. SEM micrographs revealed that the 
surface of PHB extrudates became increasingly pitted and rough but 
the internal structure remained solid during the time spent in the 
aqueous buffer media. At physiological 01 and temperature the release 
kinetics of inulin from the extrudates was closely related to loss of 
polymer but as the temperature and pH was increased to accelerated 
degradative conditions, 70°C and pH 12.9 (Majid, 1988), drug release 
became less predictable. Surface erosion of PHB and P(HB-HV) in the 
initial stages of degradation was measured by Holland et al, 1987. 
Combined dry and wet gravimetric results together with surface energy 
and goniophotometric measurements showed that in the initial stages 
of degradation little change in the bulk or mass of the sample was 
detected and an increase in the concentration of hydroxyl and 
carboxyl groups at the surface as a consequence of ester hydrolysis 
at the polymer-water interface was evident. As degradation proceeded 
bulk erosional processes became operative such that the matrix 
became more porous allowing an increasing loss of higher molecular 
weight degradation products. The period of degradation in aqueous 
media (pH 7.4) at a temperature of 70°C used by these researchers was 
typically 70 days. The process of bulk degradation was not apparent 
until day 28 after which substantial mass loss equivocal to bulk 
hydrolysis occured. As the degradative period used in the preliminary 
drug release experiments presented in this chapter was only 14 days 
it may be that the initial surface erosion observed would later have 
been followed by bulk hydrolysis. This would explain the drug release 
kinetics that were observed in the experiments where accelerating 
conditions were used. If drug diffusion through the bulk matrix
becomes important one would expect the Higughi model to apply 
(equation 2).
The Higuchi model predicts that the cumulative release of drug 
from matrices would be linear with the square root of time if the 
following assumptions are met (Brown et al, 1986).
1) initial drug loading is greater than the solubility limit of the 
drug,
2) the polymer portion of the matrix is not miscible with the release 
media,
3) the release medium provides perfect sink conditions
4) pseudo steady-state conditions exist to allow the sustained 
release of drug from the matrix.
Q = (DCs( / )(2A- Csjt)1/2 ---------<2>
where Q = quantity of drug released per unit area at time t(mg/cm3);
D = effective diffusion coefficient (cm2/s); C = inulin solubility 
in the release media (mg/ml); = porosity of the inulin-polymer 
matrix; = tortuosity of the matrix; A = weight loading of inulin in 
the volume of the matrix; t= time (s).
The rate of drug diffusion under these conditions is therefore 
dependent on the size and tortuosity of the pores. Fabrication 
variables that affect the structure of these pores are drug particle 
size (Langer and Folkman, 1980; Brown et al, 1983,1986), drug loading 
(Suzuki and Price, 1985), and the matrix preparation technique.(Rhine 
et al, 1980).
The formulation of the polymer /drug matrix can also influence 
rate of polymer degradation and therefore drug release kinetics. 
Holland et al have also shown that degradation rates occur in the 
following rank order: compressed tablets < solvent cast films < melt
pressed discs < injection moulded pieces. These differences 
correlated with the difference in degrees of crystallinity as 
measured using a differential scanning calorimeter. High 
crystallinity was associated with high resistance to hydrolytic 
attack. The drug release of inulin was therefore likely to have been 
retarded by the melt extrudate formulation. This was apparent in in 
vivo release studies where the release of 20% drug loaded 
inulin/PHB melt extrusions was negligible over 3-28 days. P(LA-GA) 
(50:50) melt extrusions with 10% drug loading however released 25% 
of the inulin over 28 days, although release was uncontrolled. The 
difference in release kinetics in vivo could be atributable to 
different degrees of crystallinity in the two melt extruded polymers.
Drug release studies from PHB have been carried out by 
Korsatko et al, 1983a, 1983b. PHB matrix tablets as sustained release 
formulations were prepared by compressing homogenous mixtures of PHB 
and 7-hydroxyethyltheophylline (HET). The tablets were 2.00mm in 
thickness and 6.00mm in diameter. A variety of drug loadings were 
studied ranging between 5% and 80%. In vitro release studies were 
performed in 0.9% NaCl at 37°C. At drug loadings below 30% w/w 
release took place over a period of 50 days whereas with drug 
loadings of 60-80% w/w release was completed within 24 hours. Release 
of drug occured initially from the surface and then proceeded by 
diffusion through aqueous pores formed by water penetration of the 
matrix of the tablet. The degradation of PHB had no significant 
effect on the release of HET in vitro.
Bissery et al, (1984) prepared PHB microspheres containing an 
anticancer drug and in vitro drug release was studied. In buffer of 
pH 7.2 at 37°C more than 90% of the loaded drug (7.4% w/w) was 
released in 10 hours. However release rate of the drug from P-dl-LA
microspheres prepared by the same method, showed that release was 
sustained over a longer period i.e. 60% of drug released in 90 hours. 
The authors were unable to explain the results.
Drug release from PHB microspheres has also been studied by
Juni et al (1986) and Brophy and Deasey (1986). Release rates were
dependent on a number of variables including drug loadings,
particulate size, solvent evaporation process, molecular weight and
model drug used. Geometry of the matrix device is also another
important variable often used to control the release kinetics of
drugs from the matrix (Fessai et al, 1979; Pitt et al, 1979).
Hofenberg (1976), presented equations describing the idealised
kinetics for erodible slabs, cylinders and spheres, indicating that
constant delivery is provided only by the slab geometry. The
cylindrical drug/polymer matrices used in the in vitro and in vivo
studies presented in this chapter would according to this theory be
expected to initially deliver the drug at a constant rate', but as
surface erosion occured, the drug release would begin to decrease as
the surface area available for release decreased. This however was
%
not observed possibly due to the time span of the experiments. The 
nature of the PHB-drug matrices therefore clearly varied and further 
study in our laboratories needs to be done before conclusive evidence 
of the mechanism of polymer degradation and therefore drug release 
can be obtained.
The rate of PLA and P(LA-GA) degradation in contrast /to PHB 
was significantly greater (p<0.001) and drug release appeared to 
follow Higuchi’s mathematical model, i.e. cumulative release is 
linear with square root of time (figures 7.5-7.6). Accelerated 
conditions of degradation were examined and only one copolymer 
composition (50:50) was examined.
The effect of copolymer composition on the release of a 
hormonal steroid, was studied by Sharon et al (1984). The release of 
the steroid was directly related to the susceptibility of each 
polymer to degradation. Copolymers and homopolymers of 1-LA, dl-LA 
were used. The rank order of polymers with increasing rate of 
biodegradation was P(75% 1-LA/25%GA), P(90% dl-LA/10%GA), P(100%
dl-LA), P(50% dl-LA/50%GA) and P(100% 1-LA). Two polymers
P(100%dl-LA) and P(50%dl-LA/50%GA), were selected for further release 
studies of the steroid since they appeared to have potential for 
development of a delivery system with a lifetime of 6 months to 1 
year.
The controlled release of peptides, typically LHRH analogues, 
from P(dl-LA/GA) systems have been studied extensively (Sanders et 
al, 1986; Hutchinson and Furr, 1987; Kaetsu et al, 1989; Asano et al, 
1989; Ogawa et al, 1989). Sanders et al (1984) prepared microspheres 
by a phase separation method. The peptide in aqueous solution was 
mixed with a solution of P( 50%dl-LA/50%GA) in dichloromethane. The 
release of the peptide from these microspheres was found to be 
triphasic. The primary phase involved diffusion of free drug-' from 
the surface of the microsphere, followed by a secondary phase where 
the release rate was too low to be therapeutically effective, 
followed by a tertiary release phase of the peptide through bulk 
erosion of the polymer.
Matrices can be formulated to give biphasic releases avoiding 
the slow secondary phase release (Hutchinson and Furr, 1985). This 
was achieved by use of low molecular weight polymer and a higher 
loading of drug. High moleculr weight P(d-LA) (intrinsic viscosity = 
1.02 dl/g) resulted in extension of the secondary phase whereas an 
implant prepared using a low molecular weight polymer (intrinsic
viscosity =0.36dl/g) exhibited no secondary phase of release. 
Molecular weight was also seen to affect the melt extrudate 
fabrication process of P(HB-HV). The average molecular weight was 
760K compared to 23K, 28K and 56K of PHB, PLA and P(LA-GA)
respectively. At this high molecular weight, even at elevated 
temperatures and extended extrusion times, the viscosity of the melt 
was too large to be extruded and if peptides had been used thermal 
degradation would certainly have occured.
Research in the area of biodegradable polymers as controlled 
drug delivery devices is a continually growing field. Biodegradable 
polymers which are not only biocompatible but also ideally release 
macromolecules in the body to give an optimal therapeutic effect have 
still to be found. Of the biodegradable, parenteral, 
controlled-release delivery systems, only one implant (Hutchinson and 
Furr, 1987) and two injectable microsphere products have been 
introduced, each of which use lactide polymer or lactide/glycolide 
copolymer as the excipient to control the release of the drug. With a 
single administration the implant (Zoladex,ICI) and one of the 
microsphere products (Decapeptyl; Ipsen Biotech) deliver luteinizing 
hormone-releasing hormone agonists for one month for the treatment of 
prostate cancer. The second microsphere product delivers 
bromocriptine for a one month period (Parlodel, Sandoz).
It has taken some time for the first parenteral 
controlled-release products to appear because of their complexicity 
as well as the need to solve many of the practical problems of 
manufacture and marketting. Polymers and copolymers of lactic and 
glycolic acid have been at the fore front of this research because of 
their well established and reported biocompatibility. However other 
biodegradable polymer formulations, in particular the polyester PHB
and its copolymers under research at Bath University and the 
polyorthoesters, currently under reseach by Heller and his collegues, 
are now being investigated as controlled peptide delivery systems 
because of their mechanism of degradation (i.e. surface erosion 
giving controllable drug release) and their biocompatibility. 
Extensive degradation studies and more succinct drug release studies 
need to be performed both in vivo and in vitro, before any real 
conclusions can be drawn from these initial release studies.
CHAPTER 8.
8.1. Concluding Discussion,
The importance of tissue reactions to polymer implantation has
been addressed by many research scientists concerned with
biocompatibility (Bischoff, 1972; Rigdon, 1974; Coleman et al, 1974;
Leong et al, 1986; Visscher et al, 1986; Sevastjanova et al, 1987;
Tamargo et al, 1989) and the techniques used to measure such tissue
reactions have been the subject of a number of reviews (Salthouse,
1976; Rae, 1986; Meachim and Pedley; 1986). Over the years the
selection of biocompatible polymers has been achieved empirically,
testing materials by implantation into animals.
The use of animal models, such as the rat and rabbit, in the
initial stages of biocompatibility testing is expensive both in
time and resources and therefore some form of in vitro pre-screening
is desirable to ensure efficient usage of subsequent animal testing.
Tissue culture methods in particular have been employed in the
evaluation of the toxic potential of polymers by a number of workers,
early work carried out notably by Guess and Autian (1964), Grasso
%
(1973) and Wilsnack (1973). At present there is no clear distinction 
between the terms biocompatibility and toxicity (Styles, 1986) and it 
is therefore assumed that the degree of toxicity measured in vitro 
may be used to predict an incompatibility in vivo.
Chapter 3 described in vitro cell culture experiments to 
determine whether in vivo biocompatibility tests could be justified 
for the polymers PHB, P(HB-HV) and their degradation products. 
Experimental evidence showed that PHB, P(HB-HV) and low 
concentrations of their monomers were not cytotoxic to CHO-K1 cells. 
However at higher concentrations of sodium HB and HV moderate to 
severe cytotoxicity occured. This cytotoxicity was believed to be due
to an osmotic effect within stagnant culture conditions since sodium
HB and HV were no more toxic than sodium chloride or sucrose on a
molar basis. The local concentration of degradation products would
never reach such high levels in vivo due a) rapid diffusion away from
the implant site and b) the slow rate of degradation of the
implanted polymers. A cell culture test system, while of obvious
benefit, can lead to incorrect conclusions due to the closed nature
of the culture as in the cases of HB and HV. It is also possible
that an underestimation of toxicity may be observed, since some
substances are inactive in their native form but may be transformed
into a toxic form by action of the liver microsomal enzyme system,
the potential for such a transformation being absent in tissue
culture (Styles, 1986). Another disadvantage of tissue culture is
that it can only test for acute toxicity as only short culture
periods can be maintained. Therefore if a polymer is judged to be
compatible in cell culture tests then in vivo testing will have to be
performed not only to substantiate in vitro evidence of
biocompatibility but also to establish the biocompatibility of
%
materials for long term implantation. The in vitro cell culture tests 
represented a first step in assessing the biocompatibility of PHB, 
P(HB-HV) and their monomers. However cell culture was not able to 
model the haemodynamic, haemotological and reticulo-endothelial 
compensatory mechanisms found in vivo.
In vivo biocompatibility tests were designed to determine the 
tissue reactions to implanted PHB, P(HB-HV) and their monomers. With 
regard to the proposed use of these materials as drug delivery 
systems, the protocol concentrated on assessment of inflammatory 
reactions in soft tissue and blood compatibility. The overall 
inflammatory response to the polymers and monomers in vivo was
assessed, the results of which are reported in chapter 6. Individual 
aspects of the inflammatory response were examined in vitro, the 
results of which are documented in chapters 3-5. The purpose of this 
general discussion is to interelate data reported in chapters 3-6.
Implantation or injection of any material into soft tissue 
will initiate an inflammatory response if only that resulting from 
the surgical trauma induced. Injection or implantation causes acute 
tissue damage and vascular beds are disturbed. One of the first 
results of such damage is the leakage of plasma proteins, 
erythrocytes, white blood cells and platelets (Bult and Herman, 1985; 
Ito et al, 1989) to the site of trauma to aid tissue repair and wound 
healing. Tissue damage also leads to the release of inflammatory 
mediators which increase vascular permeability and chemotactically 
attract cells of the immune response, primarily PMNs and macrophages, 
(Behling and Spector, 1986; Marchant et al., 1983,1986; Callis et al, 
1988; Williams et al, 1989). Exacerbation or resolution of this 
inflammatory response is then dependent on
1) interaction of the polymers with plasma proteins
* v
2) macrophage adherence/ activation/ phagocytosis
3) fibrin formation
4) tissue encapsulation
A summary of the biochemical and cellular events, that can 
occur following implantation of a material into soft tissue in the 
short term (acute phase), and long term (chronic phase), are 
presented in figures 8.1 and 8.2 respectively. The magnitude and 
duration of the inflammatory response is often related to the 
interaction of inflammatory cells, PMNs and macrophages, with the 
biomaterial. These cells are chemotactically attracted to the 
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figure 8.1 Summary of I ho biochemical events of the acute phase of 
inflammation to an implanted prosthesis. ^  indicates a promoting or 
activating effect on a particular process; ^  indicates an increase effect; 
PMN, polymorphonuclear leucocyte; PG, prostaglandins, IgE, immunoglobulin 
1&E; Ag, antigen; and ?, unconfirmed effects.




























Figure 8.2 Summary of the biochemical event of chronic inflammation to an 
implanted prosthesis and its wear and corrosion products, ©indicates an 
activating or promoting effect on a particular process; ^  an increase in 
effect; MIF, migration inhibition factor; and PG prostaglandins. 
(Reproduced from T. Rae, Fundamental Aspects of Biocompatibility; Ed. 
D.F. Williams, 1981.)
hydrolases (Rae, 1981), all of which are released by damaged tissue 
cells. Histamine and PGE2 increase vascular permeability 
(Baggiolini, 1985) leading to an increase in plasma exudation, and in 
the initial stages of the inflammatory reaction, 1-3 days, PMNs
extravate into the area of inflammation. Differential increases in 
vascular permeability due to release of chemical mediators from the 
inflammatory cells depend on the number of inflammatory cell polymer 
interactions which then often relate to the extent of tissue damage 
observed during implantation of the different polymers (Ziats et al, 
1988). Vascular permeability studies in vivo, reported in chapter 6, 
showed that injection of PHB and P(HB-HV) into the gluteal muscle of 
male Wistar rats did not significantly (p>0.1) increase the 
permeability of the vasculature. A small increase in vascular 
permeability was observed which was considered to be attributable to 
the trauma of injection. Although the effects on vascular
permeability in vivo were measured only after 2 and 4 hours 
injection, the little effect on increase of vascular permeability 
correlated well with a mild and transient inflammatory response, 
observed macroscopically over the first 3 days following polymer 
implantation.
The increase in vascular permeability seen after implantation 
of polymers compared to that measured following the insertion of a 
needle (sham injection) was insignificant. This correlated with data 
on PGE2 production and release by cultured macrophages in vitro,
reported in chapter 4. It is generally accepted that PGE2
biosynthesis is involved in the development of an acute inflammatory 
response in several models of acute inflammation (Ferreira and Vane, 
1979; Bonta and Parnham, 1978). PGE2 exerts its pro-inflaramatory 
activity by dilatation of the resistance vessels, thereby drastically
increasing blood flow through the affected tissue. However the 
biosynthesis of vasodilating prostaglandins is a rate-limiting factor 
in the fluid exudation since simultaneous application of PGE2 and 
PGEi together with inflammatory mediators like carrageenan and 
zymosan greatly potentiates the early exudation (Williams, 1979). In 
studies with PHB and P(HB-HV) an initial significant production and 
release of PGE2 by macrophages in culture during the first hour of 
contact was evident. This was believed to be a result of macrophage 
activation. After 2 hours, PGE2 production and release decreased due 
to either an acute release of the prostaglandin upon polymer contact 
causing depletion of PGE2 and a latent period during which the 
prostaglandin is resynthesised, or cellular down regulation of PGE2 
release, or the production of chemical inhibitors of prostaglandin 
production. The measured small effect on the permeability of the 
vasculature around the area of implantation of the polymers in the 
initial stages of the inflammatory response, and the subsequent 
decrease of PGE2 production and release from activated macrophages 
in the later stages of the inflammatory response would predispose to 
an inflammatory response which would likely be quickly resolved and 
not exacerbated.
PGE2 is produced and released only on activation of the 
inflammatory cells (Lasser, 1980;). However adhesion of these cells 
to the biomaterial is required before activation of the cell occurs
j
(Rabinovitch, 1970). Therefore the presence of these cells in the 
inflammatory exudate around an implanted polymer does not necessarily 
correlate with subsequent activation. Adhesion to the polymer surface 
by these cells is thought to occur to an adsorbed protein layer.
One of the first events that occurs following implantation of 
a polymer into soft tissue, is the adsorption of plasma proteins onto
the polymer surface. Proteins which may adsorb to the surfaces of
biomedical polymers are widespread ranging from albumin, thrombin,
fibrinogen, to extracellular matrix proteins such as fibronectin and
IgG immunoglobulins (Vroman et al, 1980; van Wachem et al, 1987; Pitt
et al, 1988). Then as a function of the plasma protein adsorbed,
inflammatory cells such as PMNs and macrophages may adhere. PMNs and
macrophages both have receptors for the Fc portion of gammaglobulin
which will cause cell adhesion if a surface adsorbs gammaglobulin
(Rae, 1981; Anderson and Miller, 1984). Activation can then occur via
a number of interfacial processes, the mechanisms of which are yet to
be defined. These proteins therefore act as opsonins, interacting
with different populations of cells to induce possible activation
(Patarroyo et al, 1988; Bonfield et al, 1989). In particular,
interactions of the opsonins with the receptors that exist on PMNs
and the macrophages can cause the cell,to phagocytose (Pommier et al,
1983) or secrete products to the surrounding environment (Ziats et
al, 1988) which may resolve or exacerbate the inflammatory response.
Studies in a number of laboratories suggest that biomedical polymers « *
depending on their structure and composition, preferentially and 
differentially adsorb certain plasma proteins (Marchant et al, 1986; 
Lee et al, 1989; McCoy et al, 1989). These properties may influence 
subsequent cellular attraction to the site of polymer implantation as 
well as cellular adhesion followed by activation. This in turn 
induces the release of more inflammatory mediators into the 
implantation area, chemotactically attracting more inflammatory cells 
to the area.
Research by Bonfield et al (1989), has linked the adsorption 
of certain plasma proteins to the activation of macrophages and 
subsequent release of another important inflammatory mediator,
interleukin 1 (IL1). These workers found that when Biomer, PDMS, PEE,
Dacron and PTFE adsorbed IgG and fibrinogen, the resulting production
of IL1 was retarded in comparison with the protein coated polystyrene
controls. This implied that the interaction between IgG and
fibrinogen with polymers caused a decrease in cellular activation.
Conversely if the polymer remained uncoated or was pre-coated with
albumin no suppression of IL1 production and release was observed.
The suppression observed in these studies could be the result of a
variety of factors including protein-cell interactions, induction of
IL1 inhibitors or direct cellular down-regulation, which in turn
could play a part in the the inhibition of IL1 secretion from
activated monocytes. This type of response was also believed to occur
with PHB and P(HB-HV) since both uncoated polymers initially
stimulated the macrophage to produce another important inflammatory
mediator, PGE2 . This could have been explained by direct cellular
down-regulation mediated by the biomedical polymer itself, or other'
cellular down-regulation mechanisms. However in view of the protein
adsorption data presented in chapter 5, where albumin and
%
gammaglobulin equally competed with each other for adsorption to the 
surface of PHB, then in whole blood where the concentration of 
albumin is greater it would be predicted that macrophages would not 
adhere well to PHB polymer surfaces since albumin does not contain 
the necessary recognition sites for macrophage binding. Therefore 
activation of macrophages which led to a burst in PGE2 production and 
release in vitro in the presence of uncoated PHB, would not occur in 
vivo. However, P(HB-HV) preferentially adsorbed IgG, which include 
the receptors for macrophage attachment. Thus it could be predicted 
that IgG-coated P(HB-HV) could activate macrophages leading to the 
release of PGE2 , which would increase vascular permeability and
destruction of the tissue cells leading to exacerbation of the 
inflammatory response. This is contradicted by the work of Bonfield 
et al. who showed that biomedical polymers pre-coated with IgG, 
appeared either to suppress or have no effect on the production of 
the inflammatory mediator IL1. This suggests either that protein cell 
interactions or the surface of the biomedical polymers inhibited 
mediator production by unknown cellular down-regulation mechanisms.
Marchant et al (1983) used a cage implant system to quantitate
the humoral and cellular components of the inflammatory response to
the biodegradable hydrogel, poly(2-hydroxyl-ethyl-glutamine), (PHBG).
They illustrated the importance of cell-surface adhesion to
exocytosis of inflammatory mediators into the site of inflammation.
Exocytosis of mediators was insignificant in the presence of the
chemotactic stimulus when the cells were non-adherent. The authors
concluded that a nonadhesive pathway to exocytosis by PMN’s does not
play a major role in providing extra-cellular enzymes in the exudate.
Utilizing in vitro studies, Henson (1980) has shown that neutrophils
adherent to complement-coated and immunoglobulin-coated%
nonphagocytosable surfaces may release enzymes by direct extrusion of 
the granules to the exterior of the cell. Henson also observed that 
the amount of enzyme released during phagocytosis was dependent on 
the size of the polymer particle, with larger particles inducing 
greater amounts of enzyme release. He also suggested that the 
specific mode of cell activation caused by a normal inflammatory 
response is dependent on the size of the implant and that a material 
in powder or particulate form, suitable for phagocytosis, may provoke 
a different degree of response than the same material in a 
non-phagocytosble form, such as a film. This may have further 
implications regarding inflammatory cell function, the extent and
duration of the different stages of the inflammatory response and the 
mechanisms by which inflammatory cells respond to a foreign body 
stimulus. Furthermore, the availability of the two pathways for 
expression of cell activation, phagocytosis versus exocytosis, may 
result in problems of interpretation of cell culture studies where 
particulates are used.
Following PMN migration and phagocytosis/exocytosis by these 
cells, enzymes are released into the surrounding area and 
macrophages, associated with the later (chronic) stages of 
inflammation are chemotactically attracted to this area. Macrophage 
accumulation following intraperitoneal injection of polymers is 
documented in chapter 4, The extent of activation of these cells by 
PHB and P(HB-HV) was assessed in vitro by assay of PGE2 (see chapter
4) and in vivo by assay of acid phosphatase (chapter 6). Both PMNs 
and macrophages contain intracellular aeid phosphatase (Salthouse and 
Matlaga, 1981; Marchant et al., 1986) the greatest amount of which is 
found in the macrophage. However the measured acid phosphatase 
activity could reflect both the acute and chronic phases of 
inflammation. Examination of data in chapters 4 and 6 reveals that 
there does not appear to be a direct correlation between PMN 
concentrations and the acid phosphatase levels. In contrast a 
correlation was observed with the alkaline phosphatase levels. At 
later time points the contribution from other leukocytes namely 
macrophages undoubtably became more important. A direct correlation 
is seen between the macrophage accumulation data documented in 
chapter 4 and the acid phosphatase activity documented in chapter 6 
over a 40 day implantation period. Peak acid phosphatase activity 
occurred at approximately the same time points as maximum macrophage 
accumulation. Both these parameters were greatest, after injection
of PHB microspheres, on days 4-8. Increases were observed after 
injection of P(HB-HV) microspheres but they were not as large as 
those observed with the homopolymer. The temporary increases could 
have been caused by attempted phagocytosis of the polymer 
microspheres resulting in exocytosis of enzymes and inflammatory 
mediators such as PGE2 . However all results relating to aspects of 
the inflammatory response indicated that the duration of the
inflammatory response was acute, that exacerbation did not occur and 
that phagocytosis did not occur. Injection of PHB and P(HB-HV)
microspheres and even implantation of polymer films did not adversely 
affect the soft tissue into which they were implanted. It can
therefore be concluded that the polymers themselves are inert and 
well tolerated. The histological assessment of the implantation of 
these polymers in soft tissue also correlated well with the results 
of vascular permeability, enzyme histochemistry and macrophage
activation.
It was conceivable that biodegradation of these polymers 
could initiate a series of acute inflammatory conditions within the 
tissue in response to the degradation products which -could eventually 
lead to necrosis of the tissue. Therefore each aspect of the 
inflammatory response was assessed with respect to high 
concentrations of the degradative products. It was assumed that 
effects due to release of soluble materials should only be 
attributable to the monomers as no additives, stabilisers or 
catalysts, used in synthetic production of biopolymers, are present 
in these bacterial biosynthesised polymers. The assessment of the 
inflammatory response to doses of the two monomers, far exceeding any 
expected concentration which would result from degradation of the 
polymers in vivo, indicated that even at high doses the soft tissue
inflammatory response was transient only and no necrosis was 
observed. In vitro observations of the inflammatory response to high 
doses of monomers showed marked increases in measures of cytotoxicity 
i.e. increase in cellular death (as documented in the cell culture
section) and increases in LDH production and release observed in
cultured macrophages. This apparent contradiction to in vivo studies 
is likely to be due to overestimation of the toxicity in relatively 
stagnant culture conditions. The overall results of the cellular and 
biochemical tests indicated that PHB, P(HB-HV) and their degradation 
products were well tolerated in soft tissue and therefore 
biocompatible with this tissue.
Protein adsorption to polymer surfaces was assessed as an 
indication of the potential of a material to be thrombogenic (chapter
5). Due to limited clinical experience ex vivo and in vivo work could 
not be done. The data collected in this work showed that PHB
preferentially adsorbed albumin to its surface and that platelet
adhesion to coated and uncoated polymer was minimal. Such findings 
with reference to well documented blood compatible polymers, indicate 
that PHB may be a nonthrombogenic material. P(HB-HV), preferentially 
adsorbed IgG and adsorbed a greater number of platelets indicating 
its potential thrombogenicity.
Each aspect of the inflammatory response used to assess 
biocompatibility has recognised limitations as described in the 
individual chapters. However by using a range of experiments a 
substantial picture has been formed on the effects on the 
physiological enviroment of the implantation of PHB, P(HB-HV) and 
their degradation products. Aspects of the inflammatory response and 
the adsorbed plasma protein profile correlated well and a 
comprehensive picture of the biochemical events and cellular changes
following implantation/injection was obtained.
The biocompatibility of these biodegradable polymers has been 
assessed exclusively in the soft tissue assessing the magnitude and 
duration of the inflammatory response. A number of parameters were 
standardised throughout the toxicity evaluation programme including 
the animal model used and the physical form of polymer presentation 
in culture or in vivo. The rat was used throughout all in vivo tests 
and was the animal of choice, as inbred strains of the male Wistar 
rat can led to good reproc.lucibj.lily over many generations and allowed 
comparisons to be made. The number of animals required per experiment 
was large and the use of rabbits as the animal model would have been 
expensive. The main disadvantage of the rat was its relatively short 
life span, 18-24 months, which did not allow long term measurements 
of biocompatibility, such as the assessment of carcinogenic effects. 
However use of two animal models would have been useful as species 
respond differently to the same stimuli (Williams, 1986). In general 
the mononuclear cell predominates in the rabbit whereas the PMN 
appears with greater frequency in the rat. It is usually assumed that 
man is less sensitive* than the rabbit or may be better equipped to 
cope with the introduction of a foreign material than some of the 
lower species. The physical form of the polymers was standardised, as 
either smooth films or microspheres of approximate diameter 40um. It 
is well known that different physical forms of the same material may 
differentially influence the inflammatory reaction to these materials 
(Wood, 1970; Sevastjanova et al, 1987; Bakker et al., 1988). The 
implantation site was standardised in soft tissue, but implantation 
site is known to affect the degree of inflammation seen (Hench and 
Etheridge, 1982; van Blitterswijk et al., 1986).
Further studies using variations in implantation site, animal
model, physical forms and size of the implant, and in the case of the 
copolymer different mole fractions of HV, are needed in order that
the assessment of biocompatibility of PHB and P(HB-HV) can be
conclusive. However preliminary studies in vitro and in vivo on the
biocompatibility of these polymers and their use as biodegradable




Microspheres were produced by a solvent evaporation process at 22 °C 
and at atmospheric pressure. The standard procedure involved 
dissolving the required amount of polymer in chloroform by reflux. 
The mixture was poured rapidly into an aqueous phase containing 2% 
v/v polyvinylalcohol (FVA) as an emulsifier and stirred at a constant 
rate of 1400rpm. The resulting emulsion was agitated at 22°C for 24 
hours during which the chloroform had evaporated. The partially dried 
microspheres were allowed to settle and the aqueous phase containing 
the polymeric dispersing phase was replaced with distilled water. 
When all the chloroform had evaporated the microspheres were 
collected and isolated by centrifugation. They were then washed and 
dried in vaccuo at 45°C for 24 hours then stored ready for use.
Film production.
4% w/v polymer solutions were prepared* by refluxing in redistilled 
chloroform. Polymer solutions were cast onto clean, dry glass plates 
using a thin layer chromatography (TLC) applicator. The clearance 
setting of the TLC applicator was chosen to produce dry films of 
thickness 90-100um. The resultant cast films were dried slowly in 
draught free conditions for 2 hours and then overnight in a vaccuum 
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